
<html lang="en"     class="pb-page"  data-request-id="b888b09e-c7a0-4e41-af54-b43d1d2a0584"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-4;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.0c01468"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease" /></meta><meta name="dc.Creator" content="Chufeng  Zhang" /></meta><meta name="dc.Creator" content="Wenyan  Qi" /></meta><meta name="dc.Creator" content="Yong  Li" /></meta><meta name="dc.Creator" content="Minghai  Tang" /></meta><meta name="dc.Creator" content="Tao  Yang" /></meta><meta name="dc.Creator" content="Kongjun  Liu" /></meta><meta name="dc.Creator" content="Yong  Chen" /></meta><meta name="dc.Creator" content="Dexin  Deng" /></meta><meta name="dc.Creator" content="Mingli  Xiang" /></meta><meta name="dc.Creator" content="Lijuan  Chen" /></meta><meta name="dc.Description" content="TYK2 mediates signaling of IL-23, IL-12, and Type I IFN-driven responses that are critical in immune-mediated diseases. Herein, we report the design, synthesis, and structure–activity relationships..." /></meta><meta name="Description" content="TYK2 mediates signaling of IL-23, IL-12, and Type I IFN-driven responses that are critical in immune-mediated diseases. Herein, we report the design, synthesis, and structure–activity relationships..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 16, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01468" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01468" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01468" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01468" /></link>
        
    
    

<title>Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01468" /></meta><meta property="og:title" content="Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0020.jpeg" /></meta><meta property="og:description" content="TYK2 mediates signaling of IL-23, IL-12, and Type I IFN-driven responses that are critical in immune-mediated diseases. Herein, we report the design, synthesis, and structure–activity relationships (SARs) of 3-(4-(2-((1H-indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile derivatives as selective TYK2 inhibitors. Among them, compound 14l exhibited acceptable TYK2 inhibition with an IC50 value of 9 nM, showed satisfactory selectivity characteristics over the other three homologous JAK kinases, and performed good functional potency in the JAK/STAT signaling pathway on lymphocyte lines and human whole blood. In liver microsomal assay studies, the clearance rate and half-life of 14l were 11.4 mL/min/g and 121.6 min, respectively. Furthermore, in a dextran sulfate sodium colitis model, 14l reduced the production of pro-inflammatory cytokines IL-6 and TNF-α and improved the inflammation symptoms of mucosal infiltration, thickening, and edema. Taken together, 14l was a selective TYK2 inhibitor and could be used to treat immune diseases deserving further investigation." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="TYK2 mediates signaling of IL-23, IL-12, and Type I IFN-driven responses that are critical in immune-mediated diseases. Herein, we report the design, synthesis, and structure–activity relationships (SARs) of 3-(4-(2-((1H-indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile derivatives as selective TYK2 inhibitors. Among them, compound 14l exhibited acceptable TYK2 inhibition with an IC50 value of 9 nM, showed satisfactory selectivity characteristics over the other three homologous JAK kinases, and performed good functional potency in the JAK/STAT signaling pathway on lymphocyte lines and human whole blood. In liver microsomal assay studies, the clearance rate and half-life of 14l were 11.4 mL/min/g and 121.6 min, respectively. Furthermore, in a dextran sulfate sodium colitis model, 14l reduced the production of pro-inflammatory cytokines IL-6 and TNF-α and improved the inflammation symptoms of mucosal infiltration, thickening, and edema. Taken together, 14l was a selective TYK2 inhibitor and could be used to treat immune diseases deserving further investigation." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0020.jpeg" /></meta><meta name="twitter:title" content="Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01468"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01468">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01468&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01468&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01468&amp;href=/doi/10.1021/acs.jmedchem.0c01468" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1966-1988</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01186" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01504" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 3-(4-(2-((1<i>H</i>-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Chufeng Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chufeng Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chufeng++Zhang">Chufeng Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenyan Qi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenyan Qi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenyan++Qi">Wenyan Qi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yong Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yong Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yong++Li">Yong Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Minghai Tang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Minghai Tang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Minghai++Tang">Minghai Tang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tao Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tao Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tao++Yang">Tao Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kongjun Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kongjun Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kongjun++Liu">Kongjun Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yong Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yong Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yong++Chen">Yong Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dexin Deng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dexin Deng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dexin++Deng">Dexin Deng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mingli Xiang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mingli Xiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#d2aabbb3bcb58dbfbbbcb5bebb92a1b1a7fcb7b6a7fcb1bc"><span class="__cf_email__" data-cfemail="ed95848c838ab28084838a8184ad9e8e98c3888998c38e83">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mingli++Xiang">Mingli Xiang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Lijuan Chen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lijuan Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#22414a474c4e4b4857434c131017621314110c414d4f"><span class="__cf_email__" data-cfemail="96f5fef3f8fafffce3f7f8a7a4a3d6a7a0a5b8f5f9fb">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lijuan++Chen">Lijuan Chen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8076-163X" title="Orcid link">http://orcid.org/0000-0002-8076-163X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01468&amp;href=/doi/10.1021%2Facs.jmedchem.0c01468" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1966–1988</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 16, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 August 2020</li><li><span class="item_label"><b>Published</b> online</span>16 February 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 February 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01468" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01468</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1966%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DChufeng%2BZhang%252C%2BWenyan%2BQi%252C%2BYong%2BLi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D4%26contentID%3Dacs.jmedchem.0c01468%26title%3DDiscovery%2Bof%2B3-%25284-%25282-%2528%25281H-Indol-5-yl%2529amino%2529-5-fluoropyrimidin-4-yl%2529-1H-pyrazol-1-yl%2529propanenitrile%2BDerivatives%2Bas%2BSelective%2BTYK2%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BInflammatory%2BBowel%2BDisease%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1988%26publicationDate%3DFebruary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01468"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1860</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01468" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Chufeng&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Wenyan&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Yong&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Minghai&quot;,&quot;last_name&quot;:&quot;Tang&quot;},{&quot;first_name&quot;:&quot;Tao&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Kongjun&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Yong&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Dexin&quot;,&quot;last_name&quot;:&quot;Deng&quot;},{&quot;first_name&quot;:&quot;Mingli&quot;,&quot;last_name&quot;:&quot;Xiang&quot;},{&quot;first_name&quot;:&quot;Lijuan&quot;,&quot;last_name&quot;:&quot;Chen&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;1966-1988&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01468&quot;},&quot;abstract&quot;:&quot;TYK2 mediates signaling of IL-23, IL-12, and Type I IFN-driven responses that are critical in immune-mediated diseases. Herein, we report the design, synthesis, and structure–activity relationships (SARs) of 3-(4-(2-((1H-indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile derivatives as selective TYK2 inhibitors. Among them, compound 14l exhibited acceptable TYK2 inhibition with an IC50 value of 9 nM, showed satisfactory selectivity characteristics over the other three homologous JAK kinases, and performed good functional potency in the JAK/STAT signaling pathway on lymphocyte lines and human whole blood. In liver microsomal assay studies, the clearance rate and half-life of 14l were 11.4 mL/min/g and 121.6 min, respectively. Furthermore, in a dextran sulfate sodium colitis model, 14l reduced the production of pro-inflammatory cytokines IL-6 and TNF-α and improved the inflammation symptoms of mucosal infiltration, thickening, and edema. Taken together, 14l was a selective TYK2 inhibitor a&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01468&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01468" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01468&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01468" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01468&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01468" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01468&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01468&amp;href=/doi/10.1021/acs.jmedchem.0c01468" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01468" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01468" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (14 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01468%26sid%3Dliteratum%253Aachs%26pmid%3D33593051%26genre%3Darticle%26aulast%3DZhang%26date%3D2021%26atitle%3DDiscovery%2Bof%2B3-%25284-%25282-%2528%25281H-Indol-5-yl%2529amino%2529-5-fluoropyrimidin-4-yl%2529-1H-pyrazol-1-yl%2529propanenitrile%2BDerivatives%2Bas%2BSelective%2BTYK2%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BInflammatory%2BBowel%2BDisease%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D4%26spage%3D1966%26epage%3D1988%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (7)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=291161" title="Inflammation">Inflammation</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/4" title="Go to Volume 64, Issue 4"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/jmcmar.2021.64.issue-4/20210225/jmcmar.2021.64.issue-4.largecover.jpg" alt="Go to Volume 64, Issue 4"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">TYK2 mediates signaling of IL-23, IL-12, and Type I IFN-driven responses that are critical in immune-mediated diseases. Herein, we report the design, synthesis, and structure–activity relationships (SARs) of 3-(4-(2-((1<i>H</i>-indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile derivatives as selective TYK2 inhibitors. Among them, compound <b>14l</b> exhibited acceptable TYK2 inhibition with an IC<sub>50</sub> value of 9 nM, showed satisfactory selectivity characteristics over the other three homologous JAK kinases, and performed good functional potency in the JAK/STAT signaling pathway on lymphocyte lines and human whole blood. In liver microsomal assay studies, the clearance rate and half-life of <b>14l</b> were 11.4 mL/min/g and 121.6 min, respectively. Furthermore, in a dextran sulfate sodium colitis model, <b>14l</b> reduced the production of pro-inflammatory cytokines IL-6 and TNF-α and improved the inflammation symptoms of mucosal infiltration, thickening, and edema. Taken together, <b>14l</b> was a selective TYK2 inhibitor and could be used to treat immune diseases deserving further investigation.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54182" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54182" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Inflammatory bowel disease (IBD) is a noninfectious chronic inflammation of the gastrointestinal tract, including Crohn’s disease (CD), ulcerative colitis (UC), and uncertain colitis. IBD reduces the patient’s quality of life and brings health and economic burden to communities around the world. Moreover, its pathogenesis is very complicated, accompanied by malnutrition of commensal flora.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The JAK/STAT pathway signal transduction regulator is one of the main promising targets of IBD therapeutic methods apart from 5-aminosalicylates and biological therapies.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2−4)</a> Janus kinases (JAKs, including JAK1, JAK2, JAK3, and TYK2) can form homodimers and heterodimers, each of which can further bind to the juxtamembrane region of specific cytokine receptors, modulating gene expression and affecting immune-mediated diseases, gene transcription, and cell proliferation, differentiation, and survival.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a></div><div class="NLM_p">JAK inhibitors are commonly used for the treatment of autoimmune diseases and hematopoietic disorders (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The first pan-JAK inhibitor tofacitinib (<b>1</b>) was used to treat moderate or severe active UC. Unfortunately, in its phase II trial for UC, the absolute neutrophil count decreased below 1.5 × 10<sup>9</sup> cells/l,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> which was attributed to the simultaneous inhibition of JAK2-mediated erythropoietin and GM-CSF signaling, causing anemia, neutropenia, and thrombocytopenia.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Additionally, its nonselectivity resulted in significant adverse reactions, especially herpes zoster manifestations and pulmonary embolism.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> Ruxolitinib (<b>2</b>) was used for the treatment of patients with intermediate or high-risk myelofibrosis.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Low-dose baricitinib (<b>3</b>) was approved for the treatment of moderate to severe rheumatoid arthritis considering the risk of thrombosis. Peficitinib<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> (<b>4</b>) and upadacitinib<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> (<b>5</b>) were successively launched in 2019 to treat rheumatoid arthritis. TYK2-related inhibitors include brepocitinib (PF-06700841)<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> (<b>7</b>, Phase II) for the treatment of chronic plaque psoriasis and PF-06826647 (<b>8</b>, Phase II) for the treatment of severe to moderate plaque psoriasis and in early clinical development for the treatment of IBD.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Recently, an allosteric TYK2 inhibitor BMS-986165<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> (<b>6</b>) quickly entered phase III clinical studies for the treatment of moderate to severe psoriasis and completely prevented epithelial hyperplasia in the prophylactic treatment of mice before induction of colitis.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Clinical development of JAK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">TYK2 is the first identified member of JAKs<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> that mediates a variety of antiviral and immunoregulatory cytokine signals in immune cells and nonimmune cells, especially the Th17 response, which is closely related to the cytokine storm of COVID-19.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a> Genetically speaking, deficiency of human <i>Tyk2</i> gene causes defects in multiple cytokines including IL-6, IL-10, IL-12, IL-23, and Type I IFN.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> IL-23R and IL-12B polymorphisms are associated with IBD,<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a> while TYK2 targets the IL-12/Th1 and IL-23/Th17 axes.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Furthermore, knocking out TYK2 will show slower incidence and complication of disease activity in a dextran sulfate sodium (DSS) colitis model.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Thus, selectively targeting TYK2 to interfere with the JAK/STAT signaling pathway is an effective and prospective method for IBD therapy. However, IL-12 and IL-23 are mediated by heterodimerization of TYK2 and JAK2.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> For these reasons, to avoid undesirable effects such as significant hematopoiesis and provide a safe choice for treatment of inflammatory-related diseases, compared with other JAK isoforms (especially JAK2), the highly selective TYK2 inhibitor is preferred in finding IBD therapeutic candidates, which has become our pursuit.</div><div class="NLM_p">Our previous study has found that compound <b>9</b> (shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), a JAK2 and FLT3 dual-target inhibitor with a 1-isopropyl-1<i>H</i>-pyrazole head region, which projects up into the P-loop, and its 2-aminopyrimidine scaffold, was the key hydrogen acceptor/donor, which could interact with the residues of the JAK hinge region as a hinge binder.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Interestingly, it also showed excellent TYK2 activity (IC<sub>50</sub> value of 2 nM). Apparently, achieving an appropriate balance of selective inhibition in the JAK family is still an opportunity and challenge for drug development, because of the high sequence homology within the catalytic loop and the similarity of the ATP binding pocket.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Therefore, we retained the 5-methylpyrimidin-2-amine scaffold as the vital hinge binder and the 1-isopropyl-1<i>H</i>-pyrazol-4-yl group was chosen as a bridge point to the P-loop to find a more suitable and safer TYK2 inhibitor for the treatment of immune diseases instead of hematologic neoplasms, avoiding the adverse events of other off-target kinases.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Initial Structure Design Strategy</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0013.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">IC<sub>50</sub><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">JAK1</th><th class="colsep0 rowsep0" align="center">JAK2</th><th class="colsep0 rowsep0" align="center" char=".">JAK3</th><th class="colsep0 rowsep0" align="center" char=".">TYK2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="left">0.7</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="char" char=".">41</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="char" char=".">688</td><td class="colsep0 rowsep0" align="char" char=".">13</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values were determined from KinaseProfiler of Eurofins. The data are averages of two independent experiments. Assays were run at the <i>K</i><sub>m</sub> for ATP. In the KinaseProfiler assay format, the ATP <i>K</i><sub>m</sub> for JAK1, JAK2, JAK3, and TYK2 have been determined to be 45, 45, 10, and 15 μM, respectively.</p></div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86827" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86827" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Structure–Activity Relationship (SAR) Discussion</h3><div class="NLM_p">Initially, a series of <i>N</i>-substituted-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-amine derivatives were synthesized and evaluated for their JAK1–3 and TYK2 kinase activities. Fortunately, compound <b>10</b> was obtained and it preliminarily showed certain TYK2 selectivity over JAK2, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Considering that the solvent-exposed area can fine-tune the binding interaction and cyclization modification is a common strategy in drug discovery, the 3-fluoro-4-substituted phenyl group was replaced by a 1-substituted indolin-5-yl group by cyclizing compound <b>10</b> and different substituents were introduced on the N atom of the indoline ring to obtain compounds <b>11a–11s</b> for exploring the structure–activity relationship of selective TYK2 inhibitors (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Enzymatic Potencies and JAK2/TYK2 Selectivity of <b>11a–11s</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0014.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0015.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values were determined from KinaseProfiler of Eurofins. Assays were run at the <i>K</i><sub>m</sub> for ATP. The data are averages of two independent experiments.</p></div></div><div></div></div><div class="NLM_p">Compounds (<b>11d</b>, <b>11e</b>, <b>11l–11n</b>, selectivity JAK2/TYK2 > 2-fold) with hydrophobic aromatic substituents exhibited relatively good TYK2 selectivity over JAK2, which was presumably due to the poor tolerance of the JAK2 protein to these compounds. In contrast, hydrophilic substituents like thiomorpholine 1,1-dioxide (<b>11o</b>), morpholine (<b>11p</b>), proline (<b>11q</b>, <b>11r</b>), and ethane-1,2-diol (<b>11s</b>) could be easily accommodated by JAK2 (IC<sub>50</sub> < 21nM); these compounds showed good TYK2 activity but dissatisfactory selectivity. The methylated indole-2-one derivative (<b>11g</b>) was relatively hydrophobic than <b>11f</b>, and it showed decreased TYK2 potency (62.98 vs 12.32 nM) but increased JAK2 activity (12.56 vs 25.04 nM). These results suggested that the solvent-exposed region would form a JAK enzyme potency gap.</div><div class="NLM_p">To clarify the reason for the difference in selectivity, molecular docking was performed to analyze the nonconserved residues of the ATP binding sites of compound <b>11e</b> between JAK2 and TYK2. The results showed that the sulfonamide group can form a hydrogen-bonding interaction with positively charged Arg901 of the P-loop of TYK2 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). If <b>11e</b> had the same combination mode in JAK2, the oxygen atom of the sulfonamide group would form a hydrogen bond with Gln853 rather than Ser936 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). The hydrogen bond formed by the sulfonamide group with Arg901 (TYK2) or Ser936 (JAK2) may be the key factor of JAK2/TYK2 selectivity, as we all know that the molecule conformation may vary from any imperceptible changes in the structure and further affect the activity and binding capacity. That is the reason why so many structurally similar compounds in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> show different selectivities. This interesting research direction was attributed to the potential interaction of displacement. For this reason, in our endeavor to improve the selectivity for TYK2, the 4-trifluoromethylbenzenesulfonamide substituent in the structure of compound <b>11e</b> (with about 5-fold selectivity for TYK2 over JAK2) was fixed in the subsequent modification.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Docking results of <b>11e</b> in the (A) TYK2 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GJ3">4GJ3</a>) and (B) JAK2 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further evaluate the influence of activity made by different substituents around the hinge binder, compounds <b>12a–12g</b> were synthesized, and the results are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_007.pdf" class="ext-link">Table S1</a>. Changing the pyrimidine to a pyridine group (<b>12a</b> and <b>12b</b>) led to a sharp decrease in the kinase efficacy, indicating that reducing the N atoms in the skeleton would reduce the overall activity. Meanwhile, exchanging the position of the nitrogen atom (<b>12c</b>) also reduced the inhibitory effect compared to <b>11e</b>. Previous docking results revealed that the C5 position (R<sub>2</sub> substituent) of pyrimidine was close to the hydrophobic binding pockets composed of Leu903, Met978, Val911, Ser985, Leu1030, and Gly1040<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> near the hinge region of TYK2 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>); so, we further investigated the effect of other substituents of R<sub>2</sub> on the activity influences, such as fluoro (<b>12d</b>), methoxyl (<b>12e</b>), or hydro (<b>12f</b>) groups. <b>12d</b> and <b>12e</b> displayed similar lower potency of TYK2 compared to the 5-methyl substituent of pyrimidine, but both maintained %Ctrl values around 50% at 100 nM. Removing the methyl substituent of pyrimidine (<b>12f</b>) resulted in a significant loss in activity, highlighting the importance of the C5 small substituent. The activity was significantly decreased when the methyl group at R<sub>3</sub> (<b>12g</b>) indicating that the substituent near the hydrogen acceptor of pyrimidine could affect the hydrogen-bonding interaction with the hinge region. We then evaluated the metabolic stability of <b>11e</b> in vitro. Unfortunately, <b>11e</b> had a high clearance rate (Cl) of 351.8 mL/min/g and a half-life (<i>T</i><sub>1/2</sub>) of 3.94 min in human liver microsomes (HLMs). However, lipophilic fluoro substituent (<b>12d</b>) showed improved <i>T</i><sub>1/2</sub> and Cl, with 26.86 min and 51.6 mL/min/g, respectively (compounds with <i>T</i><sub>1/2</sub> > 30 min were defined here as stable in HLMs).</div><div class="NLM_p">Deepening the understanding of small molecule-specific differences between the JAKs could promote and strengthen the selectivity toward TYK2, which may be driven by the availability of JAK to specific kinase domain conformations, such as the glycine-rich P-loop.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> By analyzing the previously reported crystal structure of TYK2 with tofacitinib, its terminal cyano group formed polar interactions with the glycine-rich loop including Gly909, Lys910, and Val911, through the head region of the piperidine ring.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Additionally, the pyrazole ring was located below the P-loop, which played a similar role to the piperidine ring. Then, compounds <b>13a–13l</b> were synthesized to discuss the SAR with the P-loop, and the compounds whose TYK2 inhibition rate was greater than 50% at 100 nM were chosen to determine the IC<sub>50</sub> values (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_007.pdf" class="ext-link">S2</a>). By varying the R<sub>4</sub> moiety, we observed that compound <b>13a</b>, which has no substituent at the N1 position of the pyrazole ring, has weak activity against TYK2 that may be attributed to the unfavorable interaction with the P-loop. This result was further proved in <b>13e</b>, in which the pyrazole ring was replaced by a furan ring. Compounds <b>13c</b> and <b>13d</b> whose methyl groups were near the pyrimidine ring lost potency to the JAK family, demonstrating that the magic methyl effect was not suitable here. Later, the structure–activity relationship revealed that small and flexible substituents at the N1 position would benefit the TYK2 activity (<b>13b</b>, <b>13f</b>, <b>11e</b>, <b>13g</b>, <b>13i–13k</b> vs <b>13h</b>, <b>13l</b>). Among them, <b>13b</b> exhibited unacceptable TYK2 activity (IC<sub>50</sub> = 148 nM) and <b>13f</b> (<i>n</i>-propyl substituted) showed similar TYK2 and JAK2 activity to <b>11e</b> (isopropyl substituted). <b>13g</b> (cyclopropyl substituted) and <b>13h</b> (cyclopropanecarboxyl substituted) reduced the inhibitory ability of TYK2. Regrettably, they all had a short half-life (<i>T</i><sub>1/2</sub> < 5 min). <b>13i</b> and <b>13k</b>, another two selective JAK2/TYK2 inhibitors (13.5- and 8.97-fold, respectively), were limited by metabolism (<i>T</i><sub>1/2</sub> = 19.47 and 15.3 min, respectively). Considering that most JAK inhibitors contain cyano groups, such as tofacitinib, the aliphatic nitrile was introduced into the pyrazole and <b>13j</b> was synthesized. <b>13j</b> showed good JAK2/TYK2 selectivity (10.5-fold) with a relatively short half-life (<i>T</i><sub>1/2</sub> = 22 min).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Enzymatic Potencies and the Metabolic Stability of <b>13b</b>, <b>13f</b>, <b>13g</b>, and <b>13i–13k</b><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0016.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0017.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values were determined from KinaseProfiler of Eurofins. Assays were run at the <i>K</i><sub>m</sub> for ATP. The data are averages of two independent experiments.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">In vitro stability in cryopreserved human liver microsomes.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">NT, not tested.</p></div></div><div></div></div><div class="NLM_p">Plagued by the problem of metabolic stability and encouraged by the JAK2/TYK2 selectivity of <b>13j</b>, the cyano group was chosen for further structural modification and optimization, which was relatively robust and could not readily metabolize.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In early research, we found that compounds with a 5-F pyrimidine structure were less active on JAK2 than 5-methylpyrimidine.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Furthermore, due to the introduction of the fluorine atom at the 5-position of the pyrimidine ring, the electron cloud density of the pyrimidine ring can be reduced, and the metabolism of such a scaffold is relatively stable.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Accordingly, 5-F pyrimidine was selected as the exploration in the following optimization process. At the same time, we turned our attention to the modification of the indole ring and defined two main goals: (1) to decrease the activity on JAK2 while maintaining TYK2 and (2) to improve the metabolic stability of compounds.</div><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> (and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_007.pdf" class="ext-link">Table S3</a>), the indoline substituent (<b>14a</b>) could retain the potency against TYK2, with an extremely short <i>T</i><sub>1/2</sub> (3.2 min). In contrast, the kinase activity of isoindolin-1-one (<b>14b</b>) was equipotent with <b>14a</b>, exhibiting slightly improved metabolic stability in vitro (8-fold kinase selective over JAK2). In addition, we were curious about the cyclopropyl substituent (one of the candidate substituents of pyrazole due to its selective advantage of <b>13i</b>), whether it was appropriate for improving selectivity among isoindolin-1-one analogues. The results showed that <b>14c</b> lost the potency of TYK2 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_007.pdf" class="ext-link">Table S3</a>). Then, we reintroduced a methyl group into the 5-position of pyrimidine to adjust the conformation of compounds. However, compared with <b>14b</b>, the methyl group at the pyrimidine C5 position (<b>14d</b>) was a pan-JAK inhibitor with increased HLM clearance (178 mL/min/g), which confirmed that 5-fluoropyrimidine has a significant advantage in metabolic stability.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Enzymatic Potencies and the Metabolic Stability of Compounds <b>14a</b>, <b>14b</b>, and <b>14d–14n</b><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0018.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0019.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values were determined from KinaseProfiler of Eurofins. Assays were run at the <i>K</i><sub>m</sub> for ATP. The data are averages of two independent experiments.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">In vitro stability in cryopreserved human liver microsomes.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">NT, not tested.</p></div></div><div></div></div><div class="NLM_p last">Considering that the N1 site of indoline could be a metabolic site, the terminal amino group was terminated, assuming that the metabolic site would be blocked. So, we introduced trifluoromethyl sulfonyl, 4-(trifluoromethyl) benzenesulfonamide, and 4-(trifluoromethyl)benzamide (<b>14e–14g</b>) on the terminal amide of <b>14a</b>; all of them showed acceptable potency, but improvements in clearance were not observed (<i>T</i><sub>1/2</sub> < 20 min). Notably, the strong electron-withdrawing trifluoromethyl substituent improved the selectivity with approximately 50-fold against JAK2 (<b>14e</b>). The difference in activity of compounds <b>14g</b> and <b>14h</b> reflected the importance of terminal trifluoromethyl. Some flexible terminal substituents (<b>14i</b> and <b>14j</b>) could increase the metabolic stability but showed poor selectivity. To get rid of the dilemma caused by metabolic stability, indoline was replaced by indole and compounds <b>14k–14n</b> were synthesized to affect the molecular conformation and further improve the metabolic stability. Compared with the screening hit <b>14e</b>, <b>14l</b> showed significant improvement in metabolic stability while maintaining the TYK2 activity. In liver microsomal assay studies, the clearance rate and half-life of <b>14l</b> were 11.4 mL/min/g and 121.6 min, respectively. In addition, the substitution of indoline with indole caused loss of affinity for TYK2 and JAK2 (<b>14m</b> and <b>14n</b>) and only compound <b>14l</b> showed acceptable TYK2 inhibitory activity (IC<sub>50</sub> = 9 nM) with 17.4-fold selectivity against JAK2. This is probably because the rigid indole ring structure affected the placement of the N-substituted group and further altered the conformation of the whole molecule. The difference in activity between <b>14l</b> and <b>14o</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_007.pdf" class="ext-link">Table S3</a>) again proved the importance of the cyano substituent, which can effectively enhance the interaction between target proteins and ligands.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Binding Mode of <b>14l</b> with TYK2 by Molecular Modeling</h3><div class="NLM_p">The possible binding mode of the preferred compound <b>14l</b> with TYK2 was studied by molecular docking. The predicted binding mode in molecular docking studies is shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. The Arg901 of the TYK2 glycine-rich loop not only interacted with the oxygen atom of the trifluoromethanesulfonyl group to form a hydrogen bond but also formed a Pi-cation interaction with the indole ring. In the docking results of JAK2, the trifluoromethanesulfonyl group served as a tail toward the solvent, projected to Asp939. Comparing the electrostatic surface potentials near the ATP binding site, it could be found that there was a significant charge difference between TYK2 and JAK2.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Nonconserved residues in the ATP binding site were analyzed. The glycine-rich loop of TYK2 started with Arg901 and Asp902, while JAK2 started with Gln853 and Gln854.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The difference in the electrostatic surface potential may be the reason for preference of TYK2 binding. Meanwhile, the result elucidated that the fluorine atom of the <b>14l</b> pyrimidine skeleton penetrated deep into the hydrophobic pocket formed by the Met978 gate-keeping residues, Leu1030, Val911, Ala928, and Ile960 in TYK2. As previously envisaged, 2-aminopyrimidine formed two hydrogen-bonding interactions with the hinge region, Val981 of TYK2 and Leu932 of JAK2, respectively. The aliphatic nitrile of the N substituent of pyrazole tended to stay away from the P-loop to form a hydrogen-bonding interaction with Arg1027 in TYK2.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Predicted binding conformation of <b>14l</b> with (A) TYK2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GJ3">4GJ3</a>) and (B) JAK2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>). (C) Surface electrostatic potential of <b>14l</b> and TYK2 docking result and (D) surface electrostatic potential of<b>14l</b> and JAK2 docking result. Blue color represents the positive electrostatic potential and red the negative electrostatic potential.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Kinase Selectivity of <b>14l</b></h3><div class="NLM_p">To examine the selectivity of <b>14l</b>, we tested the compound’s inhibitory activity against human protein kinases, inflammation-related targets, and lipid kinases at a concentration of 0.1 μM in Eurofins Kinase Analysis Service (a total of 155 species; <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_007.pdf" class="ext-link">Table S4</a>). The results showed that compound <b>14l</b> had satisfactory selectivity, except for serine/threonine kinase-16 (STK16). STK16 (also known as MPSK1) is a rarely studied member of the NAK kinase family.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> It was reported that some JAK inhibitors such as baricitinib and fedratinib could inhibit the NAK family kinase due to the conserved binding modes between NAK/JAK.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> However, the undesirable influences of high affinity of JAK inhibitors with STK16 (i.e., the off-target effect) are still unknown. Meanwhile, its inhibition rate of FLT3 was only 32% at a concentration of 0.1 μM, by which we achieved our original intention to reduce off-target effects. Consequently, compound <b>14l</b> can be considered as a biochemical selective TYK2 inhibitor related to inflammation.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Kinome-wide selectivity profiling of <b>14l</b> at 0.1 μM. Green circles denote <75% inhibition. Red circles denote >75% inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Evaluation of the Inhibitory Profile of JAK/STAT Cytokine Signal Transduction Inhibitor <b>14l</b> in Human Whole Blood (HWB)</h3><div class="NLM_p">The potency of <b>14l</b> was established in total human whole blood assays of different cytokine-triggered JAK signaling complexes to phosphorylate downstream STAT, monitored by flow cytometry (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). At the same time, we measured the human plasma protein binding to correct for free-drug potency. In particular, compared with the potency against IFN-α/pSTAT3 (depending on TYK2/JAK1) (HWB IC<sub>50</sub> (free) = 91.4 (26.5) nM), <b>14l</b> showed good functional potency against IL-12/pSTAT4 (depending on JAK2/TYK2) (HWB IC<sub>50</sub> (free) = 49.9 (14.5) nM). Low functional potency in a JAK2/TYK2-dependent IL-23 was observed (HWB IC<sub>50</sub> (free) = 652.4 (189.2) nM). The cellular selectivity between IFN-α (TYK2/JAK1) and IL-27 (JAK1/JAK2) was only 12.8-fold, which was less selective compared with the kinase screening results (17.4-fold). Then, we recognized that the intracellular concentration of ATP is very different from the concentrations utilized in biochemical enzyme assays. The cellular concentration of ATP is in the 1–5 mM range, and the JAK kinase family exhibited a significantly low <i>K</i><sub>m</sub> ATP value in the biochemical preliminary screening process, which would lead to a significant loss of potency in cellular selectivity.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> However, <b>14l</b> was shown to be >1000 nM in JAK1 and JAK3 biochemical potency yet still showed a cellular potency of 467 nM in IL-21 (JAK1/JAK3 dependent). This is a significant disconnect that a TYK2-independent cellular pathway can be modulated by a compound without JAK1 or JAK3 activity. Actually, besides JAK1 and JAK3, JAK2 is also responsible for STAT3 activation to a certain extent.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> If the compound has the ability to inhibit JAK2, there is a significant decline in STAT3 activation, which may cause the compound to have a slight inhibitory effect on IL-21 HWB.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Cytokine Inhibition Profile of <b>14l</b> in Human Whole Blood</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cytokine</th><th class="colsep0 rowsep0" align="center">pSTAT</th><th class="colsep0 rowsep0" align="center">JAK signaling complex</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">Free IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IFN-α</td><td class="colsep0 rowsep0" align="left">pSTAT3</td><td class="colsep0 rowsep0" align="left">TYK2/JAK1</td><td class="colsep0 rowsep0" align="char" char=".">91.4</td><td class="colsep0 rowsep0" align="char" char=".">26.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-12</td><td class="colsep0 rowsep0" align="left">pSTAT4</td><td class="colsep0 rowsep0" align="left">JAK2/TYK2</td><td class="colsep0 rowsep0" align="char" char=".">49.9</td><td class="colsep0 rowsep0" align="char" char=".">14.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-23</td><td class="colsep0 rowsep0" align="left">pSTAT3</td><td class="colsep0 rowsep0" align="left">JAK2/TYK2</td><td class="colsep0 rowsep0" align="char" char=".">652.4</td><td class="colsep0 rowsep0" align="char" char=".">189.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-21</td><td class="colsep0 rowsep0" align="left">pSTAT3</td><td class="colsep0 rowsep0" align="left">JAK1/JAK3</td><td class="colsep0 rowsep0" align="char" char=".">1611.7</td><td class="colsep0 rowsep0" align="char" char=".">467.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-27</td><td class="colsep0 rowsep0" align="left">pSTAT3</td><td class="colsep0 rowsep0" align="left">JAK1/JAK2</td><td class="colsep0 rowsep0" align="char" char=".">1172.0</td><td class="colsep0 rowsep0" align="char" char=".">339.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">In vitro assays. All IC<sub>50</sub> values reported represent geometric mean values from at least three separate experiments.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Free IC<sub>50</sub> = HWB IC<sub>50</sub>* human plasma free fraction, and the human plasma free fraction was 0.29, measured at 2 μM compound concentration (assuming blood to plasma concentration ratio = 1).</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Immunoblotting Confirmed the Inhibition of <b>14l</b> in the JAK/STAT Signaling Pathway</h3><div class="NLM_p">The activation of JAKs is initiated by distinct cytokines, this event makes JAKs match with each other as well as STAT phosphorylation. TYK2 is involved in the JAK1/JAK2-mediated IL-6 signaling pathway or paired with JAK1 to mediate Type I interferons. To verify the effectiveness of <b>14l</b>, we tested the inhibition of STAT phosphorylation with compound concentrations in different cytokines, such as IL-4, IL-6, GM-CSF, and IFN-α, as shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. After stimulation with IL-6 and IFN-α at a concentration of 100 to 5000 nM, compound <b>14l</b> reduced JAK1/JAK2/TYK2 and JAK1/TYK2-dependent signal transduction in a dose-dependent manner and remarkably reduced IFN-α-induced phosphorylation at 10 000 nM. Furthermore, GM-CSF and IL-4 stimulated STAT5 and STAT6 phosphorylation triggered by the JAK2 homodimer and JAK1/JAK3, respectively, and <b>14l</b> exhibited a weak inhibitory effect at a concentration of 10 000 nM because the selective TYK2 inhibitor may not be sufficient to completely inhibit these types of signaling pathways.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>14l</b> inhibited IL-6-, IFN-α-, GM-CSF-, and IL-4-induced phosphorylation of STAT in vitro. (A) IL-6-activated JAK1/JAK2/TYK2-dependent STAT3 phosphorylation in TF-1 cells. (B) IFN-α-activated JAK1/TYK2-dependent STAT1 phosphorylation in H9 cells. (C) GM-CSF-activated JAK2-dependent STAT5 phosphorylation in TF-1 cells. (D) IL-4-activated JAK1/JAK3-dependent STAT6 phosphorylation in THP-1 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Pharmacokinetics</h3><div class="NLM_p">Subsequently, on the basis of TYK2 selectivity and acceptable in vitro metabolic stability, we evaluated the pharmacokinetic parameters of <b>14l</b> in rats at 5 mg/kg iv or 20 mg/kg po (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). After oral administration, the area under the concentration–time curve (AUC<sub>(0-t)</sub>) was 13.89 μg/L*h. The clearance rate (Cl) and apparent distribution volume (<i>V</i><sub>ss</sub>) were 20.55 (L/min/kg) and 6564.28 (L/kg), respectively. The low exposure and high clearance value of <b>14l</b> led to the low oral bioavailability (<i>F</i> = 11.96%) in vivo. Overall, the pharmacokinetic properties of <b>14l</b> need to be further optimized.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic Parameters of <b>14l</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PK parameters</th><th class="colsep0 rowsep0" align="center" char=".">iv</th><th class="colsep0 rowsep0" align="center">PK parameters</th><th class="colsep0 rowsep0" align="center" char=".">p.o.</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>(0-t)</sub> (μg/L*h)</td><td class="colsep0 rowsep0" align="char" char=".">29.00</td><td class="colsep0 rowsep0" align="left">AUC<sub>(0-t)</sub> (μg/L*h)</td><td class="colsep0 rowsep0" align="char" char=".">13.89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT(0-t) (h)</td><td class="colsep0 rowsep0" align="char" char=".">4.98</td><td class="colsep0 rowsep0" align="left">MRT(0-t) (h)</td><td class="colsep0 rowsep0" align="char" char=".">2.76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">5.95</td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">3.64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (L/min/kg)</td><td class="colsep0 rowsep0" align="char" char=".">1.58</td><td class="colsep0 rowsep0" align="left">Cl (L/min/kg)</td><td class="colsep0 rowsep0" align="char" char=".">20.55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="char" char=".">985.41</td><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="char" char=".">6564.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μg/L)</td><td class="colsep0 rowsep0" align="char" char=".">48.55</td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μg/L)</td><td class="colsep0 rowsep0" align="char" char=".">8.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"><i>F</i></td><td class="colsep0 rowsep0" align="char" char=".">11.96%</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Male Sprague-Dawley rats, 5 mg/kg iv (4% ethanol, 96% saline); 20 mg/kg po (0.5% DMSO, 2% EtOH, 2.5% Solutol HS 15, 95% saline).</p></div></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Evaluation of the Therapeutic Effect of <b>14l</b> in an Acute Mice Colitis Model</h3><div class="NLM_p">Targeting TYK2 to interfere with the JAK/STAT signaling pathway is an effective prospective method for the treatment of IBD.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Based on the good enzymatic selectivity of TYK2 over JAK2, the potency on the JAK/STAT signaling pathway, and the metabolic stability, we choose oral dextran sulfate sodium (DSS), one of the most commonly used mice IBD models,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> to confirm the <b>14l</b> in vivo efficacy. We used an acute mice colitis model induced by 2.5% (wt/vol) DSS in vivo to induce colonic epithelial injury and selected tofacitinib as a positive control, as shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>. On the 7th day, <b>14l</b> of different concentrations was continuously used for treatment, oral administration (p.o.), twice a day (bid.). It was observed that during the treatment, the DSS group and vehicle group mice had decreased appetite, continuous weight loss, increased disease activity index (DAI), and weak movement. After <b>14l</b> treatment, the weight loss trend of mice was relieved, body weight began to recover on day 9, and the severity of disease symptoms was reduced as evidenced by improvements in fecal occult blood and watery stools compared to the DSS-treated group. The weight recovery and DAI score of the 20 mg/kg dose group of <b>14l</b> were slightly better than those of tofacitinib at the end of the observation period on day 12 (in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A,B). At the end of the treatment period, the length of the colon was measured and corresponding pathological sections were taken, which indirectly reflected the degree of inflammation in the colon. In the normal group, the length of the colon was about 7.1 cm, and the intestinal canal was full of formed feces. In the DSS group, the intestinal mucosa was unclear and irregular, the colon shortened to 4.6 cm, and the intestinal wall was congested and swollen. The length of the colon in the 10 mg/kg dose of <b>14l</b> group was longer than that in the vehicle group (<i>p</i> < 0.05) and that in the 20 mg/kg dose of <b>14l</b> group was significantly longer (<i>p</i> < 0.001).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Therapeutic efficacy of <b>14l</b> in the acute mice colitis model. (A) Disease activity index (DAI = weight loss score + mice status + stool consistency score + bleeding score) of C57BL/6 mice treated with <b>14l</b> (10 or 20 mg/kg), oral administration (p.o.), twice a day (bid.). *<i>P</i> < 0.05; **<i>P</i> < 0.01 versus vehicle group. (B) Record of the initial weight from day 0 to day 12. *<i>P</i> < 0.05; **<i>P</i> < 0.01 versus vehicle group. (C) Gross views of the colons in the different experimental groups at the end of administration. (D) Lengths of colons in each group. <sup>#</sup><i>P</i> < 0.05; <sup>##</sup><i>P</i> < 0.01; <sup>###</sup><i>P</i> < 0.001 versus normal group. *<i>P</i> < 0.05, <sup>**</sup><i>P</i> < 0.01, <sup>***</sup><i>P</i> < 0.001 versus vehicle group, <i>n</i> = 8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From histopathological observations of the colon (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), we found obvious inflammatory infiltration, crypt damage, and detachment of part of the epithelial cells from the mucosal surface in the DSS and vehicle groups compared with the normal group. Crypt surface irregularities are still observed in 10 mg/kg <b>14l</b> group, and submucosal edemas are also observed in the tofacitinib group. However, after oral administration of 20 mg/kg <b>14l</b>, the epithelial and mucosal structures are normalized, and the recovery of crypts is better than that with tofacitinib (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). Thus, according to histological score standards (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_007.pdf" class="ext-link">Supporting Information</a>), <b>14l</b> can treat colonic inflammation and significantly improve the inflammation of mucosal infiltration, thickening, and edema (<i>P</i> < 0.05). It is reported that the signaling of the inflammatory cytokine IL-6 is believed to contribute to the development of IBD,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and the anti-inflammatory cytokine IL-10 inhibits the release of the tumor necrosis factor α (TNF-α) and is essential for maintaining gastrointestinal immune homeostasis, such as promoting epithelial regeneration, and maintaining intestinal barrier function.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Therefore, the IL-6, IL-10, and TNF-α in serum and in the colon tissues of mice were measured after treatment. The results showed (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) that after <b>14l</b> treatment of colitis, the contents of IL-6 and TNF-α in the colon tissue and serum were suppressed to a certain extent, and IL-10 secretion was also promoted. Hence, based on the in vivo evaluation, the result of the acute ulcerative colitis model in mice indicated that compound <b>14l</b> exhibited anti-inflammatory activity and had a good therapeutic effect on IBD in a dose-dependent manner.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of <b>14l</b> on histopathology in DSS-induced colitis. (A) Representative photomicrographs of colon tissue sections stained with hematoxylin and eosin (H&E) (magnifications, ×100 and ×200). Arrows indicate crypt abscess (black), inflammatory cell infiltration (white), epithelium surface erosion (blue), submucosal edema (yellow), and crypts/regeneration of crypts (green) (B). Histopathological score of each group after microscopic analysis of tissue sections. *<i>P</i> < 0.05 versus vehicle group, <i>n</i> = 8. Histopathological score = inflammation + mucosal damage + crypt damage + range of lesions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <b>14l</b> suppressed the secretion of IL-6 and TNF-α and promoted the IL-10. Levels of IL-6 (A), IL-10 (B), and TNF-α (C) in the colon tissue. Levels of IL-6 (D), IL-10 (E), and TNF-α (F) in serum. *<i>P</i> < 0.05, <sup>**</sup><i>P</i> < 0.01, <sup>***</sup><i>P</i> < 0.001 versus vehicle group, <i>n</i> = 8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Chemistry</h3><div class="NLM_p">2,4-Chloropyrimidine derivatives and a series of boric acid ester were synthesized by the Suzuki reaction, as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Then, they underwent a Buchwald–Hartwig reaction with a commercially available or synthetic aniline after reduction, such as <i>tert</i>-butyl 5-aminoindoline-1-carboxylate, as shown in <a class="ref internalNav" href="#sch2" aria-label="Schemes 2">Schemes 2</a> and <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Subsequently, HATU or diisopropylethylamine (DIEA) was used to react with carboxylic acid or acid chloride.</div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Preparation of Compound <b>16a–16u</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf), 1,4-dioxane/H<sub>2</sub>O, 98 °C, 3–4 h.</p></p></figure><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Preparation of Compounds <b>11a–11s, 12a–12g, 13a–13l, 14a</b>, and <b>14e–14j</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) di-<i>tert</i>-butyl dicarbonate, 4-dimethylaminopyridine (4-DMAP), tetrahydrofuran (THF), 60 °C, 3 h; (b) H<sub>2</sub>, Pd/C, EtOH, rt, 12 h; (c) Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 110 °C, 4 h; (d) trifluoroacetic acid (TFA), dichloromethane (DCM), rt., 4 h; (e) (i) HATU, DIEA, DMF or (ii) DIEA, DCM, 0 °C;</p></p></figure><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Preparation of Compound <b>14b–14d, 14k–14o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 110 °C, 4 h; (b) K<sub>2</sub>CO<sub>3</sub>, MeOH/H<sub>2</sub>O, 100 °C, 4 h; (c) DIEA, DCM, 0 °C; (d) NaH, dry DMF; (e) H<sub>2</sub>, Pd/C, EtOH, rt, 12 h;</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37314" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37314" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this study, we have described the biochemical enzyme process of developing a selective inhibitor of TYK2, by exploring a series of substituents in the solvent-exposed area to adjust the selectivity, and confirmed the superiority of the hinge region scaffold, gradually pulling apart the difference between the inhibitory activities of JAK2 and TYK2. Through preliminary screening, compound <b>14l</b> was discovered, which was stable in human liver microsomes. Since the ATP concentration screened by biochemical kinase was under the <i>K</i><sub>m</sub> condition, not the intracellular concentration of ATP, the selectivity of <b>14l</b> in whole blood did not match the biochemical enzyme results perfectly. In the dextran sodium sulfate-induced mice colitis model, <b>14l</b> could significantly improve the weight loss in mice, tissue inflammation, and DAI score and normalize the colonic epithelial and mucosal structures to a certain extent. Furthermore, the contents of IL-6 and TNF-α in the colon tissue and serum were suppressed, and IL-10 secretion was also promoted compared to the pan-JAK inhibitor tofacitinib. However, the weakness of pharmacokinetic properties confirms that <b>14l</b> still needs optimization. Overall, <b>14l</b> is a potential lead compound for drug discovery against TYK2 and deserves further development in autoimmune diseases.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20115" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20115" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Chemical Methods</h3><div class="NLM_p">All of the chemical solvents and reagents were purchased from commercially available sources and used directly. We performed thin layer chromatography (TLC) on 0.20 mm Silica Gel 60 F<sub>254</sub> plates (Qingdao Haiyang Chemical, China), which were visualized under UV light (254 or 365 nm). Flash column chromatography was carried out using fritted solid loaders packed with Scharlau silica gel (0.04–0.06 mm) on a Biotage FlashMaster Personal + flash chromatography. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker AVANCE 400 spectrometer (Bruker Company, Germany) using tetramethylsilane (TMS) as an internal standard and the results of chemical shifts were given in ppm (parts per million). Mass spectra were recorded on a Q-TOF Premier mass spectrometer (Micromass, Manchester, U.K.). Each compound’s purity was determined to be ≥95% with a Waters e2695 series LC system (column, Xtimate C18, 4.6 mm × 150 mm, 5 μm; mobile phase, methanol (60%)/H<sub>2</sub>O (40%); low rate, 1.0 mL/min; UV wavelength, 254–400 nM; temperature, 25 °C; injection volume, 10 μL).</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> General Method for the Preparation of Intermediates <b>16a–16u</b></h4><div class="NLM_p last">To a mixture of 2,4-chloropyrimidine derivative (1 equiv), boric acid derivatives (1.1 equiv), PdCl<sub>2</sub>(dppf) (0.1 equiv), and K<sub>2</sub>CO<sub>3</sub> (3 equiv), H<sub>2</sub>O/1,4-dioxane (1/8, v/v) was added via a syringe. The reaction mixture was heated under an argon atmosphere at 70 °C for 4 h, cooled to room temperature, concentrated under reduced pressure, and purified by counter-current chromatography and flash column chromatography to obtain the intermediates <b>16a–16u</b>; yield: 75–88%.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 2-Chloro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidine (<b>16a</b>)</h4><div class="NLM_p last"><b>16a</b> was obtained from 2,4-dichloro-5-methylpyrimidine (<b>15a</b>) and 1-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.53 (s, 1H), 8.48 (s, 1H), 8.11 (s, 1H), 4.64 (hept, <i>J</i> = 6.7 Hz, 1H), 2.42 (s, 3H), 1.47 (d, <i>J</i> = 6.7 Hz, 6H). HRMS-ESI: calcd for C<sub>11</sub>H<sub>14</sub>ClN<sub>4</sub> [M + H]<sup>+</sup> 237.0907, found: 237.0917.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 2-Chloro-5-methyl-4-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidine (<b>16b</b>)</h4><div class="NLM_p last"><b>16b</b> was obtained from 2,4-dichloro-5-methylpyrimidine (<b>15a</b>) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.52 (s, 1H), 8.48 (s, 1H), 8.09 (s, 1H), 3.94 (s, 3H), 2.40 (s, 3H). HRMS-ESI: calcd for C<sub>9</sub>H<sub>9</sub>ClKN<sub>4</sub> [M + K]<sup>+</sup> 247.0153, found: 247.0146.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 2-Chloro-5-methyl-4-(1-methyl-1<i>H</i>-pyrazol-5-yl)pyrimidine (<b>16c</b>)</h4><div class="NLM_p last"><b>16c</b> was obtained from 2,4-dichloro-5-methylpyrimidine (<b>15a</b>) and 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.83 (s, 1H), 7.53 (d, <i>J</i> = 2.0 Hz, 1H), 6.98 (d, <i>J</i> = 2.0 Hz, 1H), 4.22 (s, 3H), 2.35 (s, 3H). HRMS-ESI: calcd for C<sub>9</sub>H<sub>10</sub>ClN<sub>4</sub> [M + H]<sup>+</sup> 209.0594, found: 209.0603.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2-Chloro-5-methyl-4-(1,3,5-trimethyl-1<i>H</i>-pyrazol-4-yl)pyrimidine (<b>16d</b>)</h4><div class="NLM_p last"><b>16d</b> was obtained from 2,4-dichloro-5-methylpyrimidine (<b>15a</b>) and 1,3,5-trimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.65 (s, 1H), 3.72 (s, 3H), 2.14 (s, 3H), 2.14 (s, 3H), 2.04 (s, 3H). HRMS-ESI: calcd for C<sub>11</sub>H<sub>13</sub>ClKN<sub>4</sub> [M + K]<sup>+</sup> 275.0466, found: 275.0465.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 2-Chloro-4-(furan-3-yl)-5-methylpyrimidine (<b>16e</b>)</h4><div class="NLM_p last"><b>16e</b> was obtained from 2,4-dichloro-5-methylpyrimidine (<b>15a</b>) and 2-(furan-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.62 (s, 1H), 8.47 (t, <i>J</i> = 1.1 Hz, 1H), 7.89 (t, <i>J</i> = 1.7 Hz, 1H), 7.09 (dd, <i>J</i> = 1.9, 0.9 Hz, 1H), 2.41 (s, 3H). HRMS-ESI: calcd for C<sub>9</sub>H<sub>8</sub>ClN<sub>2</sub>O [M + H]<sup>+</sup> 195.0325, found: 195.0319.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-Chloro-5-methyl-4-(1-propyl-1<i>H</i>-pyrazol-4-yl)pyrimidine (<b>16f</b>)</h4><div class="NLM_p last"><b>16f</b> was obtained from 2,4-dichloro-5-methylpyrimidine (<b>15a</b>) and 1-propyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.51 (s, 1H), 8.50 (s, 1H), 8.11 (s, 1H), 4.19 (t, <i>J</i> = 7.0 Hz, 2H), 2.42 (s, 3H), 1.86 (p, <i>J</i> = 7.4 Hz, 2H), 0.87 (t, <i>J</i> = 7.3 Hz, 3H). HRMS-ESI: calcd for C<sub>11</sub>H<sub>14</sub>ClN<sub>4</sub> [M + H]<sup>+</sup> 237.0907, found: 237.0903.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-Chloro-4-(1-cyclopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidine (<b>16g</b>)</h4><div class="NLM_p last"><b>16g</b> was obtained from 2,4-dichloro-5-methylpyrimidine (<b>15a</b>) and 1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.53 (s, 1H), 8.49 (s, 1H), 8.08 (s, 1H), 3.88 (dq, <i>J</i> = 7.5, 3.7 Hz, 1H), 2.41 (s, 3H), 1.17–1.14 (m, 2H), 1.07–0.98 (m, 2H). HRMS-ESI: calcd for C<sub>11</sub>H<sub>12</sub>ClN<sub>4</sub> [M + H]<sup>+</sup> 235.0750, found: 235.0746.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (4-(2-Chloro-5-methylpyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)(cyclopropyl)methanone (<b>16h</b>)</h4><div class="NLM_p last"><b>16h</b> was obtained from 2,4-dichloro-5-methylpyrimidine (<b>15a</b>) and cyclopropyl(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl)methanone. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.63 (s, 1H), 8.55 (s, 1H), 8.18 (s, 1H), 3.18–3.06 (m, 1H), 2.42 (s, 3H), 1.35–1.18 (m, 4H). HRMS-ESI: calcd for C<sub>12</sub>H<sub>12</sub>ClN<sub>4</sub>O [M + H]<sup>+</sup> 263.0700, found: 263.0706.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 2-Chloro-4-(1-cyclobutyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidine (<b>16i</b>)</h4><div class="NLM_p last"><b>16i</b> was obtained from 2,4-dichloro-5-methylpyrimidine (<b>15a</b>) and 1-cyclobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.53 (s, 1H), 8.52 (s, 1H), 8.14 (s, 1H), 5.06–4.92 (m, 1H), 2.62–2.47 (m, 2H), 2.44–2.37 (m, 2H), 2.42 (s, 3H), 1.90–1.75 (m, 2H). HRMS-ESI: calcd for C<sub>12</sub>H<sub>14</sub>ClN<sub>4</sub> [M + H]<sup>+</sup> 249.0907, found: 249.0906.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 3-(4-(2-Chloro-5-methylpyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile (<b>16j</b>)</h4><div class="NLM_p last"><b>16j</b> was obtained from 2,4-dichloro-5-methylpyrimidine (<b>15a</b>) and 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.63 (s, 1H), 8.56 (s, 1H), 8.18 (s, 1H), 4.51 (t, <i>J</i> = 6.4 Hz, 2H), 3.15 (t, <i>J</i> = 6.4 Hz, 2H), 2.42 (s, 3H). HRMS-ESI: calcd for C<sub>11</sub>H<sub>11</sub>ClN<sub>5</sub> [M + H]<sup>+</sup> 248.0703, found: 248.0704.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 2-Chloro-4-(1-(1-ethoxyethyl)-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidine (<b>16k</b>)</h4><div class="NLM_p last"><b>16k</b> was obtained from 2,4-dichloro-5-methylpyrimidine (<b>15a</b>) and 1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.62 (s, 1H), 8.55 (s, 1H), 8.17 (s, 1H), 5.68 (q, <i>J</i> = 6.0 Hz, 1H), 3.48 (dq, <i>J</i> = 9.5, 7.1 Hz, 1H), 3.25 (dq, <i>J</i> = 9.7, 7.0 Hz, 1H), 2.43 (d, <i>J</i> = 0.8 Hz, 3H), 1.65 (d, <i>J</i> = 5.9 Hz, 3H), 1.07 (t, <i>J</i> = 5.8 Hz, 3H). HRMS-ESI: calcd for C<sub>12</sub>H<sub>16</sub>ClN<sub>4</sub>O [M + H]<sup>+</sup> 267.1013, found: 267.1005.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 4-(1-Benzyl-1<i>H</i>-pyrazol-4-yl)-2-chloro-5-methylpyrimidine (<b>16l</b>)</h4><div class="NLM_p last"><b>16l</b> was obtained from 2,4-dichloro-5-methylpyrimidine (<b>15a</b>) and 1-benzyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.67 (s, 1H), 8.54 (s, 1H), 8.14 (s, 1H), 7.40–7.27 (m, 5H), 5.44 (s, 2H), 2.41 (s, 3H). HRMS-ESI: calcd for C<sub>15</sub>H<sub>14</sub>ClN<sub>4</sub> [M + H]<sup>+</sup> 285.0907, found: 285.0901.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 3-(4-(2-Chloro-5-fluoropyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile (<b>16m</b>)</h4><div class="NLM_p last"><b>16m</b> was obtained from 2,4-dichloro-5-fluoropyrimidine (<b>15b</b>) and 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.82 (d, <i>J</i> = 2.8 Hz, 1H), 8.71 (d, <i>J</i> = 1.7 Hz, 1H), 8.20 (d, <i>J</i> = 1.6 Hz, 1H), 4.54 (t, <i>J</i> = 6.4 Hz, 2H), 3.16 (t, <i>J</i> = 6.4 Hz, 2H). HRMS-ESI: calcd for C<sub>10</sub>H<sub>7</sub>ClFN<sub>5</sub>Na [M + Na]<sup>+</sup> 274.0272, found: 274.0271.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 2-Chloro-4-(1-cyclobutyl-1<i>H</i>-pyrazol-4-yl)-5-fluoropyrimidine (<b>16n</b>)</h4><div class="NLM_p last"><b>16n</b> was obtained from 2,4-dichloro-5-fluoropyrimidine (<b>15b</b>) and 1-cyclobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.78 (d, <i>J</i> = 2.8 Hz, 1H), 8.58 (d, <i>J</i> = 1.7 Hz, 1H), 8.14 (d, <i>J</i> = 1.7 Hz, 1H), 4.99 (p, <i>J</i> = 8.4 Hz, 1H), 2.61–2.46 (m, 2H), 2.46–2.34 (m, 2H), 1.89–1.74 (m, 2H). HRMS-ESI: calcd for C<sub>11</sub>H<sub>11</sub>ClFN<sub>4</sub> [M + H]<sup>+</sup> 253.0656, found: 253.0666.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2-Chloro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyridine (<b>16o</b>)</h4><div class="NLM_p last"><b>16o</b> was obtained from 4-bromo-2-chloro-5-methylpyridine (<b>15c</b>) and 1-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.35 (s, 1H), 8.23 (s, 1H), 7.98 (s, 1H), 7.61 (s, 1H), 4.57 (hept, <i>J</i> = 6.8 Hz, 1H), 2.39 (s, 3H), 1.47 (d, <i>J</i> = 6.7 Hz, 6H). HRMS-ESI: calcd for C<sub>12</sub>H<sub>15</sub>ClN<sub>3</sub> [M + H]<sup>+</sup> 236.0955, found: 236.0956.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 6-Chloro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-<i>N</i>-methylnicotinamide (<b>16p</b>)</h4><div class="NLM_p last">4,6-Dichloronicotinic acid (5.0 g, 1.0 equiv, 0.026 mol) was dissolved in DCM and a single drop of DMF, and oxalyl chloride (6.7 mL, 3.0 equiv) was added at 0 °C subsequently over 5 min. The reaction mixture was stirred at 0 °C for 4 h and then concentrated under reduced pressure to obtain a brown oil. The oil was dissolved in DCM and then added to methylamine (30% in ethanol) to prepare 4,6-dichloro-<i>N</i>-methylnicotinamide (<b>15d</b>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.67 (s, 1H), 8.47 (s, 1H), 7.89 (s, 1H), 2.78 (d, <i>J</i> = 4.6 Hz, 3H). <b>16p</b> was obtained from <b>15d</b> and 1-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.49 (t, <i>J</i> = 4.5 Hz, 3H), 8.09 (s, 1H), 7.89 (s, 1H), 4.53 (hept, <i>J</i> = 6.7 Hz, 1H), 2.78 (d, <i>J</i> = 4.6 Hz, 3H), 1.46 (d, <i>J</i> = 6.6 Hz, 6H). HRMS-ESI: calcd for C<sub>13</sub>H<sub>16</sub>ClN<sub>4</sub>O [M + H]<sup>+</sup> 279.1013, found: 279.1013.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 4-Chloro-6-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidine (<b>16q</b>)</h4><div class="NLM_p last"><b>16q</b> was obtained from 4,6-dichloropyrimidine (<b>15e</b>) and 1-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.89 (d, <i>J</i> = 1.1 Hz, 1H), 8.64 (s, 1H), 8.22 (s, 1H), 7.99 (d, <i>J</i> = 1.1 Hz, 1H), 4.57 (hept, <i>J</i> = 6.7 Hz, 1H), 1.46 (d, <i>J</i> = 6.7 Hz, 6H). HRMS-ESI: calcd for C<sub>10</sub>H<sub>12</sub>ClN<sub>4</sub> [M + H]<sup>+</sup> 223.0750, found: 223.0746.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-Chloro-5-fluoro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidine (<b>16r</b>)</h4><div class="NLM_p last"><b>16r</b> was obtained from 2,4-dichloro-5-fluoropyrimidine (<b>15b</b>) and 1-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.80 (d, <i>J</i> = 2.8 Hz, 1H), 8.57 (d, <i>J</i> = 1.6 Hz, 1H), 8.12 (d, <i>J</i> = 1.8 Hz, 1H), 4.67 (hept, <i>J</i> = 6.6 Hz, 1H), 1.47 (d, <i>J</i> = 6.7 Hz, 6H). HRMS-ESI: calcd for C<sub>10</sub>H<sub>11</sub>ClFN<sub>4</sub> [M + H]<sup>+</sup> 241.0656, found: 241.0660.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-Chloro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methoxypyrimidine (<b>16s</b>)</h4><div class="NLM_p last"><b>16s</b> was obtained from 2,4-dichloro-5-methoxypyrimidine (<b>15f</b>) and 1-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.49 (s, 1H), 8.46 (s, 1H), 8.16 (s, 1H), 4.64 (hept, <i>J</i> = 6.6 Hz, 1H), 4.05 (s, 3H), 1.48 (d, <i>J</i> = 6.7 Hz, 6H). HRMS-ESI: calcd for C<sub>11</sub>H<sub>14</sub>ClN<sub>4</sub>O [M + H]<sup>+</sup> 253.0856, found: 253.0856.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 2-Chloro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidine (<b>16t</b>)</h4><div class="NLM_p last"><b>16t</b> was obtained from 2,4-dichloropyrimidine (<b>15g</b>) and 1-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.61 (d, <i>J</i> = 5.3 Hz, 1H), 8.59 (s, 1H), 8.17 (s, 1H), 7.76 (d, <i>J</i> = 5.3 Hz, 1H), 4.57 (hept, <i>J</i> = 6.7 Hz, 1H), 1.46 (d, <i>J</i> = 6.7 Hz, 6H). HRMS-ESI: calcd for C<sub>10</sub>H<sub>11</sub>ClN<sub>4</sub>Na [M + Na]<sup>+</sup> 245.0570, found: 245.0570.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2-Chloro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-6-methylpyrimidine (<b>16u</b>)</h4><div class="NLM_p last"><b>16u</b> was obtained from 2,4-dichloro-6-methylpyrimidine (<b>15h</b>) and 1-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.56 (s, 1H), 8.14 (s, 1H), 7.68 (s, 1H), 4.57 (hept, <i>J</i> = 6.7 Hz, 1H), 2.45 (s, 3H), 1.46 (d, <i>J</i> = 6.7 Hz, 6H). HRMS-ESI: calcd for C<sub>11</sub>H<sub>14</sub>ClN<sub>4</sub> [M + H]<sup>+</sup> 237.0907, found: 237.0901.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>tert</i>-Butyl 5-nitroindoline-1-carboxylate (<b>18</b>)</h4><div class="NLM_p last">5-Nitroindoline (<b>17</b>, 0.50 g, 3.0 mmol) and di-<i>tert</i>-butyl dicarbonate (0.97 g, 4.4 mmol) were dissolved in anhydrous tetrahydrofuran (10 mL) at ambient temperature. Then, 4-dimethylaminopyridine (0.054 g, 0.44 mmol) was added to the reaction mixture and stirred at 60 °C for 3 h. The mixture was extracted with ethyl acetate (3 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated in vacuo and purified by flash column chromatography to get <b>18</b> as a brown solid. Yield: 87%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.11 (dd, <i>J</i> = 8.9, 2.5 Hz, 1H), 8.09–8.04 (m, 1H), 7.74 (s, 1H), 4.02 (t, <i>J</i> = 8.8 Hz, 2H), 3.16 (t, <i>J</i> = 8.8 Hz, 2H), 1.52 (s, 9H). HRMS-ESI: calcd for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>NaO<sub>4</sub> [M + Na]<sup>+</sup> 287.1008, found: 287.1002.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>tert</i>-Butyl 5-Amino-2,3-dihydro-1<i>H</i>-indole-1-carboxylate (<b>19</b>)</h4><div class="NLM_p last"><b>18</b> (0.50 g, 1.9 mmol) was dissolved in EtOH (100 mL) and a catalytic amount of 10% Pd/C was added under a H<sub>2</sub> atmosphere. Then, the mixture was stirred at room temperature for 12 h, filtered, and concentrated in vacuo to give the title intermediate <b>19</b>. Yield: 90%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.22 (d, <i>J</i> = 127.4 Hz, 1H), 6.44 (s, 1H), 6.34 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 4.71 (s, 2H), 3.80 (t, <i>J</i> = 8.5 Hz, 2H), 2.91 (t, <i>J</i> = 8.5 Hz, 2H), 1.47 (s, 9H). HRMS-ESI: calcd for C<sub>13</sub>H<sub>18</sub>N<sub>2</sub>NaO<sub>2</sub> [M + Na]<sup>+</sup> 257.1266, found: 257.1261.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>tert</i>-Butyl 5-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)indoline-1-carboxylate (<b>20a</b>)</h4><div class="NLM_p last">2-Chloro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methyl-pyrimidine (1.0 g, 4.2 mmol, 1.0 equiv), <i>tert</i>-butyl 5-aminoindoline-1-carboxylate (1.2 g, 5.1 mmol, 1.2 equiv), Cs<sub>2</sub>CO<sub>3</sub> (2.8g, 8.4 mmol, 2.0 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (0.2 g, 0.21 mmol, 0.05 equiv), and xantphos (0.2 g, 0.42 mmol, 0.1 equiv) were allowed to react under an argon atmosphere at 100 °C for 4 h. Then, the solvent was evaporated, diluted with ethyl acetate, filtered with diatomite, and purified by flash column chromatography to get <b>19a</b> as a white solid. Yield: 70%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.20 (s, 1H), 8.32 (s, 1H), 8.25 (s, 1H), 8.07 (s, 1H), 7.72 (s, 1H), 7.60 (s, 1H), 7.50 (dd, <i>J</i> = 8.6, 2.2 Hz, 1H), 4.63 (hept, <i>J</i> = 6.6 Hz, 1H), 3.90 (t, <i>J</i> = 8.6 Hz, 2H), 3.07 (t, <i>J</i> = 8.6 Hz, 2H), 2.31 (s, 3H), 1.52 (s, 9H), 1.49 (d, <i>J</i> = 6.6 Hz, 6H). HRMS-ESI: calcd for C<sub>24</sub>H<sub>31</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 435.2508, found: 435.2507.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>tert</i>-Butyl 5-((4-(1-(2-Cyanoethyl)-1<i>H</i>-pyrazol-4-yl)-5-fluoropyrimidin-2-yl)amino)indoline-1-carboxylate (<b>20b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.48 (s, 1H), 8.51 (d, <i>J</i> = 1.9 Hz, 1H), 8.49 (d, <i>J</i> = 2.9 Hz, 1H), 8.13 (d, <i>J</i> = 1.3 Hz, 1H), 7.71–7.46 (m, 3H), 4.54 (t, <i>J</i> = 6.4 Hz, 2H), 3.90 (t, <i>J</i> = 8.6 Hz, 2H), 3.14 (t, <i>J</i> = 6.4 Hz, 2H), 3.08 (t, <i>J</i> = 8.6 Hz, 2H), 1.51 (s, 9H). HRMS-ESI: calcd for C<sub>23</sub>H<sub>25</sub>FN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 450.2054, found: 450.2058.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N</i>-(4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)indolin-5-amine (<b>21a</b>)</h4><div class="NLM_p last">TFA-mediated Boc was removed from <b>20a</b> in DCM (TFA/DCM = 1:1) at rt. for 4 h. Then, the mixture was concentrated under reduced pressure, purified with ether, and filtered to give the desired product <b>21a</b>. White solid. Yield: 35%. HRMS-ESI: calcd for C<sub>19</sub>H<sub>23</sub>N<sub>6</sub> [M + H]<sup>+</sup> 335.1984, found: 335.1982.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 1-(Ethylsulfonyl)-<i>N</i>-(4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)indolin-5-amine (<b>11a</b>)</h4><div class="NLM_p last"><b>21a</b> (100 mg, 0.3 mmol, 1 equiv) and DIEA (65 μL, 0.4 mmol, 1.3 equiv) were stirred in dichloromethane as ethanesulfonyl chloride (32 μL, 0.33 mmol, 1.1 equiv) was added dropwise. The mixture was stirred at 0 °C for 4 h. Then, water was added and the organic phase was purified to obtain <b>11a</b>. White solid. Yield: 85%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.28 (s, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 8.07 (s, 1H), 7.77 (d, <i>J</i> = 2.2 Hz, 1H), 7.55 (dd, <i>J</i> = 8.7, 2.2 Hz, 1H), 7.17 (d, <i>J</i> = 8.7 Hz, 1H), 4.62 (h, <i>J</i> = 6.6 Hz, 1H), 3.96 (t, <i>J</i> = 8.4 Hz, 2H), 3.20–3.09 (m, 4H), 2.31 (s, 3H), 1.48 (d, <i>J</i> = 6.7 Hz, 6H), 1.20 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.86, 158.93, 157.74, 139.34, 137.75, 136.07, 132.57, 129.48, 120.63, 117.98, 116.46, 116.27, 114.11, 53.81, 50.55, 42.86, 28.46, 23.04, 17.15, 7.94. HRMS-ESI: calcd for C<sub>21</sub>H<sub>27</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 427.1916, found: 427.1916.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-(4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)-1-(propylsulfonyl)indolin-5-amine (<b>11b</b>)</h4><div class="NLM_p last"><b>21a</b> and propane-1-sulfonyl chloride were used by the method of <b>11a</b> to get <b>11b</b>. White solid. Yield: 85%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.28 (s, 1H), 8.33 (s, 1H), 8.26 (s, 1H), 8.08 (d, <i>J</i> = 1.8 Hz, 1H), 7.77 (d, <i>J</i> = 2.1 Hz, 1H), 7.55 (dd, <i>J</i> = 8.6, 1.8 Hz, 1H), 7.17 (d, <i>J</i> = 8.7 Hz, 1H), 4.63 (p, <i>J</i> = 6.6 Hz, 1H), 3.95 (t, <i>J</i> = 8.4 Hz, 2H), 3.17–3.01 (m, 4H), 2.30 (d, <i>J</i> = 2.9 Hz, 3H), 1.69 (h, <i>J</i> = 7.4 Hz, 2H), 1.48 (dd, <i>J</i> = 6.7, 1.8 Hz, 6H), 0.95 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.87, 158.93, 157.75, 139.34, 137.77, 136.02, 132.62, 129.49, 120.62, 117.98, 116.47, 116.27, 114.15, 53.81, 50.46, 49.54, 28.44, 23.04, 17.15, 16.85, 13.22. HRMS-ESI: calcd for C<sub>22</sub>H<sub>29</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 441.2073, found: 441.2072.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 1-(Cyclopropylsulfonyl)-<i>N</i>-(4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)indolin-5-amine (<b>11c</b>)</h4><div class="NLM_p last"><b>21a</b> and cyclopropanesulfonyl chloride were used by the method of <b>11a</b> to get <b>11c</b>. White solid. Yield: 85%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.30 (s, 1H), 8.33 (s, 1H), 8.26 (s, 1H), 8.08 (s, 1H), 7.80 (s, 1H), 7.55 (d, <i>J</i> = 8.9 Hz, 1H), 7.21 (d, <i>J</i> = 8.7 Hz, 1H), 4.63 (p, <i>J</i> = 6.7 Hz, 1H), 3.98 (t, <i>J</i> = 8.3 Hz, 2H), 3.13 (s, 2H), 2.31 (s, 3H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H), 1.27–1.16 (m, 1H), 1.02–0.95 (m, 2H), 0.97–0.86 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.87, 158.93, 157.75, 139.34, 137.99, 136.04, 133.17, 129.48, 120.63, 117.94, 116.49, 116.11, 115.01, 53.82, 50.92, 28.76, 26.22, 23.04, 17.16, 4.41. HRMS-ESI: calcd for C<sub>22</sub>H<sub>26</sub>N<sub>6</sub>NaO<sub>2</sub>S [M + Na]<sup>+</sup> 461.1736, found: 461.1741.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> <i>N</i>-(4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)-1-((4-methoxyphen-yl)sulfonyl)indolin-5-amine (<b>11d</b>)</h4><div class="NLM_p last"><b>21a</b> and 4-methoxybenzenesulfonyl chloride were used by the method of <b>11a</b> to get <b>11d</b>. White solid. Yield: 90%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.30 (s, 1H), 8.31 (s, 1H), 8.25 (s, 1H), 8.07 (s, 1H), 7.75–7.65 (m, 3H), 7.60 (dd, <i>J</i> = 8.7, 2.3 Hz, 1H), 7.42 (d, <i>J</i> = 8.7 Hz, 1H), 7.06 (d, <i>J</i> = 8.9 Hz, 2H), 4.63 (hept, <i>J</i> = 6.5 Hz, 1H), 3.86 (t, <i>J</i> = 8.2 Hz, 2H), 3.78 (s, 3H), 2.83 (t, <i>J</i> = 8.2 Hz, 2H), 2.30 (s, 3H), 1.48 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.52, 159.84, 158.85, 157.74, 139.34, 138.20, 135.39, 133.22, 129.91, 129.50, 128.10, 120.58, 117.84, 116.55, 115.82, 115.39, 114.97, 56.11, 53.81, 50.58, 28.18, 23.03, 17.15. HRMS-ESI: calcd for C<sub>26</sub>H<sub>29</sub>N<sub>6</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 505.2022, found: 505.1999.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-(4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)-1-((4-(trifluorometh-yl)phenyl)sulfonyl)indolin-5-amine (<b>11e</b>)</h4><div class="NLM_p last"><b>21a</b> and 4-(trifluoromethyl) benzenesulfonyl chloride were used by the method of <b>11a</b> to get <b>11e</b>. White solid. Yield: 90%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.34 (s, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 8.08 (s, 1H), 8.02 (d, <i>J</i> = 8.3 Hz, 2H), 7.95 (d, <i>J</i> = 8.3 Hz, 2H), 7.71 (d, <i>J</i> = 2.4 Hz, 1H), 7.64 (d, <i>J</i> = 8.7 Hz, 1H), 7.45 (d, <i>J</i> = 8.8 Hz, 1H), 4.63 (p, <i>J</i> = 6.6 Hz, 1H), 3.96 (t, <i>J</i> = 8.3 Hz, 2H), 2.87 (t, <i>J</i> = 8.2 Hz, 2H), 2.31 (s, 3H), 1.48 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.82, 158.81, 157.75, 140.49, 139.35, 138.64, 134.51, 133.75, 133.42, 133.29, 129.47, 128.63, 127.05, 127.01, 122.42, 120.57, 117.88, 116.64, 115.85, 115.29, 53.81, 50.75, 28.14, 22.99, 17.15. HRMS-ESI: calcd for C<sub>26</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 543.1790, found: 543.1791.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 5-((5-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)indolin-1-yl)sulfonyl)indolin-2-one (<b>11f</b>)</h4><div class="NLM_p last"><b>21a</b> and 2-oxoindoline-5-sulfonyl chloride were used by the method of <b>11a</b> to get <b>11f</b>. White solid. Yield: 90%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.76 (s, 1H), 9.28 (s, 1H), 8.31 (s, 1H), 8.25 (s, 1H), 8.06 (s, 1H), 7.66 (s, 1H), 7.63–7.61 (m, 2H), 7.59–7.54 (m, 1H), 7.38 (d, <i>J</i> = 8.8 Hz, 1H), 6.90 (d, <i>J</i> = 8.7 Hz, 1H), 4.62 (p, <i>J</i> = 6.6 Hz, 1H), 3.87 (t, <i>J</i> = 8.2 Hz, 2H), 3.52 (s, 2H), 2.87 (t, <i>J</i> = 8.3 Hz, 2H), 2.30 (s, 3H), 1.47 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.82, 159.84, 158.84, 157.73, 148.99, 139.34, 138.02, 135.43, 133.05, 129.50, 128.78, 128.68, 127.34, 123.88, 120.57, 117.88, 116.52, 115.91, 115.04, 109.51, 53.81, 50.57, 36.04, 28.15, 23.04, 17.16. HRMS-ESI: calcd for C<sub>27</sub>H<sub>28</sub>N<sub>7</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 530.1974, found: 530.1971.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 5-((5-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)indolin-1-yl)sulfonyl)-1-methylindolin-2-one (<b>11g</b>)</h4><div class="NLM_p last"><b>21a</b> and 1-methyl-2-oxoindoline-5-sulfonyl chloride were used by the method of <b>11a</b> to get <b>11g</b>. White solid. Yield: 90%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.28 (s, 1H), 8.31 (s, 1H), 8.24 (s, 1H), 8.05 (s, 1H), 7.77–7.63 (m, 3H), 7.57 (dd, <i>J</i> = 8.7, 2.2 Hz, 1H), 7.40 (d, <i>J</i> = 8.7 Hz, 1H), 7.08 (d, <i>J</i> = 8.3 Hz, 1H), 4.65–4.56 (m, 1H), 3.89 (t, <i>J</i> = 8.3 Hz, 2H), 3.59 (s, 2H), 3.09 (s, 3H), 2.86 (t, <i>J</i> = 8.3 Hz, 2H), 2.30 (d, <i>J</i> = 4.5 Hz, 3H), 1.47 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 174.94, 159.79, 158.83, 157.75, 150.05, 139.34, 138.04, 135.42, 133.08, 129.50, 129.30, 128.66, 126.30, 123.46, 120.56, 117.97, 116.53, 115.99, 115.13, 108.72, 53.81, 50.61, 35.40, 28.16, 26.52, 23.03, 17.14. HRMS-ESI: calcd for C<sub>28</sub>H<sub>29</sub>N<sub>7</sub>NaO<sub>3</sub>S [M + Na]<sup>+</sup> 566.1950, found: 566.1957.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 1-(5-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)indolin-1-yl)ethan-1-one (<b>11h</b>)</h4><div class="NLM_p last"><b>21a</b> and acetyl chloride were used by the method of <b>11a</b> to get <b>11h</b>. White solid. Yield: 90%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.24 (s, 1H), 8.33 (s, 1H), 8.26 (s, 1H), 8.08 (s, 1H), 7.95 (d, <i>J</i> = 8.7 Hz, 1H), 7.76 (s, 1H), 7.49 (dd, <i>J</i> = 8.7, 2.2 Hz, 1H), 4.64 (p, <i>J</i> = 6.6 Hz, 1H), 4.08 (t, <i>J</i> = 8.4 Hz, 2H), 3.16 (t, <i>J</i> = 8.5 Hz, 2H), 2.31 (s, 3H), 2.14 (s, 3H), 1.49 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.02, 159.86, 158.96, 157.71, 139.32, 137.28, 137.25, 132.36, 129.46, 120.68, 117.24, 116.33, 116.16, 115.63, 53.81, 48.67, 28.13, 24.25, 23.04, 17.15. HRMS-ESI: calcd for C<sub>21</sub>H<sub>25</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 377.2090, found: 377.2083.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Cyclopropyl(5-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)indolin-1-yl)methanone (<b>11i</b>)</h4><div class="NLM_p last"><b>21a</b> and cyclopropanecarbonyl chloride were used by the method of <b>11a</b> to get <b>11i</b>. White solid. Yield: 89%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.25 (s, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 8.07 (s, 1H), 7.93 (d, <i>J</i> = 8.7 Hz, 1H), 7.77 (s, 1H), 7.48 (d, <i>J</i> = 9.1 Hz, 1H), 4.63 (hept, <i>J</i> = 6.6 Hz, 1H), 4.28 (t, <i>J</i> = 8.0 Hz, 2H), 3.19 (t, <i>J</i> = 8.3 Hz, 2H), 2.31 (s, 3H), 1.92 (s, 1H), 1.48 (d, <i>J</i> = 6.7 Hz, 6H), 0.93–0.73 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.65, 159.86, 158.96, 157.71, 139.31, 137.48, 137.22, 132.36, 129.44, 120.68, 117.20, 116.34, 115.59, 53.81, 48.19, 28.10, 23.04, 17.16, 13.43, 8.00. HRMS-ESI: calcd for C<sub>23</sub>H<sub>26</sub>N<sub>6</sub>NaO [M + Na]<sup>+</sup> 425.2066, found: 425.2063.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (2,2-Difluorocyclopropyl)(5-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin -2-yl)amino)indolin-1-yl)methanone (<b>11j</b>)</h4><div class="NLM_p last">2,2-Difluorocyclopropane-1-carboxylic acid (86 mg, 0.7 mmol, 1.2 equiv) was first activated with HATU (296 mg, 0.7 mmol, 1.2 equiv) and DIEA (214 μL, 1.3 mmol, 2.0 equiv) in <i>N</i>,<i>N</i>-dimethylformamide for 30 min, and then <b>21a</b> (213 mg, 0.64 mmol, 1.0 equiv) was added and allowed to react at room temperature for 12 h. After the reaction was completed, the reaction solution was extracted with dichloromethane and purified to obtain <b>11j</b>. White solid. Yield: 40%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.31 (s, 1H), 8.33 (s, 1H), 8.27 (s, 1H), 8.08 (s, 1H), 7.94 (d, <i>J</i> = 8.7 Hz, 1H), 7.81 (s, 1H), 7.53 (dd, <i>J</i> = 8.8, 2.2 Hz, 1H), 4.63 (hept, <i>J</i> = 6.6 Hz, 1H), 4.36 (td, <i>J</i> = 10.1, 7.0 Hz, 1H), 4.12 (td, <i>J</i> = 9.9, 6.9 Hz, 1H), 3.27–3.08 (m, 3H), 2.31 (s, 3H), 2.12–1.88 (m, 2H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.16, 159.37, 158.40, 157.24, 138.82, 137.46, 136.21, 132.23, 128.98, 120.15, 116.72, 115.99, 115.88, 115.07, 53.32, 47.89, 27.53, 26.65, 22.54, 16.66. HRMS-ESI: calcd for C<sub>23</sub>H<sub>25</sub>F<sub>2</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 439.2058, found: 439.2051.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> ((1<i>S</i>,2<i>S</i>)-2-Fluorocyclopropyl)(5-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyri-midin-2-yl)amino)indolin-1-yl)methanone (<b>11k</b>)</h4><div class="NLM_p last"><b>21a</b> and (1<i>S</i>,2<i>S</i>)-2-fluorocyclopropanecarboxylic acid were used by the method of <b>11j</b> to get <b>11k</b>. White solid. Yield: 50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.27 (s, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 8.08 (s, 1H), 7.94 (d, <i>J</i> = 8.7 Hz, 1H), 7.79 (s, 1H), 7.51 (d, <i>J</i> = 9.1 Hz, 1H), 5.14–4.89 (m, 1H), 4.63 (p, <i>J</i> = 6.7 Hz, 1H), 4.33 (q, <i>J</i> = 9.5 Hz, 1H), 4.20 (q, <i>J</i> = 9.3 Hz, 1H), 3.21 (s, 2H), 2.31 (s, 3H), 2.22 (p, <i>J</i> = 7.0 Hz, 1H), 1.73–1.58 (m, 1H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H), 1.18–1.00 (m, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ163.40, 159.37, 158.44, 157.22, 138.81, 137.01, 136.73, 131.94, 128.97, 120.17, 116.72, 115.89, 115.74, 115.10, 72.98, 70.76, 53.31, 47.56, 27.55, 22.54, 21.67, 21.55, 16.66. HRMS-ESI: calcd for C<sub>23</sub>H<sub>26</sub>FN<sub>6</sub>O [M + H]<sup>+</sup> 421.2152, found: 421.2143.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (2-Fluoro-5-(trifluoromethyl)phenyl)(5-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-meth-ylpyrimidin-2-yl)amino)indolin-1-yl)methanone (<b>11l</b>)</h4><div class="NLM_p last"><b>21a</b> and 2-fluoro-5-(trifluoromethyl)benzoyl chloride were used by the method of <b>11a</b> to get <b>11l</b>. White solid. Yield: 70%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.39 (s, 1H), 8.33 (s, 1H), 8.27 (s, 1H), 8.09 (d, <i>J</i> = 5.1 Hz, 1H), 8.08–7.99 (m, 2H), 7.98–7.90 (m, 1H), 7.85 (s, 1H), 7.68–7.57 (m, 2H), 4.68–4.56 (m, <i>J</i> = 6.5 Hz, 1H), 3.87 (t, <i>J</i> = 8.2 Hz, 2H), 3.14 (t, <i>J</i> = 8.2 Hz, 2H), 2.31 (s, 3H), 1.48 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.28, 159.86, 158.88, 157.75, 139.35, 138.69, 136.11, 133.49, 129.57, 129.47, 127.00, 126.94, 126.81, 126.58, 126.26, 126.23, 125.38, 122.67, 120.65, 118.10, 117.87, 117.20, 117.02, 116.60, 115.49, 53.82, 49.65, 28.28, 23.00, 17.15. HRMS-ESI: calcd for C<sub>27</sub>H<sub>25</sub>F<sub>4</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 525.2026, found: 525.2055.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (5-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)indolin-1-yl) (3-(trifluoromethyl)phenyl)methanone (<b>11m</b>)</h4><div class="NLM_p last"><b>21a</b> and 3-(trifluoromethyl) benzoyl chloride were used by the method of <b>11a</b> to get <b>11m</b>. White solid. Yield: 70%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.34 (s, 1H), 8.32 (s, 1H), 8.27 (s, 1H), 8.08 (s, 1H), 8.06–8.00 (m, 1H), 7.97–7.85 (m, 3H), 7.83 (s, 1H), 7.73 (t, <i>J</i> = 7.8 Hz, 1H), 7.62 (s, 1H), 4.62 (hept, <i>J</i> = 6.7 Hz, 1H), 4.01 (q, <i>J</i> = 10.5, 8.8 Hz, 2H), 3.11 (t, <i>J</i> = 8.2 Hz, 2H), 2.31 (s, 3H), 1.47 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.12, 159.87, 158.90, 157.74, 139.33, 138.75, 138.30, 133.42, 131.44, 130.13, 129.45, 126.94, 125.74, 124.22, 123.04, 120.66, 117.37, 117.10, 116.55, 115.44, 53.83, 50.95, 28.64, 23.01, 17.15. HRMS-ESI: calcd for C<sub>27</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 507.2120, found: 507.2151.</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 1-(5-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)indolin-1-yl)-2-(3-(trifluoromethoxy)phenyl)ethan-1-one (<b>11n</b>)</h4><div class="NLM_p last"><b>21a</b> and 2-(4-(trifluoromethoxy)phenyl)acetyl chloride were used by the method of <b>11a</b> to get <b>11n</b>. White solid. Yield: 67%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.27 (s, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 8.07 (s, 1H), 7.95 (d, <i>J</i> = 8.7 Hz, 1H), 7.79 (s, 1H), 7.53–7.42 (m, 2H), 7.36–7.29 (m, 2H), 7.25 (d, <i>J</i> = 8.3 Hz, 1H), 4.63 (hept, <i>J</i> = 6.6 Hz, 1H), 4.19 (t, <i>J</i> = 8.4 Hz, 2H), 3.92 (s, 2H), 3.19 (t, <i>J</i> = 8.4 Hz, 2H), 2.31 (s, 3H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.00, 159.85, 158.93, 157.73, 148.72, 139.31, 138.72, 137.54, 137.20, 132.47, 130.37, 129.47, 129.44, 122.68, 121.87, 120.67, 119.36, 117.21, 116.39, 116.35, 115.56, 53.81, 48.18, 41.58, 28.19, 23.03, 17.15. HRMS-ESI: calcd for C<sub>28</sub>H<sub>28</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 537.2226, found: 537.2230.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 2-(1,1-Dioxidothiomorpholino)-1-(5-((4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methyl-pyrimidin-2-yl)amino)indolin-1-yl)ethan-1-one (<b>11o</b>)</h4><div class="NLM_p last"><b>21a</b> and 2-(1,1-dioxidothio-morpholino)acetic acid were used by the method of <b>11j</b> to get <b>11o</b>. White solid. Yield: 50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.27 (s, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 8.07 (s, 1H), 7.97 (d, <i>J</i> = 8.7 Hz, 1H), 7.77 (d, <i>J</i> = 2.2 Hz, 1H), 7.51 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 4.66–4.54 (m, 1H), 4.16–4.07 (m, 2H), 3.55 (s, 2H), 3.21–3.06 (m, 10H), 2.31 (s, 3H), 1.49 (s, 3H), 1.47 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.48, 159.87, 158.93, 157.72, 139.32, 137.54, 137.21, 132.25, 129.46, 120.66, 117.19, 116.39, 116.32, 115.55, 59.11, 53.82, 51.18, 50.49, 47.25, 28.36, 23.05, 17.16. HRMS-ESI: calcd for C<sub>25</sub>H<sub>31</sub>N<sub>7</sub>NaO<sub>3</sub>S [M + Na]<sup>+</sup> 532.2107, found: 532.2210.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 1-(5-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)indolin-1-yl)-3-morpholinopropan-1-one (<b>11p</b>)</h4><div class="NLM_p last"><b>21a</b> and 3-morpholinopropanoic acid were used by the method of <b>11j</b> to get <b>11p</b>. White solid. Yield: 50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.26 (s, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 8.07 (s, 1H), 7.98 (d, <i>J</i> = 8.8 Hz, 1H), 7.77 (s, 1H), 7.50 (d, <i>J</i> = 8.9 Hz, 1H), 4.62 (h, <i>J</i> = 6.6 Hz, 1H), 4.10 (t, <i>J</i> = 8.5 Hz, 2H), 3.61 (s, 4H), 3.44 (s, 2H), 3.16 (t, <i>J</i> = 8.3 Hz, 2H), 2.66 (s, 4H), 2.48 (s, 2H), 2.31 (s, 3H), 1.48 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.86, 158.94, 157.71, 139.32, 137.38, 137.23, 132.40, 129.44, 120.67, 117.21, 116.37, 116.30, 115.59, 66.21, 59.15, 58.04, 53.82, 53.55, 47.92, 28.14, 23.05, 17.16. HRMS-ESI: calcd for C<sub>26</sub>H<sub>34</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 476.2774, found: 476.2773.</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (<i>R</i>)-5-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)-1-prolylindoline (<b>11q</b>)</h4><div class="NLM_p last">(<i>R</i>)-Boc-pyrrolidine-2-carboxylic acid and <b>21a</b> were used by the method of <b>11j</b>. Then, TFA-mediated Boc was removed and further purified to get <b>11q</b>. White solid. Yield: 35%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.28 (s, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 8.08 (s, 1H), 7.99 (d, <i>J</i> = 8.7 Hz, 1H), 7.79 (s, 1H), 7.51 (d, <i>J</i> = 8.8 Hz, 1H), 4.63 (p, <i>J</i> = 6.8 Hz, 1H), 4.23 (q, <i>J</i> = 9.1 Hz, 1H), 4.06 (q, <i>J</i> = 9.1 Hz, 1H), 3.86 (t, <i>J</i> = 6.9 Hz, 1H), 3.38 (q, <i>J</i> = 7.0 Hz, 1H), 3.17 (t, <i>J</i> = 8.3 Hz, 2H), 3.10–2.97 (m, 1H), 2.79–2.64 (m, 1H), 2.31 (s, 3H), 2.17–2.00 (m, 1H), 1.84–1.60 (m, 3H), 1.48 (d, <i>J</i> = 6.5 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.38, 159.85, 158.85, 157.74, 139.33, 138.48, 136.27, 132.95, 129.49, 127.79, 120.61, 117.20, 116.61, 115.48, 59.27, 53.83, 47.84, 46.18, 28.84, 28.36, 24.45, 23.02, 17.16. HRMS-ESI: calcd for C<sub>24</sub>H<sub>30</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 432.2512, found: 432.2498.</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (<i>R</i>)-1-(2-(5-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)indoline-1-carbonyl)pyrrolidine-1-carbonyl)cyclopropane-1-carbonitrile (<b>11r</b>)</h4><div class="NLM_p last"><b>11q</b> and 1-cyano-1-cyclopropanecarboxylic acid were used by the method of <b>11j</b> to get <b>11r</b>. White solid. Yield: 50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.28 (s, 1H), 8.32 (s, 1H), 8.27 (s, 1H), 8.07 (s, 1H), 7.93 (d, <i>J</i> = 8.8 Hz, 1H), 7.78 (s, 1H), 7.50 (d, <i>J</i> = 8.9 Hz, 1H), 4.74–4.56 (m, 2H), 4.30–4.06 (m, 2H), 4.00–3.81 (m, 2H), 3.19 (t, <i>J</i> = 8.4 Hz, 2H), 2.31 (s, 3H), 2.19–1.84 (m, 4H), 1.69–1.53 (m, 2H), 1.48 (d, <i>J</i> = 6.6 Hz, 6H), 1.49–1.42 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.73, 162.45, 159.88, 158.91, 157.71, 139.31, 137.72, 137.04, 132.41, 129.47, 120.67, 120.35, 117.08, 116.60, 116.42, 115.43, 60.16, 53.82, 48.60, 47.79, 28.67, 28.30, 25.22, 23.05, 17.17, 16.29, 15.80, 13.69. HRMS-ESI: calcd for C<sub>29</sub>H<sub>33</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup> 525.2726, found: 525.2726.</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> (<i>S</i>)-3-(5-((4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)indolin-1-yl)propane-1,2-diol (<b>11s</b>)</h4><div class="NLM_p last"><b>21a</b> (100 mg, 0.29 mmol, 1.0 equiv) was reacted with (<i>R</i>)-(+)-2,2-dimethyl-1,3-dioxolane-4-carboxaldehyde (72 μL, 0.58 mmol, 2.0 equiv) in acetonitrile for 30 min and then sodium triacetoxyborohydride (213 mg, 1.0 mmol, 3.5 equiv) was added and allowed to react overnight at room temperature. Then, the organic phase was concentrated to dryness and a hydrochloric acid ethanol solution was added. After the reaction was completed, the reaction solution was spin-dried, extracted with dichloromethane, and the organic phase was further purified to get <b>11s</b>. White solid. Yield: 45%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.84 (s, 1H), 8.28 (s, 1H), 8.18 (s, 1H), 8.04 (s, 1H), 7.47 (d, <i>J</i> = 2.1 Hz, 1H), 7.32 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 6.43 (d, <i>J</i> = 8.5 Hz, 1H), 4.68 (s, 1H), 4.61 (dt, <i>J</i> = 13.5, 6.7 Hz, 2H), 3.71 (s, 1H), 3.44–3.32 (m, 4H), 3.09 (dd, <i>J</i> = 13.6, 4.8 Hz, 1H), 2.94–2.83 (m, 3H), 2.28 (s, 3H), 1.47 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.79, 159.39, 157.60, 148.40, 139.28, 132.05, 129.66, 129.28, 120.83, 118.63, 117.14, 115.40, 106.79, 70.71, 64.61, 55.06, 54.09, 53.77, 29.05, 23.05, 17.10. HRMS-ESI: calcd for C<sub>22</sub>H<sub>28</sub>N<sub>6</sub>NaO<sub>2</sub> [M + Na]<sup>+</sup> 431.2171, found: 431.2164.</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 5-Nitro-1-((4-(trifluoromethyl)phenyl)sulfonyl)indoline (<b>22</b>)</h4><div class="NLM_p last"><b>17</b> and 4-(trifluoro methyl)benzenesulfonyl chloride were used by the method of <b>11a</b> to get <b>22</b>. White solid. Yield: 70%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.19–8.11 (m, 3H), 8.07 (dt, <i>J</i> = 2.5, 1.3 Hz, 1H), 8.02 (d, <i>J</i> = 8.3 Hz, 2H), 7.65 (d, <i>J</i> = 8.9 Hz, 1H), 4.12 (t, <i>J</i> = 8.6 Hz, 2H), 3.14 (t, <i>J</i> = 8.6 Hz, 2H). HRMS-ESI: calcd for C<sub>15</sub>H<sub>12</sub>F<sub>3</sub>N<sub>2</sub>O<sub>4</sub>S [M + H]<sup>+</sup> 373.0470, found: 374.0471.</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 1-((4-(Trifluoromethyl)phenyl)sulfonyl)indolin-5-amine (<b>23</b>)</h4><div class="NLM_p last"><b>22</b> was used by the method of <b>19</b> to get <b>23</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.90 (q, <i>J</i> = 8.6 Hz, 4H), 7.19 (d, <i>J</i> = 8.5 Hz, 1H), 6.42 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 6.34 (d, <i>J</i> = 2.2 Hz, 1H), 4.97 (s, 2H), 3.86 (t, <i>J</i> = 8.1 Hz, 2H), 2.57 (t, <i>J</i> = 8.1 Hz, 2H). HRMS-ESI: calcd for C<sub>15</sub>H<sub>14</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 343.0728, found: 343.0729.</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> <i>N</i>-(4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyridin-2-yl)-1-((4-(trifluoromethyl) phenyl)sulfonyl)indolin-5-amine (<b>12a</b>)</h4><div class="NLM_p last"><b>12a</b> was obtained from <b>23</b> and <b>16o</b>. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.84 (s, 1H), 8.11 (s, 1H), 8.03–7.90 (m, 5H), 7.76 (s, 1H), 7.60 (s, 1H), 7.47 (dd, <i>J</i> = 8.7, 2.2 Hz, 1H), 7.42 (d, <i>J</i> = 8.7 Hz, 1H), 6.86 (s, 1H), 4.57 (hept, <i>J</i> = 6.8 Hz, 1H), 3.94 (t, <i>J</i> = 8.2 Hz, 2H), 2.81 (t, <i>J</i> = 8.2 Hz, 2H), 2.27 (s, 3H), 1.46 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 155.06, 148.68, 141.42, 140.53, 139.87, 137.83, 133.76, 133.72, 133.55, 133.40, 128.60, 127.52, 127.06, 127.02, 126.99, 126.95, 125.14, 122.43, 120.39, 119.16, 117.09, 115.65, 114.99, 108.67, 53.67, 50.74, 28.20, 23.08, 17.83. HRMS-ESI: calcd for C<sub>27</sub>H<sub>27</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 542.1838, found: 542.1854.</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-<i>N</i>-methyl-6-((1-((4-(trifluoromethyl)phenyl)sulfonyl)indolin-5-yl)amino)nicotinamide (<b>12b</b>)</h4><div class="NLM_p last"><b>12b</b> was obtained from <b>23</b> and <b>16p</b>, White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 8.62 (d, <i>J</i> = 3.4 Hz, 2H), 8.24 (s, 1H), 8.07 (d, <i>J</i> = 8.2 Hz, 2H), 7.98 (d, <i>J</i> = 8.3 Hz, 2H), 7.86 (s, 1H), 7.54 (d, <i>J</i> = 8.6 Hz, 1H), 7.19–7.07 (m, 3H), 4.51 (hept, <i>J</i> = 6.8 Hz, 1H), 4.00 (t, <i>J</i> = 8.4 Hz, 2H), 2.94 (t, <i>J</i> = 8.3 Hz, 2H), 2.79 (d, <i>J</i> = 4.3 Hz, 3H), 1.43 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.66, 154.17, 151.73, 150.05, 140.47, 137.60, 137.38, 135.99, 134.58, 133.89, 133.57, 128.66, 127.40, 127.20, 127.16, 125.13, 122.50, 122.21, 120.22, 115.67, 110.63, 101.93, 53.69, 50.81, 27.87, 26.43, 23.04. HRMS-ESI: calcd for C<sub>28</sub>H<sub>28</sub>F<sub>3</sub>N<sub>6</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 585.1896, found: 585.1883.</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> <i>N</i>-(6-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-4-yl)-1-((4-(trifluoromethyl)phenyl)sulfonyl)indolin-5-amine (<b>12c</b>)</h4><div class="NLM_p last"><b>12c</b> was obtained from <b>23</b> and <b>16q</b>. Yellow solid. Yield: 77%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.48 (s, 1H), 8.52 (s, 1H), 8.32 (s, 1H), 8.03 (d, <i>J</i> = 8.3 Hz, 2H), 7.97 (d, <i>J</i> = 8.5 Hz, 2H), 7.95 (s, 1H), 7.58 (s, 1H), 7.46 (s, 2H), 6.85 (s, 1H), 4.56 (p, <i>J</i> = 6.6 Hz, 1H), 3.96 (t, <i>J</i> = 8.3 Hz, 2H), 2.89 (t, <i>J</i> = 8.3 Hz, 2H), 1.45 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.88, 158.63, 157.21, 140.39, 137.35, 137.24, 135.81, 133.59, 128.64, 127.80, 127.15, 127.11, 121.06, 119.51, 117.62, 115.24, 100.41, 53.83, 50.77, 28.01, 23.02. HRMS-ESI: calcd for C<sub>25</sub>H<sub>24</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 529.1634, found: 529.1631.</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> <i>N</i>-(5-Fluoro-4-(1-isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)-1-((4-(trifluoro-methyl)phenyl)sulfonyl)indolin-5-amine (<b>12d</b>)</h4><div class="NLM_p last"><b>12d</b> was obtained from <b>23</b> and <b>16r</b>. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.60 (s, 1H), 8.48 (d, <i>J</i> = 3.0 Hz, 1H), 8.38 (d, <i>J</i> = 1.9 Hz, 1H), 8.08 (s, 1H), 8.02 (d, <i>J</i> = 8.4 Hz, 2H), 7.96 (d, <i>J</i> = 8.4 Hz, 2H), 7.62 (d, <i>J</i> = 7.5 Hz, 2H), 7.46 (d, <i>J</i> = 9.3 Hz, 1H), 4.66 (p, <i>J</i> = 6.6 Hz, 1H), 3.95 (t, <i>J</i> = 8.3 Hz, 2H), 2.87 (t, <i>J</i> = 8.2 Hz, 2H), 1.47 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.79, 156.77, 150.02, 147.53, 147.10, 146.97, 146.21, 145.98, 140.42, 139.00, 138.17, 134.91, 133.76, 133.44, 133.36, 129.96, 128.65, 127.10, 127.06, 125.14, 122.43, 117.97, 115.96, 115.60, 115.54, 115.28, 53.98, 50.76, 28.09, 22.95. HRMS-ESI: calcd for C<sub>25</sub>H<sub>23</sub>F<sub>4</sub>N<sub>6</sub>NaO<sub>2</sub>S [M + Na]<sup>+</sup> 569.1359, found: 569.1350.</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> <i>N</i>-(4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-5-methoxypyrimidin-2-yl)-1-((4-(trifluoro-methyl)phenyl)sulfonyl)indolin-5-amine (<b>12e</b>)</h4><div class="NLM_p last"><b>12e</b> was obtained from <b>23</b> and <b>16s</b>. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.26 (s, 1H), 8.36 (s, 1H), 8.29 (s, 1H), 8.13 (s, 1H), 8.01 (d, <i>J</i> = 8.4 Hz, 2H), 7.95 (d, <i>J</i> = 8.4 Hz, 2H), 7.67 (d, <i>J</i> = 2.2 Hz, 1H), 7.62 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 7.43 (d, <i>J</i> = 8.7 Hz, 1H), 4.65–4.57 (m, 1H), 3.96 (t, <i>J</i> = 8.3 Hz, 2H), 3.93 (s, 3H), 2.85 (t, <i>J</i> = 8.2 Hz, 2H), 1.46 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 154.88, 148.58, 143.63, 142.65, 140.49, 139.39, 139.01, 134.18, 133.72, 133.34, 130.09, 128.64, 127.07, 127.03, 125.15, 122.44, 117.58, 117.29, 115.39, 115.22, 55.71, 53.73, 50.75, 28.16, 23.02. HRMS-ESI: calcd for C<sub>26</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 559.1739, found: 559.1736.</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> <i>N</i>-(4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)-1-((4-(trifluoromethyl)phenyl)sulfonyl)indolin-5-amine (<b>12f</b>)</h4><div class="NLM_p last"><b>12f</b> was obtained from <b>23</b> and <b>16t</b>. White solid. Yield: 70%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.54 (s, 1H), 8.48 (s, 1H), 8.41 (d, <i>J</i> = 5.2 Hz, 1H), 8.13 (s, 1H), 8.06 (d, <i>J</i> = 8.2 Hz, 2H), 7.99 (d, <i>J</i> = 8.3 Hz, 2H), 7.76–7.71 (m, 2H), 7.51 (d, <i>J</i> = 8.6 Hz, 1H), 7.11 (d, <i>J</i> = 5.1 Hz, 1H), 4.62 (hept, <i>J</i> = 6.6 Hz, 1H), 4.00 (t, <i>J</i> = 8.3 Hz, 2H), 2.92 (t, <i>J</i> = 8.2 Hz, 2H), 1.50 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.39, 159.62, 158.47, 140.43, 138.25, 138.10, 134.83, 133.75, 133.43, 133.30, 128.64, 128.46, 127.09, 125.14, 122.42, 120.98, 118.26, 116.29, 115.24, 107.79, 53.91, 50.75, 28.10, 23.00. HRMS-ESI: calcd for C<sub>25</sub>H<sub>24</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 529.1634, found: 529.1627.</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> <i>N</i>-(4-(1-Isopropyl-1<i>H</i>-pyrazol-4-yl)-6-methylpyrimidin-2-yl)-1-((4-(trifluoro-methyl)phenyl)sulfonyl)indolin-5-amine (<b>12g</b>)</h4><div class="NLM_p last"><b>12g</b> was obtained from <b>23</b> and <b>16u</b>. White solid. Yield: 77%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.43 (s, 1H), 8.40 (s, 1H), 8.06 (s, 1H), 8.02 (d, <i>J</i> = 8.3 Hz, 2H), 7.95 (d, <i>J</i> = 8.4 Hz, 2H), 7.78–7.69 (m, 2H), 7.45 (d, <i>J</i> = 8.6 Hz, 1H), 7.00 (s, 1H), 4.57 (hept, <i>J</i> = 6.7 Hz, 1H), 3.95 (t, <i>J</i> = 8.3 Hz, 2H), 2.88 (t, <i>J</i> = 8.2 Hz, 2H), 2.34 (s, 3H), 1.46 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.83, 160.28, 159.34, 140.49, 138.52, 138.01, 134.63, 133.74, 133.42, 133.29, 128.64, 128.25, 127.09, 127.05, 122.43, 121.12, 118.02, 116.09, 115.26, 106.93, 53.86, 50.74, 28.13, 24.13, 23.01. HRMS-ESI: calcd for C<sub>26</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 543.1790, found: 543.1786.</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> <i>N</i>-(5-Methyl-4-(1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)-1-((4-(trifluoromethyl)phenyl)sulfonyl)indolin-5-amine (<b>13a</b>)</h4><div class="NLM_p last"><b>13a</b> was obtained from <b>23</b> and <b>16k</b>; then, the organic phase was concentrated to dryness, and a solution of hydrochloric acid in ethanol was added and allowed to react overnight at room temperature. After the reaction was completed, the reaction solution was dried and extracted with dichloromethane and further purified to get <b>13a</b>. White solid. Yield: 45%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.22 (s, 1H), 9.27 (s, 1H), 8.23 (s, 1H), 8.19 (s, 1H), 8.08 (s, 1H), 7.94 (d, <i>J</i> = 8.3 Hz, 2H), 7.88 (d, <i>J</i> = 8.4 Hz, 2H), 7.60 (d, <i>J</i> = 9.0 Hz, 2H), 7.38 (d, <i>J</i> = 8.5 Hz, 1H), 3.88 (t, <i>J</i> = 8.3 Hz, 2H), 2.79 (t, <i>J</i> = 8.2 Hz, 2H), 2.24 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.78, 158.82, 158.06, 157.11, 140.47, 138.63, 134.50, 133.74, 133.42, 133.29, 128.64, 127.05, 120.43, 117.84, 116.83, 115.84, 115.27, 50.74, 28.13, 17.18. HRMS-ESI: calcd for C<sub>23</sub>H<sub>20</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 501.1321, found: 501.1316.</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> <i>N</i>-(5-Methyl-4-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)-1-((4-(trifluoromethyl) phenyl)sulfonyl)indolin-5-amine (<b>13b</b>)</h4><div class="NLM_p last"><b>13b</b> was obtained from <b>23</b> and <b>16b</b>. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.34 (s, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 8.05 (s, 1H), 8.01 (d, <i>J</i> = 8.3 Hz, 2H), 7.95 (d, <i>J</i> = 8.4 Hz, 2H), 7.71–7.62 (m, 2H), 7.45 (d, <i>J</i> = 8.7 Hz, 1H), 3.99 (t, <i>J</i> = 8.3 Hz, 2H), 3.94 (s, 3H), 2.86 (t, <i>J</i> = 8.2 Hz, 2H), 2.29 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.86, 158.82, 157.64, 140.48, 139.72, 138.61, 134.52, 133.74, 133.42, 133.31, 132.55, 128.64, 127.08, 127.04, 122.43, 122.97, 117.82, 116.65, 115.84, 115.32, 50.74, 28.12, 17.17. HRMS-ESI: calcd for C<sub>24</sub>H<sub>22</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 515.1477, found: 515.1474.</div></div><div id="sec4_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> <i>N</i>-(5-Methyl-4-(1-methyl-1<i>H</i>-pyrazol-5-yl)pyrimidin-2-yl)-1-((4-(trifluoromethyl) phenyl)sulfonyl)indolin-5-amine (<b>13c</b>)</h4><div class="NLM_p last"><b>13c</b> was obtained from <b>23</b> and <b>16c</b>. White solid. Yield: 78%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.55 (s, 1H), 8.45 (s, 1H), 8.01 (d, <i>J</i> = 8.3 Hz, 2H), 7.95 (d, <i>J</i> = 8.4 Hz, 2H), 7.59–7.52 (m, 3H), 7.43 (d, <i>J</i> = 8.6 Hz, 1H), 6.66 (d, <i>J</i> = 2.0 Hz, 1H), 3.96 (d, <i>J</i> = 8.2 Hz, 2H), 3.93 (s, 3H), 2.84 (t, <i>J</i> = 8.2 Hz, 2H), 2.18 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.62, 158.68, 155.96, 140.44, 138.39, 137.95, 135.10, 133.76, 133.44, 133.39, 128.64, 127.08, 127.04, 125.14, 122.43, 119.43, 118.48, 116.50, 115.25, 108.91, 50.76, 38.83, 28.05, 16.05. HRMS-ESI: calcd for C<sub>24</sub>H<sub>22</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 515.1477, found: 515.1472.</div></div><div id="sec4_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> <i>N</i>-(5-Methyl-4-(1,3,5-trimethyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)-1-((4-(trifluoro-methyl)phenyl)sulfonyl)indolin-5-amine (<b>13d</b>)</h4><div class="NLM_p last"><b>13d</b> was obtained from <b>23</b> and <b>16d</b>. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.43 (s, 1H), 8.35 (s, 1H), 7.99 (d, <i>J</i> = 8.3 Hz, 2H), 7.93 (d, <i>J</i> = 8.3 Hz, 2H), 7.61 (d, <i>J</i> = 9.2 Hz, 2H), 7.39 (d, <i>J</i> = 8.5 Hz, 1H), 3.93 (t, <i>J</i> = 8.2 Hz, 2H), 3.71 (s, 3H), 2.81 (t, <i>J</i> = 8.2 Hz, 2H), 2.14 (s, 3H), 2.05 (s, 3H), 2.00 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.70, 159.52, 158.79, 144.49, 140.45, 138.54, 137.94, 134.58, 133.73, 133.41, 133.31, 128.62, 127.01, 125.14, 122.42, 119.83, 117.83, 116.66, 115.86, 115.27, 50.73, 36.21, 28.09, 15.30, 12.87, 10.69. HRMS-ESI: calcd for C<sub>26</sub>H<sub>25</sub>F<sub>3</sub>N<sub>6</sub>NaO<sub>2</sub>S [M + Na]<sup>+</sup> 565.1609, found: 565.1609.</div></div><div id="sec4_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> <i>N</i>-(4-(Furan-3-yl)-5-methylpyrimidin-2-yl)-1-((4-(trifluoromethyl)phenyl)sulfonyl)indolin-5-amine (<b>13e</b>)</h4><div class="NLM_p last"><b>13e</b> was obtained from <b>23</b> and <b>16e</b>. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.43 (s, 1H), 8.32 (s, 2H), 8.01 (d, <i>J</i> = 8.3 Hz, 2H), 7.95 (d, <i>J</i> = 8.4 Hz, 2H), 7.84 (t, <i>J</i> = 1.7 Hz, 1H), 7.70–7.62 (m, 2H), 7.45 (d, <i>J</i> = 8.6 Hz, 1H), 7.07 (d, <i>J</i> = 1.8 Hz, 1H), 3.95 (t, <i>J</i> = 8.2 Hz, 2H), 2.86 (t, <i>J</i> = 8.2 Hz, 2H), 2.29 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.06, 158.89, 157.29, 145.08, 144.12, 140.47, 138.47, 134.66, 133.30, 128.62, 127.09, 127.05, 127.01, 126.98, 125.48, 117.95, 117.87, 115.97, 115.27, 110.69, 50.73, 28.12, 17.09. HRMS-ESI: calcd for C<sub>24</sub>H<sub>20</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 501.1208, found: 501.1206.</div></div><div id="sec4_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> <i>N</i>-(5-Methyl-4-(1-propyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)-1-((4-(trifluoromethyl) phenyl)sulfonyl)indolin-5-amine (<b>13f</b>)</h4><div class="NLM_p last"><b>13f</b> was obtained from <b>23</b> and <b>16f</b>. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.33 (s, 1H), 8.33 (s, 1H), 8.26 (s, 1H), 8.09–8.05 (m, 1H), 8.01 (d, <i>J</i> = 8.3 Hz, 2H), 7.95 (d, <i>J</i> = 8.4 Hz, 2H), 7.65 (d, <i>J</i> = 8.8 Hz, 2H), 7.44 (d, <i>J</i> = 8.5 Hz, 1H), 4.17 (t, <i>J</i> = 6.9 Hz, 2H), 3.95 (t, <i>J</i> = 8.2 Hz, 2H), 2.86 (t, <i>J</i> = 8.2 Hz, 2H), 2.29 (s, 3H), 1.84 (h, <i>J</i> = 7.2 Hz, 2H), 0.86 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.84, 158.81, 157.71, 140.47, 139.69, 138.61, 134.52, 133.74, 133.42, 133.31, 131.83, 128.63, 127.07, 127.03, 125.14, 122.42, 122.66, 117.86, 116.67, 115.85, 115.30, 53.55, 50.75, 28.12, 23.57, 17.16, 11.33. HRMS-ESI: calcd for C<sub>26</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 543.1790, found: 543.1791.</div></div><div id="sec4_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> <i>N</i>-(4-(1-Cyclopropyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)-1-((4-(trifluoro-methyl)phenyl)sulfonyl)indolin-5-amine (<b>13g</b>)</h4><div class="NLM_p last"><b>13g</b> was obtained from <b>23</b> and <b>16g</b>. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.35 (s, 1H), 8.34 (s, 1H), 8.26 (s, 1H), 8.06–7.98 (m, 3H), 7.95 (d, <i>J</i> = 8.3 Hz, 2H), 7.65 (d, <i>J</i> = 14.7 Hz, 2H), 7.45 (d, <i>J</i> = 8.7 Hz, 1H), 3.95 (t, <i>J</i> = 8.3 Hz, 2H), 3.87 (tt, <i>J</i> = 8.0, 4.1 Hz, 1H), 2.86 (t, <i>J</i> = 8.3 Hz, 2H), 2.30 (s, 3H), 1.14 (p, <i>J</i> = 4.5 Hz, 2H), 1.05–0.97 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.86, 158.80, 157.49, 140.48, 139.61, 138.58, 134.54, 133.30, 131.63, 128.64, 127.08, 127.04, 125.15, 122.81, 117.88, 116.77, 115.88, 115.28, 50.75, 33.54, 28.13, 17.09, 6.79. HRMS-ESI: calcd for C<sub>26</sub>H<sub>24</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 541.1634, found: 541.1631.</div></div><div id="sec4_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Cyclopropyl(4-(5-methyl-2-((1-((4-(trifluoromethyl)phenyl)sulfonyl)indolin-5-yl) amino)pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)methanone (<b>13h</b>)</h4><div class="NLM_p last"><b>13h</b> was obtained from <b>23</b> and <b>16h</b>. White solid. Yield: 58%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.50 (s, 1H), 8.79 (s, 1H), 8.46 (s, 1H), 8.37 (s, 1H), 8.01 (d, <i>J</i> = 8.3 Hz, 2H), 7.95 (d, <i>J</i> = 8.4 Hz, 2H), 7.63 (d, <i>J</i> = 8.8 Hz, 2H), 7.45 (d, <i>J</i> = 8.5 Hz, 1H), 3.95 (t, <i>J</i> = 8.2 Hz, 2H), 3.13 (ddd, <i>J</i> = 12.3, 7.8, 4.5 Hz, 1H), 2.87 (t, <i>J</i> = 8.2 Hz, 2H), 2.35 (s, 3H), 1.25 (dd, <i>J</i> = 8.2, 3.1 Hz, 2H), 1.22 (p, <i>J</i> = 4.5, 3.9 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.94, 160.51, 158.86, 156.04, 144.53, 140.47, 138.24, 134.82, 133.75, 133.43, 133.30, 128.86, 128.64, 127.09, 127.05, 125.14, 124.48, 118.16, 118.09, 116.16, 115.22, 50.75, 28.11, 16.67, 12.42, 11.93. HRMS-ESI: calcd for C<sub>27</sub>H<sub>24</sub>F<sub>3</sub>N<sub>6</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 569.1583, found: 569.1584.</div></div><div id="sec4_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> <i>N</i>-(4-(1-Cyclobutyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)-1-((4-(trifluoro-methyl)phenyl)sulfonyl)indolin-5-amine (<b>13i</b>)</h4><div class="NLM_p last"><b>13i</b> was obtained from <b>23</b> and <b>16i</b>. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.36 (s, 1H), 8.36 (s, 1H), 8.26 (s, 1H), 8.10 (s, 1H), 8.01 (d, <i>J</i> = 8.3 Hz, 2H), 7.95 (d, <i>J</i> = 8.4 Hz, 2H), 7.70–7.60 (m, 2H), 7.44 (d, <i>J</i> = 8.8 Hz, 1H), 4.96 (p, <i>J</i> = 8.3 Hz, 1H), 3.95 (t, <i>J</i> = 8.3 Hz, 2H), 2.86 (t, <i>J</i> = 8.3 Hz, 2H), 2.61–2.51 (m, 2H), 2.47–2.35 (m, 2H), 2.30 (s, 3H), 1.88–1.75 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.85, 158.81, 157.64, 140.49, 139.78, 138.61, 134.53, 133.74, 133.42, 133.30, 130.31, 128.63, 127.06, 127.02, 122.43, 122.79, 117.87, 116.73, 115.87, 115.29, 55.70, 55.40, 50.75, 30.39, 28.13, 17.12, 14.63. HRMS-ESI: calcd for C<sub>27</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 555.1790, found: 555.1788.</div></div><div id="sec4_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 3-(4-(5-Methyl-2-((1-((4-(trifluoromethyl)phenyl)sulfonyl)indolin-5-yl)amino)pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile (<b>13j</b>)</h4><div class="NLM_p last"><b>13j</b> was obtained from <b>23</b> and <b>16j</b>. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.38 (s, 1H), 8.46 (s, 1H), 8.28 (s, 1H), 8.14 (s, 1H), 8.02 (d, <i>J</i> = 8.3 Hz, 2H), 7.95 (d, <i>J</i> = 8.4 Hz, 2H), 7.72–7.63 (m, 2H), 7.46 (d, <i>J</i> = 8.6 Hz, 1H), 4.52 (t, <i>J</i> = 6.4 Hz, 2H), 3.95 (t, <i>J</i> = 8.3 Hz, 2H), 3.15 (t, <i>J</i> = 6.3 Hz, 2H), 2.87 (t, <i>J</i> = 8.2 Hz, 2H), 2.31 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.03, 158.83, 157.38, 140.42, 138.56, 134.56, 133.75, 133.33, 133.42, 133,33, 132.41, 128.63, 127.08, 125.14, 122.43, 121.19, 118.93, 117.84, 116.76, 115.86, 115.33, 50.74, 47.52, 28.12, 18.89, 17.12. HRMS-ESI: calcd for C<sub>26</sub>H<sub>22</sub>F<sub>3</sub>N<sub>7</sub>NaO<sub>2</sub>S [M + Na]<sup>+</sup> 576.1405, found: 576.1418.</div></div><div id="sec4_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> <i>N</i>-(4-(1-(1-Ethoxyethyl)-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)-1-((4-(trifluoro methyl)phenyl)sulfonyl)indolin-5-amine (<b>13k</b>)</h4><div class="NLM_p last"><b>13k</b> was obtained from <b>23</b> and <b>16k</b>. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.38 (s, 1H), 8.45 (s, 1H), 8.29 (s, 1H), 8.13 (s, 1H), 8.02 (d, <i>J</i> = 8.3 Hz, 2H), 7.95 (d, <i>J</i> = 8.4 Hz, 2H), 7.70 (d, <i>J</i> = 2.1 Hz, 1H), 7.65 (dd, <i>J</i> = 8.7, 2.3 Hz, 1H), 7.45 (d, <i>J</i> = 8.7 Hz, 1H), 5.67 (q, <i>J</i> = 5.9 Hz, 1H), 3.96 (t, <i>J</i> = 8.3 Hz, 2H), 3.49 (dq, <i>J</i> = 9.7, 7.0 Hz, 1H), 3.26 (dq, <i>J</i> = 9.7, 7.0 Hz, 1H), 2.87 (t, <i>J</i> = 8.2 Hz, 2H), 2.32 (s, 3H), 1.66 (d, <i>J</i> = 6.0 Hz, 3H), 1.06 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.98, 158.83, 157.51, 140.49, 139.91, 138.56, 134.57, 133.74, 133.42, 133.30, 130.03, 128.64, 127.08, 127.04, 125.14, 122.43, 121.26, 117.92, 116.91, 115.90, 115.27, 87.02, 63.64, 50.74, 28.13, 21.62, 17.07, 15.19. HRMS-ESI: calcd for C<sub>27</sub>H<sub>28</sub>F<sub>3</sub>N<sub>6</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 573.1896, found: 573.1922.</div></div><div id="sec4_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> <i>N</i>-(4-(1-Benzyl-1<i>H</i>-pyrazol-4-yl)-5-methylpyrimidin-2-yl)-1-((4-(trifluoromethyl) phenyl)sulfonyl)indolin-5-amine (<b>13l</b>)</h4><div class="NLM_p last"><b>13l</b> was obtained from <b>23</b> and <b>16l</b>. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.35 (s, 1H), 8.46 (s, 1H), 8.27 (s, 1H), 8.10 (s, 1H), 8.01 (d, <i>J</i> = 8.3 Hz, 2H), 7.95 (d, <i>J</i> = 8.5 Hz, 2H), 7.68–7.61 (m, 2H), 7.44 (d, <i>J</i> = 9.4 Hz, 1H), 7.40–7.29 (m, 5H), 5.44 (s, 2H), 3.94 (t, <i>J</i> = 8.2 Hz, 2H), 2.85 (t, <i>J</i> = 8.2 Hz, 2H), 2.30 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.95, 158.80, 157.52, 140.47, 140.16, 138.57, 137.53, 134.52, 133.74, 133,42, 133.31, 132.12, 129.06, 128.63, 128.27, 127,96, 127.09, 127.05, 125.14, 121.25, 117.81, 116.73, 115.83, 115.29, 55.54, 50.74, 28.11, 17.15. HRMS-ESI: calcd for C<sub>30</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 591.1790, found: 591.1819.</div></div><div id="sec4_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 3-(4-(5-Fluoro-2-(indolin-5-ylamino)pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propane-nitrile (<b>14a</b>)</h4><div class="NLM_p last"><b>14a</b> was obtained from <b>16m</b> and <i>tert</i>-butyl 5-aminoindoline-1-carboxylate, and then the Boc protecting group was removed and purified to obtain the compound <b>14a</b>. White solid. Yield: 50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.10 (s, 1H), 8.47 (d, <i>J</i> = 2.0 Hz, 1H), 8.41 (d, <i>J</i> = 2.9 Hz, 1H), 8.09 (s, 1H), 7.40 (d, <i>J</i> = 2.1 Hz, 1H), 7.23 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 6.47 (d, <i>J</i> = 8.3 Hz, 1H), 5.19 (s, 1H), 4.53 (t, <i>J</i> = 6.4 Hz, 2H), 3.39 (td, <i>J</i> = 8.4, 2.1 Hz, 2H), 3.13 (t, <i>J</i> = 6.4 Hz, 2H), 2.91 (t, <i>J</i> = 8.4 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.59, 156.96, 146.51, 139.91, 137.64, 137.02, 132.68, 132.38, 118.89, 117.35, 116.38, 115.70, 50.46, 47.56, 28.31, 18.97. HRMS-ESI: calcd for C<sub>18</sub>H<sub>17</sub>FN<sub>7</sub> [M + H]<sup>+</sup> 350.1529, found: 350.1529.</div></div><div id="sec4_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 3-(4-(5-Fluoro-2-((1-oxoisoindolin-5-yl)amino)pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile (<b>14b</b>)</h4><div class="NLM_p last"><b>14b</b> was obtained from <b>16m</b> and 5-aminoisoindolin-1-one. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.03 (s, 1H), 8.60 (d, <i>J</i> = 3.0 Hz, 1H), 8.57 (d, <i>J</i> = 1.9 Hz, 1H), 8.26 (s, 1H), 8.22 (s, 1H), 8.10 (d, <i>J</i> = 1.9 Hz, 1H), 7.78 (dd, <i>J</i> = 8.3, 1.9 Hz, 1H), 7.59 (d, <i>J</i> = 8.4 Hz, 1H), 4.56 (t, <i>J</i> = 6.4 Hz, 2H), 4.37 (s, 2H), 3.16 (t, <i>J</i> = 6.3 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.59, 156.61, 150.39, 147.90, 146.74, 146.59, 146.35, 145.89, 144.24, 140.02, 132.93, 132.85, 125.83, 123.71, 118.88, 118.34, 116.22, 116.16, 112.38, 47.61, 45.38, 18.95. HRMS-ESI: calcd for C<sub>18</sub>H<sub>15</sub>FN<sub>7</sub>O [M + H]<sup>+</sup> 364.1322, found: 364.1313.</div></div><div id="sec4_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 5-((4-(1-Cyclobutyl-1<i>H</i>-pyrazol-4-yl)-5-fluoropyrimidin-2-yl)amino)isoindolin-1-one (<b>14c</b>)</h4><div class="NLM_p last"><b>14c</b> was obtained from <b>16n</b> and 5-aminoisoindolin-1-one. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.73 (d, <i>J</i> = 2.6 Hz, 1H), 8.54 (d, <i>J</i> = 1.6 Hz, 1H), 8.22 (s, 1H), 7.45 (d, <i>J</i> = 8.1 Hz, 1H), 6.68 (d, <i>J</i> = 8.9 Hz, 2H), 6.05 (s, 2H), 5.02 (t, <i>J</i> = 8.4 Hz, 1H), 4.95 (s, 2H), 2.61–2.54 (m, 2H), 2.47–2.40 (m, 2H), 1.88–1.80 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.04, 154.30, 154.17, 151.64, 149.09, 147.37, 146.27, 144.10, 139.68, 131.01, 130.94, 125.61, 119.38, 115.75, 115.70, 114.61, 106.45, 55.49, 50.47, 30.32, 14.63. HRMS-ESI: calcd for C<sub>19</sub>H<sub>17</sub>FN<sub>6</sub>NaO [M + Na]<sup>+</sup> 387.1346, found: 387.1342.</div></div><div id="sec4_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 3-(4-(5-Methyl-2-((1-oxoisoindolin-5-yl)amino)pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile (<b>14d</b>)</h4><div class="NLM_p last"><b>14d</b> was obtained from <b>16j</b> and 5-aminoisoindolin-1-one. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.80 (s, 1H), 8.51 (s, 1H), 8.37 (s, 1H), 8.23 (s, 1H), 8.19 (s, 1H), 8.15 (s, 1H), 7.80 (d, <i>J</i> = 7.6 Hz, 1H), 7.57 (d, <i>J</i> = 8.3 Hz, 1H), 4.53 (t, <i>J</i> = 6.4 Hz, 2H), 4.36 (s, 2H), 3.15 (t, <i>J</i> = 6.3 Hz, 2H), 2.35 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.70, 160.10, 158.65, 157.54, 145.91, 144.66, 140.47, 132.55, 125.34, 123.65, 121.10, 118.95, 118.25, 117.65, 112.29, 47.55, 45.37, 19.03, 17.17. HRMS-ESI: calcd for C<sub>19</sub>H<sub>18</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 360.1573, found: 360.1564.</div></div><div id="sec4_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 3-(4-(5-Fluoro-2-((1-((trifluoromethyl)sulfonyl)indolin-5-yl)amino)pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile (<b>14e</b>)</h4><div class="NLM_p last"><b>14e</b> was obtained from <b>14a</b> and trifluoromethanesulfonyl chloride. White solid. Yield: 45%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.72 (s, 1H), 8.54 (dd, <i>J</i> = 5.7, 2.4 Hz, 2H), 8.17 (s, 1H), 7.78 (d, <i>J</i> = 2.1 Hz, 1H), 7.68 (dd, <i>J</i> = 8.9, 2.3 Hz, 1H), 7.28 (d, <i>J</i> = 8.9 Hz, 1H), 4.55 (t, <i>J</i> = 6.4 Hz, 2H), 4.23 (t, <i>J</i> = 8.2 Hz, 2H), 3.25 (t, <i>J</i> = 8.3 Hz, 2H), 3.15 (t, <i>J</i> = 6.4 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.78, 147.68, 146.56, 146.32, 139.94, 138.98, 133.16, 132.93, 132.83, 132.75, 118.86, 118.05, 116.29, 116.27, 116.24, 114.50, 52.25, 47.58, 28.37, 18.95. HRMS-ESI: calcd for C<sub>19</sub>H<sub>16</sub>F<sub>4</sub>N<sub>7</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 482.1022, found: 482.1015.</div></div><div id="sec4_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 3-(4-(5-Fluoro-2-((1-((4-(trifluoromethyl)phenyl)sulfonyl)indolin-5-yl)amino)pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile (<b>14f</b>)</h4><div class="NLM_p last"><b>14f</b> was obtained from <b>14a</b> and 4-(trifluoromethyl)benzenesulfonyl chloride. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.62 (s, 1H), 8.53 (d, <i>J</i> = 1.9 Hz, 1H), 8.50 (d, <i>J</i> = 2.9 Hz, 1H), 8.15 (s, 1H), 8.02 (d, <i>J</i> = 8.2 Hz, 2H), 7.96 (d, <i>J</i> = 8.2 Hz, 2H), 7.68 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 7.61 (d, <i>J</i> = 2.2 Hz, 1H), 7.48 (d, <i>J</i> = 8.7 Hz, 1H), 4.55 (t, <i>J</i> = 6.3 Hz, 2H), 3.96 (t, <i>J</i> = 8.2 Hz, 2H), 3.15 (t, <i>J</i> = 6.3 Hz, 2H), 2.89 (t, <i>J</i> = 8.3 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.82, 150.07, 147.58, 146.67, 146.50, 146.26, 140.45, 139.96, 138.11, 134.99, 133.76, 133.44, 133.38, 132.80, 132.72, 128.63, 127.11, 127.06, 125.14, 122.43, 118.86, 117.96, 116.30, 116.25, 116.01, 115.30, 50.75, 47.58, 28.08, 18.95. HRMS-ESI: calcd for C<sub>25</sub>H<sub>20</sub>F<sub>4</sub>N<sub>7</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 558.1335, found: 558.1332.</div></div><div id="sec4_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 3-(4-(5-Fluoro-2-((1-(4-(trifluoromethyl)benzoyl)indolin-5-yl)amino)pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile (<b>14g</b>)</h4><div class="NLM_p last"><b>14g</b> was obtained from <b>14a</b> and 4-(trifluoromethyl)benzoyl chloride. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.63 (s, 1H), 8.56–8.50 (m, 2H), 8.16 (s, 1H), 8.07 (d, <i>J</i> = 7.8 Hz, 1H), 7.85 (q, <i>J</i> = 8.2 Hz, 4H), 7.74 (s, 1H), 7.65 (d, <i>J</i> = 8.6 Hz, 1H), 4.55 (t, <i>J</i> = 6.4 Hz, 2H), 3.98 (s, 2H), 3.14 (dt, <i>J</i> = 12.7, 7.4 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.92, 147.58, 139.93, 132.78, 128.27, 125.96, 118.86, 117.30, 116.38, 50.88, 47.58, 28.58, 18.95. HRMS-ESI: calcd for C<sub>26</sub>H<sub>20</sub>F<sub>4</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 522.1665, found: 522.1674.</div></div><div id="sec4_1_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> 3-(4-(2-((1-(4-(<i>tert</i>-Butyl)benzoyl)indolin-5-yl)amino)-5-fluoropyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile (<b>14h</b>)</h4><div class="NLM_p last"><b>14h</b> was obtained from <b>14a</b> and <b>4-(</b><i><b>tert</b></i><b>-butyl)benzoyl chloride</b>. White solid. Yield: 50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.59 (s, 1H), 8.52 (dd, <i>J</i> = 6.9, 2.3 Hz, 2H), 8.15 (s, 1H), 7.71 (d, <i>J</i> = 2.2 Hz, 1H), 7.61–7.46 (m, 5H), 4.55 (t, <i>J</i> = 6.4 Hz, 2H), 4.02 (t, <i>J</i> = 7.9 Hz, 2H), 3.12 (dt, <i>J</i> = 21.9, 7.3 Hz, 4H), 1.32 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.85, 156.97, 156.94, 153.10, 150.04, 147.55, 146.64, 146.50, 146.25, 139.92, 139.87, 137.37, 134.86, 133.42, 132.75, 132.67, 127.34, 125.56, 118.84, 117.28, 116.42, 116.36, 115.70, 51.04, 47.58, 35.03, 31.44, 28.57, 18.96. HRMS-ESI: calcd for C<sub>29</sub>H<sub>28</sub>FN<sub>7</sub>NaO [M + Na]<sup>+</sup> 532.2237, found: 532.2237.</div></div><div id="sec4_1_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> 3-(4-(2-((1-(2-(1,1-Dioxidothiomorpholino)acetyl)indolin-5-yl)amino)-5-fluoro pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile (<b>14i</b>)</h4><div class="NLM_p last"><b>14i</b> was obtained from <b>14a</b> and 2-(1,1-dioxidothiomorpholino)acetic acid. White solid. Yield: 50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.57 (s, 1H), 8.53 (d, <i>J</i> = 1.9 Hz, 1H), 8.51 (d, <i>J</i> = 2.9 Hz, 1H), 8.15 (s, 1H), 8.01 (d, <i>J</i> = 8.7 Hz, 1H), 7.68 (s, 1H), 7.56 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 4.56 (t, <i>J</i> = 6.4 Hz, 2H), 4.11 (t, <i>J</i> = 8.4 Hz, 2H), 3.56 (s, 2H), 3.22–3.11 (m, 12H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.59, 156.96, 150.00, 147.52, 146.62, 146.50, 146.28, 139.87, 137.64, 137.02, 132.76, 132.68, 132.38, 118.89, 117.35, 116.38, 115.70, 59.07, 51.17, 50.47, 47.56, 47.24, 28.31, 18.97. HRMS-ESI: calcd for C<sub>24</sub>H<sub>25</sub>FN<sub>8</sub>NaO<sub>3</sub>S [M + Na]<sup>+</sup> 547.1652, found: 547.1662.</div></div><div id="sec4_1_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 1-(5-((4-(1-(2-Cyanoethyl)-1<i>H</i>-pyrazol-4-yl)-5-fluoropyrimidin-2-yl)amino)indoline-1-carbonyl)cyclopropane-1-carbonitrile (<b>14j</b>)</h4><div class="NLM_p last"><b>14j</b> was obtained from <b>14a</b> and 1-cyanocyclopropane-1-carboxylic acid. White solid. Yield: 65%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.63 (s, 1H), 8.53 (t, <i>J</i> = 2.8 Hz, 2H), 8.15 (s, 1H), 7.85 (d, <i>J</i> = 8.7 Hz, 1H), 7.74 (d, <i>J</i> = 2.2 Hz, 1H), 7.59 (dd, <i>J</i> = 8.7, 2.3 Hz, 1H), 4.55 (t, <i>J</i> = 6.4 Hz, 2H), 4.38 (d, <i>J</i> = 7.3 Hz, 2H), 3.27 (t, <i>J</i> = 8.0 Hz, 2H), 3.15 (t, <i>J</i> = 6.4 Hz, 2H), 1.67 (d, <i>J</i> = 5.8 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.07, 156.89, 146.51, 137.94, 132.81, 122.31, 118.88, 117.28, 116.36, 116.30, 115.59, 47.57, 18.95, 15.96, 15.13. HRMS-ESI: calcd for C<sub>23</sub>H<sub>20</sub>FN<sub>8</sub>O [M + H]<sup>+</sup> 443.1744, found: 443.1740.</div></div><div id="sec4_1_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> <i>tert</i>-Butyl 5-((4-(1-(2-cyanoethyl)-1<i>H</i>-pyrazol-4-yl)-5-fluoropyrimidin-2-yl)amino)-1<i>H</i>-indole-1-carboxylate (<b>26</b>)</h4><div class="NLM_p last"><b>26</b> was obtained from <b>16m</b> and <i>tert</i>-butyl 5-amino-1<i>H</i>-indole-1-carboxylate. White solid. Yield: 65%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.63 (s, 1H), 8.54 (dd, <i>J</i> = 5.6, 2.4 Hz, 2H), 8.17 (s, 1H), 8.13 (d, <i>J</i> = 2.2 Hz, 1H), 7.96 (d, <i>J</i> = 8.9 Hz, 1H), 7.65–7.58 (m, 2H), 6.73 (d, <i>J</i> = 3.7 Hz, 1H), 4.56 (t, <i>J</i> = 6.4 Hz, 2H), 3.15 (t, <i>J</i> = 6.4 Hz, 2H), 1.64 (s, 9H). HRMS-ESI: calcd for C<sub>23</sub>H<sub>23</sub>FN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 448.1897, found: 448.1888.</div></div><div id="sec4_1_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> 3-(4-(2-((1<i>H</i>-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propane-nitrile (<b>27</b>)</h4><div class="NLM_p last"><b>26</b> was dissolved in a mixed solvent of methanol/water (V/V = 1/3), and 3eq of potassium carbonate was added and then refluxed for 4 h. After the reaction was completed, the methanol in the reaction system was spin-dried and extracted with ethyl acetate. The organic phase was concentrated to dryness to obtain <b>27</b>. Gery solid. Yield: 70%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.91 (s, 1H), 9.31 (s, 1H), 8.52–8.41 (m, 2H), 8.14 (s, 1H), 7.97 (d, <i>J</i> = 1.9 Hz, 1H), 7.44–7.25 (m, 4H), 4.55 (t, <i>J</i> = 6.4 Hz, 2H), 3.15 (t, <i>J</i> = 6.4 Hz, 2H). HRMS-ESI: calcd for C<sub>18</sub>H<sub>15</sub>FN<sub>7</sub> [M + H]<sup>+</sup> 348.1373, found: 348.1364.</div></div><div id="sec4_1_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> 3-(4-(5-Fluoro-2-((1-methyl-1<i>H</i>-indol-5-yl)amino)pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile (<b>14k</b>)</h4><div class="NLM_p last"><b>14k</b> was obtained from <b>16m</b> and 1-methyl-1<i>H</i>-indol-5-amine. White solid. Yield: 65%. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.27–8.21 (m, 2H), 8.16 (s, 1H), 7.87 (s, 1H), 7.35–7.28 (m, 2H), 7.13 (s, 1H), 7.05 (d, <i>J</i> = 3.0 Hz, 1H), 6.46 (d, <i>J</i> = 3.0 Hz, 1H), 4.44 (t, <i>J</i> = 6.7 Hz, 2H), 3.79 (s, 3H), 2.99 (t, <i>J</i> = 6.6 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 157.39, 150.29, 147.79, 146.76, 146.63, 145.66, 145.42, 141.21, 141.16, 133.81, 131.80, 131.54, 131.46, 129.53, 128.68, 117.53, 116.62, 112.50, 109.32, 100.86, 47.87, 32.98, 19.19. HRMS-ESI: calcd for C<sub>19</sub>H<sub>16</sub>FN<sub>7</sub>Na [M + Na]<sup>+</sup> 384.1349, found: 384.1346.</div></div><div id="sec4_1_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> 3-(4-(5-Fluoro-2-((1-((trifluoromethyl)sulfonyl)-1<i>H</i>-indol-5-yl)amino)pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile (<b>14l</b>)</h4><div class="NLM_p last"><b>14l</b> was obtained from <b>27</b> and trifluoromethanesulfonyl chloride. White solid. Yield: 45%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.86 (s, 1H), 8.57 (t, <i>J</i> = 2.8 Hz, 2H), 8.27 (d, <i>J</i> = 2.0 Hz, 1H), 8.21 (s, 1H), 7.85–7.75 (m, 2H), 7.72 (d, <i>J</i> = 3.8 Hz, 1H), 7.18 (d, <i>J</i> = 3.8 Hz, 1H), 4.56 (t, <i>J</i> = 6.4 Hz, 2H), 3.16 (t, <i>J</i> = 6.4 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.87, 156.84, 150.25, 147.76, 146.75, 146.63, 146.53, 146.30, 140.06, 140.00, 138.91, 132.83, 132.75, 131.60, 129.86, 127.73, 121.29, 118.87, 118.34, 118.06, 116.33, 116.27, 113.68, 113.62, 111.11, 47.60, 18.97. HRMS-ESI: calcd for C<sub>19</sub>H<sub>14</sub>F<sub>4</sub>N<sub>7</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 480.0866, found: 480.0865.</div></div><div id="sec4_1_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> 3-(4-(5-Fluoro-2-((1-((4-(trifluoromethyl)phenyl)sulfonyl)-1<i>H</i>-indol-5-yl)amino)pyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile (<b>14m</b>)</h4><div class="NLM_p last"><b>14m</b> was obtained from <b>27</b> and 4-(trifluoromethyl)benzenesulfonyl chloride. White solid. Yield: 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.53 (s, 1H), 8.95 (d, <i>J</i> = 1.6 Hz, 1H), 8.59 (d, <i>J</i> = 2.5 Hz, 1H), 8.44 (s, 1H), 8.35 (d, <i>J</i> = 8.3 Hz, 2H), 8.10 (d, <i>J</i> = 8.4 Hz, 2H), 7.97 (d, <i>J</i> = 2.0 Hz, 1H), 7.49 (d, <i>J</i> = 8.9 Hz, 1H), 7.39 (dd, <i>J</i> = 9.5, 2.6 Hz, 2H), 6.44 (d, <i>J</i> = 3.1 Hz, 1H), 4.46 (t, <i>J</i> = 6.5 Hz, 2H), 3.02 (t, <i>J</i> = 6.5 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 157.52, 147.75, 145.39, 139.90, 135.13, 133.27, 132.28, 129.73, 129.28, 128.65, 128.17, 127.80, 126.81, 124.84, 122.07, 119.35, 116.14, 111.14, 110.04, 101.73, 51.02, 22.58. HRMS-ESI: calcd for C<sub>25</sub>H<sub>18</sub>F<sub>4</sub>N<sub>7</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 556.1179, found: 556.1176.</div></div><div id="sec4_1_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> 3-(4-(2-((1-(Cyclopropanecarbonyl)-1<i>H</i>-indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1<i>H</i>-pyrazol-1-yl)propanenitrile (<b>14n</b>)</h4><div class="NLM_p last"><b>14n</b> was obtained from <b>27</b> and cyclopropanecarbonyl chloride. Yellow solid. Yield: 85%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.53 (s, 1H), 8.81 (d, <i>J</i> = 1.8 Hz, 1H), 8.58 (d, <i>J</i> = 2.6 Hz, 1H), 8.45 (s, 1H), 7.99 (d, <i>J</i> = 2.0 Hz, 1H), 7.54–7.32 (m, 3H), 6.44 (d, <i>J</i> = 3.1 Hz, 1H), 4.47 (t, <i>J</i> = 6.5 Hz, 2H), 3.17–3.08 (m, 1H), 3.03 (t, <i>J</i> = 6.5 Hz, 2H), 1.32–1.18 (m, 4H). 13C NMR (101 MHz, CDCl<sub>3</sub>) δ 173.16, 157.40, 145.92, 143.52, 143.48, 132.93, 132.08, 129.47, 129.37, 128.33, 125.18, 122.09, 117.07, 112.40, 111.29, 102.88, 29.84, 14.26, 12.35, 12.16. HRMS-ESI: calcd for C<sub>22</sub>H<sub>18</sub>FN<sub>7</sub>NaO [M + Na]<sup>+</sup> 438.1455, found: 438.1457.</div></div><div id="sec4_1_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> <i>N</i>-(4-(1-Cyclobutyl-1<i>H</i>-pyrazol-4-yl)-5-fluoropyrimidin-2-yl)-1-((trifluoromethyl) sulfonyl)-1<i>H</i>-indol-5-amine (<b>14o</b>)</h4><div class="NLM_p last"><b>14o</b> was obtained from <b>16n</b> and 1-((trifluoromethyl)sulfonyl)-1<i>H</i>-indol-5-amine. White solid. Yield: 85%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.83 (s, 1H), 8.54 (d, <i>J</i> = 2.9 Hz, 1H), 8.46 (d, <i>J</i> = 2.0 Hz, 1H), 8.30–8.25 (m, 1H), 8.18 (d, <i>J</i> = 1.4 Hz, 1H), 7.82–7.74 (m, 2H), 7.72 (d, <i>J</i> = 3.8 Hz, 1H), 7.17 (d, <i>J</i> = 3.8 Hz, 1H), 5.03 (p, <i>J</i> = 8.3 Hz, 1H), 2.57 (qd, <i>J</i> = 9.3, 2.7 Hz, 2H), 2.49–2.37 (m, 2H), 1.83 (ddd, <i>J</i> = 10.4, 8.5, 4.6 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.86, 156.83, 150.22, 147.73, 147.07, 146.95, 146.30, 146.06, 139.45, 139.40, 138.95, 131.59, 130.84, 130.76, 129.83, 127.75, 121.30, 118.37, 118.07, 115.84, 115.78, 113.67, 113.59, 111.12, 55.46, 30.29, 14.64. HRMS-ESI: calcd for C<sub>20</sub>H<sub>16</sub>F<sub>4</sub>N<sub>6</sub>NaO<sub>2</sub>S [M + Na]<sup>+</sup> 503.0889, found: 503.0891.</div></div><div id="sec4_1_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> 5-Nitro-1-((Trifluoromethyl)sulfonyl)-1<i>H</i>-indole (<b>29</b>)</h4><div class="NLM_p last"><b>29</b> was obtained from 5-nitro-1<i>H</i>-indole (<b>28</b>). 5-nitro-1<i>H</i>-indole (<b>28</b>) was reacted with 2.0 equiv NaH under the protection of anhydrous DMF nitrogen at 0 °C for 30 min, and then trifluoromethanesulfonyl chloride was added dropwise. After the reaction was completed, the reaction mixture was quenched with water, extracted with dichloromethane, and the organic phase was concentrated to purify to obtain <b>29</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.74 (d, <i>J</i> = 2.4 Hz, 1H), 8.36 (dt, <i>J</i> = 9.2, 1.7 Hz, 1H), 8.07 (s, 1H), 8.06 (d, <i>J</i> = 4.2 Hz, 1H), 7.36 (d, <i>J</i> = 3.8 Hz, 1H). HRMS-ESI: calcd for C<sub>9</sub>H<sub>5</sub>F<sub>3</sub>N<sub>2</sub>NaO<sub>4</sub>S [M + Na]<sup>+</sup> 316.9820, found: 316.9816.</div></div><div id="sec4_1_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> 1-((Trifluoromethyl)sulfonyl)-1<i>H</i>-indol-5-amine (<b>30</b>)</h4><div class="NLM_p last"><b>30</b> was obtained from <b>29</b> by the method of <b>19</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.52 (d, <i>J</i> = 3.8 Hz, 1H), 7.48 (d, <i>J</i> = 8.8 Hz, 1H), 6.89 (d, <i>J</i> = 3.8 Hz, 1H), 6.81 (d, <i>J</i> = 2.2 Hz, 1H), 6.73 (dd, <i>J</i> = 8.9, 2.3 Hz, 1H), 5.23 (s, 2H). HRMS-ESI: calcd for C<sub>9</sub>H<sub>8</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 265.0259, found: 265.0260.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i110"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01468" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80167" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80167" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01468?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01468</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">11e_in_2XA4_JAK2 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_001.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">11e_in_4GJ3_TYK2 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">14l_in_2XA4_JAK2 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">14l_in_4GJ3_TYK2 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">jmcmar_ccc (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_005.xls" class="ext-link">XLS</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_006.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Compounds <b>12a–12g</b> with different hinge binders and their enzymatic potencies (Table S1); enzymatic potencies and the metabolic stability of compounds <b>13a–13l</b> (Table S2); enzymatic potencies and the metabolic stability of compounds <b>14a–14o</b> (Table S3); kinome-wide selectivity profiling of compound <b>14l</b> @ 0.1 μM (Table S4); <sup>1</sup>H NMR, <sup>13</sup>C NMR, and HRMS-ESI of <b>14l</b>, respectively (Figures S1–S3); purity of <b>14l</b> (Figure S4); and biological assay methods (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_007.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_001.pdb">jm0c01468_si_001.pdb (384.97 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_002.pdb">jm0c01468_si_002.pdb (536.79 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_003.pdb">jm0c01468_si_003.pdb (383.25 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_004.pdb">jm0c01468_si_004.pdb (535.37 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_005.xls">jm0c01468_si_005.xls (184.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_006.csv">jm0c01468_si_006.csv (6.67 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_007.pdf">jm0c01468_si_007.pdf (461.15 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01468" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46748" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46748" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingli Xiang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e79f8e868980b88a8e89808b8ea7948492c9828392c98489"><span class="__cf_email__" data-cfemail="7f07161e1118201216111813163f0c1c0a511a1b0a511c11">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lijuan Chen</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8076-163X" title="Orcid link">http://orcid.org/0000-0002-8076-163X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8eede6ebe0e2e7e4fbefe0bfbcbbcebfb8bda0ede1e3"><span class="__cf_email__" data-cfemail="e4878c818a888d8e91858ad5d6d1a4d5d2d7ca878b89">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chufeng Zhang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenyan Qi</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong Li</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minghai Tang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tao Yang</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kongjun Liu</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong Chen</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dexin Deng</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Biotherapy
and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>C.Z., W.Q., and Y.L. contributed equally and should be considered as co-first authors. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ACK-d7e7449-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i112">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53685" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53685" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors greatly appreciate the financial support from the National Natural Science Foundation of China (81673289 and 81527806), Post-Doctor Research Project, West China Hospital, Sichuan University (2020HXBH062), and the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University. The authors thank West China College of Pharmacy Sichuan University for providing Schrodinger software and technical support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">TYK2</td><td class="NLM_def"><p class="first last">tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">JAK1</td><td class="NLM_def"><p class="first last">janus kinase 1</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">janus kinase 2</p></td></tr><tr><td class="NLM_term">JAK3</td><td class="NLM_def"><p class="first last">janus kinase 3</p></td></tr><tr><td class="NLM_term">IBD</td><td class="NLM_def"><p class="first last">inflammatory bowel disease</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducers and activators of transcription</p></td></tr><tr><td class="NLM_term">pSTAT</td><td class="NLM_def"><p class="first last">phosphorylated signal transducers and activators of transcription</p></td></tr><tr><td class="NLM_term">DSS</td><td class="NLM_def"><p class="first last">dextran sulfate sodium</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">PE</td><td class="NLM_def"><p class="first last">petroleum ether</p></td></tr><tr><td class="NLM_term">EA</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i114">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74181" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74181" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 41 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alatab, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepanlou, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikuta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahedi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisignano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeghi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abolhassani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alipour, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almadi, M. A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almasi-Hashiani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anushiravani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arabloo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atique, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badawi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baig, A. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhala, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bijani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzì, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daryani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eftekhari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haj-Mirzaian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haj-Mirzaian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasanzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashemian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Househ, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilesanmi, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafari Balalami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kengne, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malekzadeh, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meretoja, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestrovic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirrakhimov, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzaei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammad, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokdad, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monasta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negoi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourshams, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poustchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramezanzadeh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawaf, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawaf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezaei, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronfani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepehrimanesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharafi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siabani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sima, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soheili, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotoudehmanesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suleria, H. A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesfay, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsoi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wondmieneh, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarghi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirac, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malekzadeh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naghavi, M.</span></span> <span> </span><span class="NLM_article-title">The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017</span>. <i>Lancet Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1016/S2468-1253(19)30333-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2FS2468-1253%2819%2930333-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=31648971" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&pages=17-30&author=S.+Alatabauthor=S.+G.+Sepanlouauthor=K.+Ikutaauthor=H.+Vahediauthor=C.+Bisignanoauthor=S.+Safiriauthor=A.+Sadeghiauthor=M.+R.+Nixonauthor=A.+Abdoliauthor=H.+Abolhassaniauthor=V.+Alipourauthor=M.+A.+H.+Almadiauthor=A.+Almasi-Hashianiauthor=A.+Anushiravaniauthor=J.+Arablooauthor=S.+Atiqueauthor=A.+Awasthiauthor=A.+Badawiauthor=A.+A.+A.+Baigauthor=N.+Bhalaauthor=A.+Bijaniauthor=A.+Biondiauthor=A.+M.+Borz%C3%ACauthor=K.+E.+Burkeauthor=F.+Carvalhoauthor=A.+Daryaniauthor=M.+Dubeyauthor=A.+Eftekhariauthor=E.+Fernandesauthor=J.+C.+Fernandesauthor=F.+Fischerauthor=A.+Haj-Mirzaianauthor=A.+Haj-Mirzaianauthor=A.+Hasanzadehauthor=M.+Hashemianauthor=S.+I.+Hayauthor=C.+L.+Hoangauthor=M.+Househauthor=O.+S.+Ilesanmiauthor=N.+Jafari+Balalamiauthor=S.+L.+Jamesauthor=A.+P.+Kengneauthor=M.+M.+Malekzadehauthor=S.+Meratauthor=T.+J.+Meretojaauthor=T.+Mestrovicauthor=E.+M.+Mirrakhimovauthor=H.+Mirzaeiauthor=K.+A.+Mohammadauthor=A.+H.+Mokdadauthor=L.+Monastaauthor=I.+Negoiauthor=T.+H.+Nguyenauthor=C.+T.+Nguyenauthor=A.+Pourshamsauthor=H.+Poustchiauthor=M.+Rabieeauthor=N.+Rabieeauthor=K.+Ramezanzadehauthor=D.+L.+Rawafauthor=S.+Rawafauthor=N.+Rezaeiauthor=S.+R.+Robinsonauthor=L.+Ronfaniauthor=S.+Saxenaauthor=M.+Sepehrimaneshauthor=M.+A.+Shaikhauthor=Z.+Sharafiauthor=M.+Sharifauthor=S.+Siabaniauthor=A.+R.+Simaauthor=J.+A.+Singhauthor=A.+Soheiliauthor=R.+Sotoudehmaneshauthor=H.+A.+R.+Suleriaauthor=B.+E.+Tesfayauthor=B.+Tranauthor=D.+Tsoiauthor=M.+Vacanteauthor=A.+B.+Wondmienehauthor=A.+Zarghiauthor=Z.-J.+Zhangauthor=M.+Diracauthor=R.+Malekzadehauthor=M.+Naghavi&title=The+global%2C+regional%2C+and+national+burden+of+inflammatory+bowel+disease+in+195+countries+and+territories%2C+1990%E2%80%932017%3A+a+systematic+analysis+for+the+global+burden+of+disease+study+2017&doi=10.1016%2FS2468-1253%2819%2930333-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS2468-1253%2819%2930333-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2468-1253%252819%252930333-4%26sid%3Dliteratum%253Aachs%26aulast%3DAlatab%26aufirst%3DS.%26aulast%3DSepanlou%26aufirst%3DS.%2BG.%26aulast%3DIkuta%26aufirst%3DK.%26aulast%3DVahedi%26aufirst%3DH.%26aulast%3DBisignano%26aufirst%3DC.%26aulast%3DSafiri%26aufirst%3DS.%26aulast%3DSadeghi%26aufirst%3DA.%26aulast%3DNixon%26aufirst%3DM.%2BR.%26aulast%3DAbdoli%26aufirst%3DA.%26aulast%3DAbolhassani%26aufirst%3DH.%26aulast%3DAlipour%26aufirst%3DV.%26aulast%3DAlmadi%26aufirst%3DM.%2BA.%2BH.%26aulast%3DAlmasi-Hashiani%26aufirst%3DA.%26aulast%3DAnushiravani%26aufirst%3DA.%26aulast%3DArabloo%26aufirst%3DJ.%26aulast%3DAtique%26aufirst%3DS.%26aulast%3DAwasthi%26aufirst%3DA.%26aulast%3DBadawi%26aufirst%3DA.%26aulast%3DBaig%26aufirst%3DA.%2BA.%2BA.%26aulast%3DBhala%26aufirst%3DN.%26aulast%3DBijani%26aufirst%3DA.%26aulast%3DBiondi%26aufirst%3DA.%26aulast%3DBorz%25C3%25AC%26aufirst%3DA.%2BM.%26aulast%3DBurke%26aufirst%3DK.%2BE.%26aulast%3DCarvalho%26aufirst%3DF.%26aulast%3DDaryani%26aufirst%3DA.%26aulast%3DDubey%26aufirst%3DM.%26aulast%3DEftekhari%26aufirst%3DA.%26aulast%3DFernandes%26aufirst%3DE.%26aulast%3DFernandes%26aufirst%3DJ.%2BC.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DHaj-Mirzaian%26aufirst%3DA.%26aulast%3DHaj-Mirzaian%26aufirst%3DA.%26aulast%3DHasanzadeh%26aufirst%3DA.%26aulast%3DHashemian%26aufirst%3DM.%26aulast%3DHay%26aufirst%3DS.%2BI.%26aulast%3DHoang%26aufirst%3DC.%2BL.%26aulast%3DHouseh%26aufirst%3DM.%26aulast%3DIlesanmi%26aufirst%3DO.%2BS.%26aulast%3DJafari%2BBalalami%26aufirst%3DN.%26aulast%3DJames%26aufirst%3DS.%2BL.%26aulast%3DKengne%26aufirst%3DA.%2BP.%26aulast%3DMalekzadeh%26aufirst%3DM.%2BM.%26aulast%3DMerat%26aufirst%3DS.%26aulast%3DMeretoja%26aufirst%3DT.%2BJ.%26aulast%3DMestrovic%26aufirst%3DT.%26aulast%3DMirrakhimov%26aufirst%3DE.%2BM.%26aulast%3DMirzaei%26aufirst%3DH.%26aulast%3DMohammad%26aufirst%3DK.%2BA.%26aulast%3DMokdad%26aufirst%3DA.%2BH.%26aulast%3DMonasta%26aufirst%3DL.%26aulast%3DNegoi%26aufirst%3DI.%26aulast%3DNguyen%26aufirst%3DT.%2BH.%26aulast%3DNguyen%26aufirst%3DC.%2BT.%26aulast%3DPourshams%26aufirst%3DA.%26aulast%3DPoustchi%26aufirst%3DH.%26aulast%3DRabiee%26aufirst%3DM.%26aulast%3DRabiee%26aufirst%3DN.%26aulast%3DRamezanzadeh%26aufirst%3DK.%26aulast%3DRawaf%26aufirst%3DD.%2BL.%26aulast%3DRawaf%26aufirst%3DS.%26aulast%3DRezaei%26aufirst%3DN.%26aulast%3DRobinson%26aufirst%3DS.%2BR.%26aulast%3DRonfani%26aufirst%3DL.%26aulast%3DSaxena%26aufirst%3DS.%26aulast%3DSepehrimanesh%26aufirst%3DM.%26aulast%3DShaikh%26aufirst%3DM.%2BA.%26aulast%3DSharafi%26aufirst%3DZ.%26aulast%3DSharif%26aufirst%3DM.%26aulast%3DSiabani%26aufirst%3DS.%26aulast%3DSima%26aufirst%3DA.%2BR.%26aulast%3DSingh%26aufirst%3DJ.%2BA.%26aulast%3DSoheili%26aufirst%3DA.%26aulast%3DSotoudehmanesh%26aufirst%3DR.%26aulast%3DSuleria%26aufirst%3DH.%2BA.%2BR.%26aulast%3DTesfay%26aufirst%3DB.%2BE.%26aulast%3DTran%26aufirst%3DB.%26aulast%3DTsoi%26aufirst%3DD.%26aulast%3DVacante%26aufirst%3DM.%26aulast%3DWondmieneh%26aufirst%3DA.%2BB.%26aulast%3DZarghi%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DZ.-J.%26aulast%3DDirac%26aufirst%3DM.%26aulast%3DMalekzadeh%26aufirst%3DR.%26aulast%3DNaghavi%26aufirst%3DM.%26atitle%3DThe%2520global%252C%2520regional%252C%2520and%2520national%2520burden%2520of%2520inflammatory%2520bowel%2520disease%2520in%2520195%2520countries%2520and%2520territories%252C%25201990%25E2%2580%25932017%253A%2520a%2520systematic%2520analysis%2520for%2520the%2520global%2520burden%2520of%2520disease%2520study%25202017%26jtitle%3DLancet%2520Gastroenterol.%2520Hepatol.%26date%3D2020%26volume%3D5%26spage%3D17%26epage%3D30%26doi%3D10.1016%2FS2468-1253%2819%2930333-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mizoguchi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, T.</span></span> <span> </span><span class="NLM_article-title">Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models</span>. <i>Intest. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.5217/ir.2019.09154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.5217%2Fir.2019.09154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=32326669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A280%3ADC%252BB38zovVantQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2020&pages=151-167&author=E.+Mizoguchiauthor=D.+Lowauthor=Y.+Ezakiauthor=T.+Okada&title=Recent+updates+on+the+basic+mechanisms+and+pathogenesis+of+inflammatory+bowel+diseases+in+experimental+animal+models&doi=10.5217%2Fir.2019.09154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models</span></div><div class="casAuthors">Mizoguchi Emiko; Ezaki Yui; Okada Toshiyuki; Mizoguchi Emiko; Low Daren</div><div class="citationInfo"><span class="NLM_cas:title">Intestinal research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-167</span>
        ISSN:<span class="NLM_cas:issn">1598-9100</span>.
    </div><div class="casAbstract">The specific pathogenesis underlining inflammatory bowel disease (IBD) is very complicated, and it is further more difficult to clearly explain the pathophysiology of 2 major forms of IBD, Crohn's disease (CD) and ulcerative colitis (UC), and both disorders affect individuals throughout life.  Despite every extensive effort, the interplay among genetic factors, immunological factors, environmental factors and intestinal microbes is still completely unrevealed.  Animal models are indispensable to find out mechanistic details that will facilitate better preclinical setting to target specific components involved in the pathogenesis of IBD.  Based on many recent reports, dysbiosis of the commensal microbiota is implicated in the pathogenesis of several diseases, not only IBD but also colon cancer, obesity, psoriasis as well as allergic disorders, in both human and animal models.  Advanced technologies including cell-specific and inducible knockout systems, which are recently employed to mouse IBD models, have further enhanced the ability of developing new therapeutic strategies for IBD.  Furthermore, data from these mouse models highlight the critical involvement of dysregulated immune responses and impaired colonic epithelial defense system in the pathogenesis of IBD.  In this review, we will explain from the history of animal models of IBD to the recent reports of the latest compounds, therapeutic strategies, and approaches tested on IBD animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxW8KR0DOSZ5PlX7E30qdzfW6udTcc2eZtjbS_tPsAp7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zovVantQ%253D%253D&md5=fc6c235570b7aa72bab2365db1370e84</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.5217%2Fir.2019.09154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5217%252Fir.2019.09154%26sid%3Dliteratum%253Aachs%26aulast%3DMizoguchi%26aufirst%3DE.%26aulast%3DLow%26aufirst%3DD.%26aulast%3DEzaki%26aufirst%3DY.%26aulast%3DOkada%26aufirst%3DT.%26atitle%3DRecent%2520updates%2520on%2520the%2520basic%2520mechanisms%2520and%2520pathogenesis%2520of%2520inflammatory%2520bowel%2520diseases%2520in%2520experimental%2520animal%2520models%26jtitle%3DIntest.%2520Res.%26date%3D2020%26volume%3D18%26spage%3D151%26epage%3D167%26doi%3D10.5217%2Fir.2019.09154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panés, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span> <span> </span><span class="NLM_article-title">JAK Inhibitors: back to small molecules for the treatment of IBD</span>. <i>J. Crohn’s Colitis</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">S711</span>– <span class="NLM_lpage">S712</span>, <span class="refDoi"> DOI: 10.1093/ecco-jcc/jjaa109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1093%2Fecco-jcc%2Fjjaa109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=32737980" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2020&pages=S711-S712&author=J.+Pan%C3%A9sauthor=S.+Vermeire&title=JAK+Inhibitors%3A+back+to+small+molecules+for+the+treatment+of+IBD&doi=10.1093%2Fecco-jcc%2Fjjaa109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fecco-jcc%2Fjjaa109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fecco-jcc%252Fjjaa109%26sid%3Dliteratum%253Aachs%26aulast%3DPan%25C3%25A9s%26aufirst%3DJ.%26aulast%3DVermeire%26aufirst%3DS.%26atitle%3DJAK%2520Inhibitors%253A%2520back%2520to%2520small%2520molecules%2520for%2520the%2520treatment%2520of%2520IBD%26jtitle%3DJ.%2520Crohn%25E2%2580%2599s%2520Colitis%26date%3D2020%26volume%3D14%26spage%3DS711%26epage%3DS712%26doi%3D10.1093%2Fecco-jcc%2Fjjaa109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Rocha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duijvestein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faubion, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGovern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetrano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vande Casteele, N.</span></span> <span> </span><span class="NLM_article-title">JAK–STAT pathway targeting for the treatment of inflammatory bowel disease</span>. <i>Nat. Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1038/s41575-020-0273-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1038%2Fs41575-020-0273-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=32203403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A280%3ADC%252BB383msFGruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=323-337&author=A.+Salasauthor=C.+Hernandez-Rochaauthor=M.+Duijvesteinauthor=W.+Faubionauthor=D.+McGovernauthor=S.+Vermeireauthor=S.+Vetranoauthor=N.+Vande+Casteele&title=JAK%E2%80%93STAT+pathway+targeting+for+the+treatment+of+inflammatory+bowel+disease&doi=10.1038%2Fs41575-020-0273-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">JAK-STAT pathway targeting for the treatment of inflammatory bowel disease</span></div><div class="casAuthors">Salas Azucena; Salas Azucena; Hernandez-Rocha Cristian; Duijvestein Marjolijn; Faubion William; McGovern Dermot; Vermeire Severine; Vetrano Stefania; Vetrano Stefania; Vande Casteele Niels; Vande Casteele Niels</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Gastroenterology & hepatology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">323-337</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cytokines are involved in intestinal homeostasis and pathological processes associated with inflammatory bowel disease (IBD).  The biological effects of cytokines, including several involved in the pathology of Crohn's disease and ulcerative colitis, occur as a result of receptor-mediated signalling through the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) DNA-binding families of proteins.  Although therapies targeting cytokines have revolutionized IBD therapy, they have historically targeted individual cytokines, and an unmet medical need exists for patients who do not respond to or lose response to these treatments.  Several small-molecule inhibitors of JAKs that have the potential to affect multiple pro-inflammatory cytokine-dependent pathways are in clinical development for the treatment of IBD, with one agent, tofacitinib, already approved for ulcerative colitis and several other agents with demonstrated efficacy in early phase trials.  This Review describes the current understanding of JAK-STAT signalling in intestinal homeostasis and disease and the rationale for targeting this pathway as a treatment for IBD.  The available evidence for the efficacy, safety and pharmacokinetics of JAK inhibitors in IBD as well as the potential approaches to optimize treatment with these agents, such as localized delivery or combination therapy, are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSno5DPCW-EPx0LsK7uFuY7fW6udTcc2eYwNN8VTMgep7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383msFGruw%253D%253D&md5=5d99314904b35088e90dfb6b0861016d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fs41575-020-0273-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41575-020-0273-0%26sid%3Dliteratum%253Aachs%26aulast%3DSalas%26aufirst%3DA.%26aulast%3DHernandez-Rocha%26aufirst%3DC.%26aulast%3DDuijvestein%26aufirst%3DM.%26aulast%3DFaubion%26aufirst%3DW.%26aulast%3DMcGovern%26aufirst%3DD.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DVetrano%26aufirst%3DS.%26aulast%3DVande%2BCasteele%26aufirst%3DN.%26atitle%3DJAK%25E2%2580%2593STAT%2520pathway%2520targeting%2520for%2520the%2520treatment%2520of%2520inflammatory%2520bowel%2520disease%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2020%26volume%3D17%26spage%3D323%26epage%3D337%26doi%3D10.1038%2Fs41575-020-0273-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1038%2Fnrd.2017.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=29104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=843-862&author=D.+M.+Schwartzauthor=Y.+Kannoauthor=A.+Villarinoauthor=M.+Wardauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=JAK+inhibition+as+a+therapeutic+strategy+for+immune+and+inflammatory+diseases&doi=10.1038%2Fnrd.2017.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Kanno, Yuka; Villarino, Alejandro; Ward, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-862</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their assocd. signalling pathways.  Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-mol. inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.  Building on the clin. success of first-generation jakinibs, second-generation compds. that claim to be more selective are currently undergoing development and proceeding to clin. trials.  However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs.  This Review discusses the biol. of jakinibs from a translational perspective, focusing on recent insights from clin. trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TNpGT01l8rVg90H21EOLACvtfcHk0liIDNNrBCsmFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO&md5=4607422f83f94c0c7194935d6d460c31</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DVillarino%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAK%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520immune%2520and%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D843%26epage%3D862%26doi%3D10.1038%2Fnrd.2017.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2015.167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1038%2Fnrrheum.2015.167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=26633291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=25-36&author=D.+M.+Schwartzauthor=M.+Bonelliauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=Type+I%2FII+cytokines%2C+JAKs%2C+and+new+strategies+for+treating+autoimmune+diseases&doi=10.1038%2Fnrrheum.2015.167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Bonelli, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-36</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cytokines are major drivers of autoimmunity, and biol. agents targeting cytokines have revolutionized the treatment of immune-mediated diseases.  Despite the effectiveness of these drugs, they do not induce complete remission in all patients, prompting the development of alternative strategies - including targeting of intracellular signal transduction pathways downstream of cytokines.  Many cytokines that bind type I and type II cytokine receptors are crit. regulators of immune-mediated diseases and employ the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway to exert their effect.  Pharmacol. inhibition of JAKs blocks the actions of type I/II cytokines, and within the past 3 years therapeutic JAK inhibitors, or Jakinibs, have become available to rheumatologists.  Jakinibs have proven effective for the treatment of rheumatoid arthritis and other inflammatory diseases.  Adverse effects of these agents are largely related to their mode of action and include infections and hyperlipidemia.  Jakinibs are currently being investigated for a no. of new indications, and second-generation selective Jakinibs are being developed and tested.  Targeting STATs could be a future avenue for the treatment of rheumatol. diseases, although substantial challenges remain.  Nonetheless, the ability to therapeutically target intracellular signalling pathways has already created a new paradigm for the treatment of rheumatol. disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUdr1Dh92dnLVg90H21EOLACvtfcHk0liIDNNrBCsmFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ&md5=e06f7ab6424f1fbdbf481c75fa9ebd23</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2015.167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2015.167%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DBonelli%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DType%2520I%252FII%2520cytokines%252C%2520JAKs%252C%2520and%2520new%2520strategies%2520for%2520treating%2520autoimmune%2520diseases%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2016%26volume%3D12%26spage%3D25%26epage%3D36%26doi%3D10.1038%2Fnrrheum.2015.167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Vries, L. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildenberg, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonge, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Haens, G. R.</span></span> <span> </span><span class="NLM_article-title">The future of janus kinase inhibitors in inflammatory bowel disease</span>. <i>J. Crohn’s Colitis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">893</span>, <span class="refDoi"> DOI: 10.1093/ecco-jcc/jjx003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1093%2Fecco-jcc%2Fjjx003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=28158411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A280%3ADC%252BC1c3ivVejsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=885-893&author=L.+C.+S.+De%0AVriesauthor=M.+E.+Wildenbergauthor=W.+J.+De+Jongeauthor=G.+R.+D%E2%80%99Haens&title=The+future+of+janus+kinase+inhibitors+in+inflammatory+bowel+disease&doi=10.1093%2Fecco-jcc%2Fjjx003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease</span></div><div class="casAuthors">De Vries L C S; Wildenberg M E; De Jonge W J; De Vries L C S; Wildenberg M E; D'Haens G R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Crohn's & colitis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">885-893</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease, are disabling conditions characterised by chronic, relapsing inflammation of the gastrointestinal tract.  Current treatments are not universally effective or, in the case of therapeutic antibodies, are hampered by immune responses.  Janus kinase inhibitors are orally delivered small molecules that target cytokine signalling by preventing phosphorylation of Janus kinases associated with the cytokine receptor.  Subsequently, phosphorylation of signal transducers and activators of transcription that relay Janus kinase signalling and transcription of cytokines in the nucleus will be diminished.  Key cytokines in the pathogenesis of inflammatory bowel diseases are targeted by Janus kinase inhibitors.  Several Janus kinase inhibitors are in development for the treatment of inflammatory bowel diseases.  Tofacitinib, inhibiting signalling via all Janus kinase family members, was effective in phase 2 and 3 trials in moderate-severe ulcerative colitis.  GSK2586184, a Janus kinase 1 selective inhibitor, induced clinical and endoscopic response in ulcerative colitis; however, the study was discontinued at an early stage due to liver toxicity observed in systemic lupus patients receiving the drug.  Filgotinib, a Janus kinase 1 selective inhibitor investigated in treatment of Crohn's disease, was superior to placebo.  As adverse events associated with the broad immunological effect of these agents have been reported, the future application of these drugs is potentially limited.  We will discuss the treatment efficacy of Janus kinase inhibition in inflammatory bowel diseases, how current Janus kinase inhibitors available target immune responses relevant in inflammatory bowel disease, and whether more specific kinase inhibition could be effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9MSlSyh0K8d1QT_1O5WBYfW6udTcc2ebTHGwr6i9T8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3ivVejsw%253D%253D&md5=0185380438c0f04885828160a8d1d512</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fecco-jcc%2Fjjx003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fecco-jcc%252Fjjx003%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BVries%26aufirst%3DL.%2BC.%2BS.%26aulast%3DWildenberg%26aufirst%3DM.%2BE.%26aulast%3DDe%2BJonge%26aufirst%3DW.%2BJ.%26aulast%3DD%25E2%2580%2599Haens%26aufirst%3DG.%2BR.%26atitle%3DThe%2520future%2520of%2520janus%2520kinase%2520inhibitors%2520in%2520inflammatory%2520bowel%2520disease%26jtitle%3DJ.%2520Crohn%25E2%2580%2599s%2520Colitis%26date%3D2017%26volume%3D11%26spage%3D885%26epage%3D893%26doi%3D10.1093%2Fecco-jcc%2Fjjx003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span> <span> </span><span class="NLM_article-title">Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1038</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1038%2Fleu.2017.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=28119526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC2sXislyms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=1023-1038&author=E.+Leroyauthor=S.+N.+Constantinescu&title=Rethinking+JAK2+inhibition%3A+towards+novel+strategies+of+more+specific+and+versatile+janus+kinase+inhibition&doi=10.1038%2Fleu.2017.43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition</span></div><div class="casAuthors">Leroy, E.; Constantinescu, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1023-1038</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are required for cytokine receptor signaling.  Since the discovery of the highly prevalent JAK2 V617F mutation in myeloproliferative neoplasms (MPNs), JAK2 became a prime target for inhibition.  Only one approved JAK2 inhibitor exists, with pos., but not curative effects in MPNs, and promising effects in autoimmune diseases and cancer.  On the basis of recent advances in the structural features regulating both normal and mutant JAKs, as well as in small-mol. targeting, we review the current state of JAK2 inhibitor development and present novel avenues of selecting JAK2 inhibitors, with broad and narrow specificities and extend these approaches to other JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLVJS8PwHOlbVg90H21EOLACvtfcHk0liO0GJzyI4OmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXislyms7w%253D&md5=0dc333d94e27daad1d32110dee26e637</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.43%26sid%3Dliteratum%253Aachs%26aulast%3DLeroy%26aufirst%3DE.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26atitle%3DRethinking%2520JAK2%2520inhibition%253A%2520towards%2520novel%2520strategies%2520of%2520more%2520specific%2520and%2520versatile%2520janus%2520kinase%2520inhibition%26jtitle%3DLeukemia%26date%3D2017%26volume%3D31%26spage%3D1023%26epage%3D1038%26doi%3D10.1038%2Fleu.2017.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Actis, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagoonee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribaldone, D. G.</span></span> <span> </span><span class="NLM_article-title">History of inflammatory bowel diseases</span>. <i>J. Clin. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1970</span>, <span class="refDoi"> DOI: 10.3390/jcm8111970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.3390%2Fjcm8111970" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsl2htbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=1970&author=G.+C.+Actisauthor=R.+Pellicanoauthor=S.+Fagooneeauthor=D.+G.+Ribaldone&title=History+of+inflammatory+bowel+diseases&doi=10.3390%2Fjcm8111970"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">History of inflammatory bowel diseases</span></div><div class="casAuthors">Actis, Giovanni Clemente; Pellicano, Rinaldo; Fagoonee, Sharmila; Ribaldone, Davide Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1970</span>CODEN:
                <span class="NLM_cas:coden">JCMOHK</span>;
        ISSN:<span class="NLM_cas:issn">2077-0383</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the intestinal mucosa and unknown etiol.  In this review, we identified three main eras in the IBD history.  Between the 19th and the 20th century, the primary task had been the definition of the diagnostic criteria in order to differentiate the new entity from intestinal tuberculosis.  In the 20th century, an intense and prolific therapeutic research prevailed, culminating in the introduction of biol. drugs in the clin. setting.  Since the beginning of the 21st century, traditional definition criteria have been challenged by holistic criteria in an effort to seek a still unattained cure.  Centuries of worldwide efforts on IBD etiol. and therapy search have culminated in this novel strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3acTnsmLXSrVg90H21EOLACvtfcHk0ljlL9uoYzR6PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsl2htbo%253D&md5=d2c5b67d7ae268253b1f51d203d5a901</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3390%2Fjcm8111970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fjcm8111970%26sid%3Dliteratum%253Aachs%26aulast%3DActis%26aufirst%3DG.%2BC.%26aulast%3DPellicano%26aufirst%3DR.%26aulast%3DFagoonee%26aufirst%3DS.%26aulast%3DRibaldone%26aufirst%3DD.%2BG.%26atitle%3DHistory%2520of%2520inflammatory%2520bowel%2520diseases%26jtitle%3DJ.%2520Clin.%2520Med.%26date%3D2019%26volume%3D8%26spage%3D1970%26doi%3D10.3390%2Fjcm8111970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monaghan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fateen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, G. W.</span></span> <span> </span><span class="NLM_article-title">Review article: novel oral-targeted therapies in inflammatory bowel disease</span>. <i>Aliment. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1610</span>– <span class="NLM_lpage">1622</span>, <span class="refDoi"> DOI: 10.1111/apt.14669</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1111%2Fapt.14669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=29672874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A280%3ADC%252BC1MjksVCktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2018&pages=1610-1622&author=J.+R.+Whiteauthor=F.+Phillipsauthor=T.+Monaghanauthor=W.+Fateenauthor=S.+Samuelauthor=S.+Ghoshauthor=G.+W.+Moran&title=Review+article%3A+novel+oral-targeted+therapies+in+inflammatory+bowel+disease&doi=10.1111%2Fapt.14669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Review article: novel oral-targeted therapies in inflammatory bowel disease</span></div><div class="casAuthors">White J R; Phillips F; Monaghan T; Fateen W; Samuel S; Moran G W; Ghosh S</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary pharmacology & therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1610-1622</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  There is a great unmet clinical need for efficacious, tolerable, economical and orally administrated drugs for the treatment of inflammatory bowel disease (IBD).  New therapeutic avenues have become possible including the development of medications that target specific genetic pathways found to be relevant in other immune mediated diseases.  AIMS:  To provide an overview of recent clinical trials for new generation oral targeted medications that may have a future role in IBD management.  METHODS:  Pubmed and Medline searches were performed up to 1 March 2018 using keywords: "IBD", "UC", "CD", "inflammatory bowel disease" "ulcerative colitis", "Crohn's disease" in combination with "phase", "study", "trial" and "oral".  A manual search of the clinical trial register, article reference lists, abstracts from meetings of Digestive Disease Week, United European Gastroenterology Week and ECCO congress were also conducted.  RESULTS:  In randomised controlled trials primary efficacy endpoints were met for tofacitinib (JAK 1/3 inhibitor-phase III), upadacitinib (JAK 1 inhibitor-phase II) and AJM300 (α4-integrin antagonist-phase II) in ulcerative colitis.  Ozanimod (S1P receptor agonist-phase II) also demonstrated clinical remission.  For Crohn's disease, filgotinib (JAK1 inhibitor-phase II) met primary endpoints and laquinimod (quinolone-3-carboxide small molecule-phase II) was also efficacious.  Trials using mongersen (SMAD7 inhibitor) and vidofludimus (dihydroorotate dehydrogenase inhibitor) have been halted.  CONCLUSIONS:  This is potentially the start of an exciting new era in which multiple therapeutic options are at the disposal of physicians to treat IBD on an individualised basis.  Head-to-head studies with existing treatments and longer term safety data are needed for this to be possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTA18heQeJUy7FU0A1HOshhfW6udTcc2eYT74RvBlb3lbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjksVCktA%253D%253D&md5=f5d12f9a01fd3b4969781ff2acec454a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fapt.14669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fapt.14669%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%2BR.%26aulast%3DPhillips%26aufirst%3DF.%26aulast%3DMonaghan%26aufirst%3DT.%26aulast%3DFateen%26aufirst%3DW.%26aulast%3DSamuel%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DMoran%26aufirst%3DG.%2BW.%26atitle%3DReview%2520article%253A%2520novel%2520oral-targeted%2520therapies%2520in%2520inflammatory%2520bowel%2520disease%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2018%26volume%3D47%26spage%3D1610%26epage%3D1622%26doi%3D10.1111%2Fapt.14669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintás-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caulder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waeltz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3109</span>– <span class="NLM_lpage">3117</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-04-214957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1182%2Fblood-2009-04-214957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=20130243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3109-3117&author=A.+Quint%C3%A1s-Cardamaauthor=K.+Vaddiauthor=P.+Liuauthor=T.+Manshouriauthor=J.+Liauthor=P.+A.+Scherleauthor=E.+Caulderauthor=X.+Wenauthor=Y.+Liauthor=P.+Waeltzauthor=M.+Ruparauthor=T.+Burnauthor=Y.+Loauthor=J.+Kelleyauthor=M.+Covingtonauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=P.+Haleyauthor=H.+Kantarjianauthor=J.+S.+Fridmanauthor=S.+Verstovsek&title=Preclinical+characterization+of+the+selective+JAK1%2F2+inhibitor+INCB018424%3A+therapeutic+implications+for+the+treatment+of+myeloproliferative+neoplasms&doi=10.1182%2Fblood-2009-04-214957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Vaddi, Kris; Liu, Phillip; Manshouri, Taghi; Li, Jun; Scherle, Peggy A.; Caulder, Eian; Wen, Xiaoming; Li, Yanlong; Waeltz, Paul; Rupar, Mark; Burn, Timothy; Lo, Yvonne; Kelley, Jennifer; Covington, Maryanne; Shepard, Stacey; Rodgers, James D.; Haley, Patrick; Kantarjian, Hagop; Fridman, Jordan S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3109-3117</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN) phenotypes in mice, establishing JAK2 inhibition as a potential therapeutic strategy.  Although most polycythemia vera patients carry the JAK2V617F mutation, half of those with essential thrombocythemia or primary myelofibrosis do not, suggesting alternative mechanisms for constitutive JAK-STAT signaling in MPNs.  Most patients with primary myelofibrosis have elevated levels of JAK-dependent proinflammatory cytokines (eg, interleukin-6) consistent with our observation of JAK1 hyperactivation.  Accordingly, we evaluated the effectiveness of selective JAK1/2 inhibition in exptl. models relevant to MPNs and report on the effects of INCB018424, the first potent, selective, oral JAK1/JAK2 inhibitor to enter the clinic.  INCB018424 inhibited interleukin-6 signaling (50% inhibitory concn. [IC50] = 281nM), and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127nM).  In primary cultures, INCB018424 preferentially suppressed erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67nM) vs. healthy donors (IC50 > 400nM).  In a mouse model of JAK2V617F+ MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects.  Preliminary clin. results support these preclin. data and establish INCB018424 as a promising oral agent for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvKGz1l6Y-CbVg90H21EOLACvtfcHk0lhnGFxXdzWxhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D&md5=cd52b7013d76ed00ca2df22444c45160</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-04-214957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-04-214957%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCaulder%26aufirst%3DE.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWaeltz%26aufirst%3DP.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DY.%26aulast%3DKelley%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520selective%2520JAK1%252F2%2520inhibitor%2520INCB018424%253A%2520therapeutic%2520implications%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D3109%26epage%3D3117%26doi%3D10.1182%2Fblood-2009-04-214957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritomo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span> <span> </span><span class="NLM_article-title">Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4971</span>– <span class="NLM_lpage">4983</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2Fj.bmc.2018.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=30145050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyktrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=4971-4983&author=H.+Hamaguchiauthor=Y.+Amanoauthor=A.+Moritomoauthor=S.+Shirakamiauthor=Y.+Nakajimaauthor=K.+Nakaiauthor=N.+Nomuraauthor=M.+Itoauthor=Y.+Higashiauthor=T.+Inoue&title=Discovery+and+structural+characterization+of+peficitinib+%28ASP015K%29+as+a+novel+and+potent+JAK+inhibitor&doi=10.1016%2Fj.bmc.2018.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor</span></div><div class="casAuthors">Hamaguchi, Hisao; Amano, Yasushi; Moritomo, Ayako; Shirakami, Shohei; Nakajima, Yutaka; Nakai, Kazuo; Nomura, Naoko; Ito, Misato; Higashi, Yasuyuki; Inoue, Takayuki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4971-4983</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are considered promising targets for the treatment of autoimmune diseases including rheumatoid arthritis (RA) due to their important role in multiple cytokine receptor signaling pathways.  Recently, several JAK inhibitors have been developed for the treatment of RA.  Here, the authors describe the identification of the novel orally bioavailable JAK inhibitor 18, peficitinib (also known as ASP015K), which showed moderate selectivity for JAK3 over JAK1, JAK2, and TYK2 in enzyme assays.  Chem. modification at the C4-position of lead compd. 5 led to a large increase in JAK inhibitory activity and metabolic stability in liver microsomes.  Furthermore, the authors detd. the crystal structures of JAK1, JAK2, JAK3, and TYK2 in a complex with peficitinib, and revealed that the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold of peficitinib forms triple hydrogen bonds with the hinge region.  Interestingly, the binding modes of peficitinib in the ATP-binding pockets differed among JAK1, JAK2, JAK3, and TYK2.  WaterMap anal. of the crystal structures suggests that unfavorable water mols. are the likely reason for the difference in orientation of the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold to the hinge region among JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXmtQr-zPJgbVg90H21EOLACvtfcHk0lhnGFxXdzWxhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyktrnO&md5=ee50230760e7ab2300f9ccb6a42f62a8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DHamaguchi%26aufirst%3DH.%26aulast%3DAmano%26aufirst%3DY.%26aulast%3DMoritomo%26aufirst%3DA.%26aulast%3DShirakami%26aufirst%3DS.%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DNakai%26aufirst%3DK.%26aulast%3DNomura%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DHigashi%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DT.%26atitle%3DDiscovery%2520and%2520structural%2520characterization%2520of%2520peficitinib%2520%2528ASP015K%2529%2520as%2520a%2520novel%2520and%2520potent%2520JAK%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D4971%26epage%3D4983%26doi%3D10.1016%2Fj.bmc.2018.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argiriadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosebraugh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)</span>. <i>BMC Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">23</span> <span class="refDoi"> DOI: 10.1186/s41927-018-0031-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1186%2Fs41927-018-0031-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=30886973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A280%3ADC%252BB3cbls1ymuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2018&author=J.+M.+Parmentierauthor=J.+Vossauthor=C.+Graffauthor=A.+Schwartzauthor=M.+Argiriadiauthor=M.+Friedmanauthor=H.+S.+Campauthor=R.+J.+Padleyauthor=J.+S.+Georgeauthor=D.+Hylandauthor=M.+Rosebraughauthor=N.+Wishartauthor=L.+Olsonauthor=A.+J.+Long&title=In+vitro+and+in+vivo+characterization+of+the+JAK1+selectivity+of+upadacitinib+%28ABT-494%29&doi=10.1186%2Fs41927-018-0031-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)</span></div><div class="casAuthors">Parmentier Julie M; Voss Jeff; Graff Candace; Schwartz Annette; Argiriadi Maria; Friedman Michael; George Jonathan S; Hyland Deborah; Wishart Neil; Olson Lisa; Long Andrew J; Camp Heidi S; Padley Robert J; Rosebraugh Matthew</div><div class="citationInfo"><span class="NLM_cas:title">BMC rheumatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in the pathogenesis of rheumatoid arthritis.  Tofacitinib, a pan-JAK inhibitor, is the first approved JAK inhibitor for the treatment of RA and has been shown to be effective in managing disease.  However, in phase 2 dose-ranging studies tofacitinib was associated with dose-limiting tolerability and safety issues such as anemia.  Upadacitinib (ABT-494) is a selective JAK1 inhibitor that was engineered to address the hypothesis that greater JAK1 selectivity over other JAK family members will translate into a more favorable benefit:risk profile.  Upadacitinib selectively targets JAK1 dependent disease drivers such as IL-6 and IFNγ, while reducing effects on reticulocytes and natural killer (NK) cells, which potentially contributed to the tolerability issues of tofacitinib.  Methods:  Structure-based hypotheses were used to design the JAK1 selective inhibitor upadacitinib.  JAK family selectivity was defined with in vitro assays including biochemical assessments, engineered cell lines, and cytokine stimulation.  In vivo selectivity was defined by the efficacy of upadacitinib and tofacitinib in a rat adjuvant induced arthritis model, activity on reticulocyte deployment, and effect on circulating NK cells.  The translation of the preclinical JAK1 selectivity was assessed in healthy volunteers using ex vivo stimulation with JAK-dependent cytokines.  Results:  Here, we show the structural basis for the JAK1 selectivity of upadacitinib, along with the in vitro JAK family selectivity profile and subsequent in vivo physiological consequences.  Upadacitinib is ~ 60 fold selective for JAK1 over JAK2, and > 100 fold selective over JAK3 in cellular assays.  While both upadacitinib and tofacitinib demonstrated efficacy in a rat model of arthritis, the increased selectivity of upadacitinib for JAK1 resulted in a reduced effect on reticulocyte deployment and NK cell depletion relative to efficacy.  Ex vivo pharmacodynamic data obtained from Phase I healthy volunteers confirmed the JAK1 selectivity of upadactinib in a clinical setting.  Conclusions:  The data presented here highlight the JAK1 selectivity of upadacinitinib and supports its use as an effective therapy for the treatment of RA with the potential for an improved benefit:risk profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTVFFxllNWaxfKb6ELK8t0fW6udTcc2eb68_d7YN9b8bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbls1ymuw%253D%253D&md5=5ca2dcb18a98362567d2193e858cc800</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1186%2Fs41927-018-0031-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs41927-018-0031-x%26sid%3Dliteratum%253Aachs%26aulast%3DParmentier%26aufirst%3DJ.%2BM.%26aulast%3DVoss%26aufirst%3DJ.%26aulast%3DGraff%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DA.%26aulast%3DArgiriadi%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DM.%26aulast%3DCamp%26aufirst%3DH.%2BS.%26aulast%3DPadley%26aufirst%3DR.%2BJ.%26aulast%3DGeorge%26aufirst%3DJ.%2BS.%26aulast%3DHyland%26aufirst%3DD.%26aulast%3DRosebraugh%26aufirst%3DM.%26aulast%3DWishart%26aufirst%3DN.%26aulast%3DOlson%26aufirst%3DL.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520the%2520JAK1%2520selectivity%2520of%2520upadacitinib%2520%2528ABT-494%2529%26jtitle%3DBMC%2520Rheumatol.%26date%3D2018%26volume%3D2%26doi%3D10.1186%2Fs41927-018-0031-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8597</span>– <span class="NLM_lpage">8612</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8597-8612&author=A.+Fensomeauthor=C.+M.+Amblerauthor=E.+Arnoldauthor=M.+E.+Bankerauthor=M.+F.+Brownauthor=J.+Chrencikauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=I.+V.+Efremovauthor=A.+Flickauthor=B.+S.+Gerstenbergerauthor=A.+Gopalsamyauthor=M.+M.+Haywardauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+Jussifauthor=J.+D.+Knafelsauthor=D.+C.+Limburgauthor=D.+Linauthor=T.+H.+Linauthor=B.+S.+Pierceauthor=E.+Saiahauthor=R.+Sharmaauthor=P.+T.+Symanowiczauthor=J.+B.+Telliezauthor=J.+I.+Trujilloauthor=F.+F.+Vajdosauthor=F.+Vincentauthor=Z.+K.+Wanauthor=L.+Xingauthor=X.+Yangauthor=X.+Yangauthor=L.+Zhang&title=Dual+inhibition+of+TYK2+and+JAK1+for+the+treatment+of+autoimmune+diseases%3A+discovery+of+%28%28S%29-2%2C2-Difluorocyclopropyl%29%28%281+R%2C5+S%29-3-%282-%28%281-methyl-1+H-pyrazol-4-yl%29amino%29pyrimidin-4-yl%29-3%2C8-diazabicyclo%5B3.2.1%5Doctan-8-yl%29methanone+%28PF-06700841%29&doi=10.1021%2Facs.jmedchem.8b00917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span></div><div class="casAuthors">Fensome, Andrew; Ambler, Catherine M.; Arnold, Eric; Banker, Mary Ellen; Brown, Matthew F.; Chrencik, Jill; Clark, James D.; Dowty, Martin E.; Efremov, Ivan V.; Flick, Andrew; Gerstenberger, Brian S.; Gopalsamy, Ariamala; Hayward, Matthew M.; Hegen, Martin; Hollingshead, Brett D.; Jussif, Jason; Knafels, John D.; Limburg, David C.; Lin, David; Lin, Tsung H.; Pierce, Betsy S.; Saiah, Eddine; Sharma, Raman; Symanowicz, Peter T.; Telliez, Jean-Baptiste; Trujillo, John I.; Vajdos, Felix F.; Vincent, Fabien; Wan, Zhao-Kui; Xing, Li; Yang, Xiaojing; Yang, Xin; Zhang, Liying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8597-8612</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytokine signaling is an important characteristic of autoimmune diseases.  Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway.  JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6 and type-I interferon (IFN) family, while TYK2 in addn. to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling.  Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease and rheumatoid arthritis studies, leading to multiple drug approvals.  It is hypothesized that a dual JAK1/TYK2 inhibitor will provide addnl. efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes.  Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compd. 23), which is in Phase II clin. development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNhVkNWDMq7Vg90H21EOLACvtfcHk0lh15IBU-la15Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI&md5=c321512f524560cba445d070b9639e55</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00917%26sid%3Dliteratum%253Aachs%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChrencik%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DFlick%26aufirst%3DA.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DZ.%2BK.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDual%2520inhibition%2520of%2520TYK2%2520and%2520JAK1%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%253A%2520discovery%2520of%2520%2528%2528S%2529-2%252C2-Difluorocyclopropyl%2529%2528%25281%2520R%252C5%2520S%2529-3-%25282-%2528%25281-methyl-1%2520H-pyrazol-4-yl%2529amino%2529pyrimidin-4-yl%2529-3%252C8-diazabicyclo%255B3.2.1%255Doctan-8-yl%2529methanone%2520%2528PF-06700841%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8597%26epage%3D8612%26doi%3D10.1021%2Facs.jmedchem.8b00917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F. D. A.</span>; <span class="NLM_string-name">Fensome, A.</span>; <span class="NLM_string-name">Gerstenberger, B. S.</span>; <span class="NLM_string-name">Hayward, M. M.</span>; <span class="NLM_string-name">Owen, D. R.</span>; <span class="NLM_string-name">Wright, S. W.</span>; <span class="NLM_string-name">Xing, L. H.</span>; <span class="NLM_string-name">Yang, X.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[l,5-a]pyrazin-4-yl derivatives</span>. U.S. Patent <span class="NLM_patent">US2017/0240552A1</span>, Feb 21, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+F.+D.+A.+Brown&author=A.+Fensome&author=B.+S.+Gerstenberger&author=M.+M.+Hayward&author=D.+R.+Owen&author=S.+W.+Wright&author=L.+H.+Xing&author=X.+Yang&title=Pyrazolo%5Bl%2C5-a%5Dpyrazin-4-yl+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DM.%2BF.%2BD.%2BA.%26atitle%3DPyrazolo%255Bl%252C5-a%255Dpyrazin-4-yl%2520derivatives%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimalakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8973</span>– <span class="NLM_lpage">8995</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00444</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00444" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8973-8995&author=S.+T.+Wrobleskiauthor=R.+Moslinauthor=S.+Linauthor=Y.+Zhangauthor=S.+Spergelauthor=J.+Kempsonauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=D.+Shusterauthor=K.+Gilloolyauthor=X.+Yangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=C.+Chaudhryauthor=J.+Khanauthor=M.+Ruzanovauthor=J.+Tredupauthor=D.+Mulliganauthor=D.+Xieauthor=H.+Sunauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=N.+Aranibarauthor=M.+Chineyauthor=A.+Chimalakondaauthor=W.+J.+Pittsauthor=L.+Lombardoauthor=P.+H.+Carterauthor=J.+R.+Burkeauthor=D.+S.+Weinstein&title=Highly+selective+inhibition+of+tyrosine+kinase+2+%28TYK2%29+for+the+treatment+of+autoimmune+diseases%3A+discovery+of+the+allosteric+inhibitor+BMS-986165&doi=10.1021%2Facs.jmedchem.9b00444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165</span></div><div class="casAuthors">Wrobleski, Stephen T.; Moslin, Ryan; Lin, Shuqun; Zhang, Yanlei; Spergel, Steven; Kempson, James; Tokarski, John S.; Strnad, Joann; Zupa-Fernandez, Adriana; Cheng, Lihong; Shuster, David; Gillooly, Kathleen; Yang, Xiaoxia; Heimrich, Elizabeth; McIntyre, Kim W.; Chaudhry, Charu; Khan, Javed; Ruzanov, Max; Tredup, Jeffrey; Mulligan, Dawn; Xie, Dianlin; Sun, Huadong; Huang, Christine; D'Arienzo, Celia; Aranibar, Nelly; Chiney, Manoj; Chimalakonda, Anjaneya; Pitts, William J.; Lombardo, Louis; Carter, Percy H.; Burke, James R.; Weinstein, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8973-8995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases.  The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formidable challenge.  Our strategy to achieve high selectivity for TYK2 relies on targeting the TYK2 pseudokinase (JH2) domain.  Herein we report the late stage optimization efforts including a structure-guided design and water displacement strategy that led to the discovery of BMS-986165 (11, I) as a high affinity JH2 ligand and potent allosteric inhibitor of TYK2.  In addn. to unprecedented JAK isoform and kinome selectivity, I shows excellent pharmacokinetic properties with minimal profiling liabilities and is efficacious in several murine models of autoimmune disease.  On the basis of these findings, I appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clin. development as an oral treatment for autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmA75TJmytlrVg90H21EOLACvtfcHk0ljgLnbZpa9ToQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP&md5=ca161c470df002b0bdd2bf6b19920ada</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00444%26sid%3Dliteratum%253Aachs%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DKempson%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DShuster%26aufirst%3DD.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DMulligan%26aufirst%3DD.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DChiney%26aufirst%3DM.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DLombardo%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DHighly%2520selective%2520inhibition%2520of%2520tyrosine%2520kinase%25202%2520%2528TYK2%2529%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%253A%2520discovery%2520of%2520the%2520allosteric%2520inhibitor%2520BMS-986165%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8973%26epage%3D8995%26doi%3D10.1021%2Facs.jmedchem.9b00444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, M. T.</span></span> <span> </span><span class="NLM_article-title">TYK2 inhibition shows promise</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">668</span>, <span class="refDoi"> DOI: 10.1038/d41573-019-00134-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1038%2Fd41573-019-00134-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=31477862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs12nsrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=668&author=M.+T.+Villanueva&title=TYK2+inhibition+shows+promise&doi=10.1038%2Fd41573-019-00134-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">TYK2 inhibition shows promise</span></div><div class="casAuthors">Villanueva, M. Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">668</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq49wp9oc5jSLVg90H21EOLACvtfcHk0lhjv-YYMlGetw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs12nsrvP&md5=066a2dcb6b91ef52fd7608b894f4e166</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fd41573-019-00134-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41573-019-00134-4%26sid%3Dliteratum%253Aachs%26aulast%3DVillanueva%26aufirst%3DM.%2BT.%26atitle%3DTYK2%2520inhibition%2520shows%2520promise%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D668%26doi%3D10.1038%2Fd41573-019-00134-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">784</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2Fj.phrs.2016.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=27473820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12jurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=784-803&author=R.+Roskoski&title=Janus+kinase+%28JAK%29+inhibitors+in+the+treatment+of+inflammatory+and+neoplastic+diseases&doi=10.1016%2Fj.phrs.2016.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases</span></div><div class="casAuthors">Roskoski, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">784-803</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinase (JAK) family of non-receptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (tyrosine kinase-2).  Each of these proteins contains a JAK homol. pseudokinase (JH2) domain that regulates the adjacent protein kinase domain (JH1).  JAK1/2 and TYK2 are ubiquitously expressed whereas JAK3 is found predominantly in hematopoietic cells.  The Janus kinase family is regulated by numerous cytokines including interleukins, interferons, and hormones such as erythropoietin, thrombopoietin, and growth hormone.  Ligand binding to cytokine and hormone receptors leads to the activation of assocd. Janus kinases, which then mediate the phosphorylation of the receptors.  The SH2 domain of STATs (signal transducers and activators of transcription) binds to the receptor phosphotyrosines thereby promoting STAT phosphorylation by the Janus kinases and consequent activation.  STAT dimers are translocated to the nucleus where they participate in the regulation of the expression of thousands of proteins.  JAK-STAT dysregulation results in autoimmune disorders such as rheumatoid arthritis, ulcerative colitis, and Crohn disease.  JAK-STAT dysregulation also plays a role in the pathogenesis of myelofibrosis, polycythemia vera, and other myeloproliferative illnesses.  An activating JAK2 V617F mutation occurs in 95% of people with polycythemia vera and in a lower percentage of people with other neoplasms.  JAK1/3 signaling participates in the pathogenesis of inflammatory afflictions while JAK1/2 signaling participates in the development of several malignancies including leukemias and lymphomas as well as myeloproliferative neoplasms.  Tofacitinib is a pan-JAK inhibitor that is approved by the FDA for the treatment of rheumatoid arthritis and ruxolitinib is a JAK1/2 inhibitor that is approved for the treatment of polycythemia vera and myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov32m4UjOrv7Vg90H21EOLACvtfcHk0lhjv-YYMlGetw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12jurzJ&md5=a45fba1bb110eff4d5c1b31b78c1b3ac</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DJanus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520in%2520the%2520treatment%2520of%2520inflammatory%2520and%2520neoplastic%2520diseases%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D784%26epage%3D803%26doi%3D10.1016%2Fj.phrs.2016.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotival, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, S.</span></span> <span> </span><span class="NLM_article-title">Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>, <span class="NLM_elocation-id">e0225289</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0225289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1371%2Fjournal.pone.0225289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=31961910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFCru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&author=Z.+Liauthor=M.+Rotivalauthor=E.+Patinauthor=F.+Michelauthor=S.+Pellegrini&title=Two+common+disease-associated+TYK2+variants+impact+exon+splicing+and+TYK2+dosage&doi=10.1371%2Fjournal.pone.0225289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage</span></div><div class="casAuthors">Li, Zhi; Rotival, Maxime; Patin, Etienne; Michel, Frederique; Pellegrini, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0225289</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">TYK2 belongs to the JAK protein tyrosine kinase family and mediates signaling of numerous antiviral and immunoregulatory cytokines (type I and type III IFNs, IL-10, IL-12, IL-22, IL-23) in immune and non-immune cells.  After many years of genetic assocn. studies, TYK2 is recognized as a susceptibility gene for some inflammatory and autoimmune diseases (AID).  Seven TYK2 variants have been assocd. with AIDs in Europeans, and establishing their causality remains challenging.  Previous work showed that a protective variant (P1104A) is hypomorphic and also a risk allele for mycobacterial infection.  Here, we have studied two AID-assocd. common TYK2 variants: rs12720270 located in intron 7 and rs2304256, a non-synonymous variant in exon 8 that causes a valine to phenylalanine substitution (c.1084 G > T, Val362Phe).  We found that this amino acid substitution does not alter TYK2 expression, catalytic activity or ability to relay signaling in EBV-B cell lines or in reconstituted TYK2-null cells.  Based on in silico predictions that these variants may impact splicing of exon 8, we: (i) analyzed TYK2 transcripts in genotyped EBV-B cells and in CRISPR/Cas9-edited cells, (ii) measured splicing using minigene assays, and (iii) performed eQTL (expression quant. trait locus) anal. of TYK2 transcripts in primary monocytes and whole blood cells.  Our results reveal that the two variants promote the inclusion of exon 8, which, we demonstrate, is essential for TYK2 binding to cognate receptors.  In addn. and in line with GTEx (Genetic Tissue Expression) data, our eQTL results show that rs2304256 mildly enhances TYK2 expression in whole blood.  In all, these findings suggest that these TYK2 variants are not neutral but instead have a potential impact in AID.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS_S2jEHTx4bVg90H21EOLACvtfcHk0lhjv-YYMlGetw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFCru7g%253D&md5=0de778b5c248a6a88a08e33c791f8255</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0225289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0225289%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DRotival%26aufirst%3DM.%26aulast%3DPatin%26aufirst%3DE.%26aulast%3DMichel%26aufirst%3DF.%26aulast%3DPellegrini%26aufirst%3DS.%26atitle%3DTwo%2520common%2520disease-associated%2520TYK2%2520variants%2520impact%2520exon%2520splicing%2520and%2520TYK2%2520dosage%26jtitle%3DPLoS%2520One%26date%3D2020%26volume%3D15%26doi%3D10.1371%2Fjournal.pone.0225289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. O.</span></span> <span> </span><span class="NLM_article-title">TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib</span>. <i>J. Microbiol., Immunol. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">368</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1016/j.jmii.2020.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2Fj.jmii.2020.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=32205092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsFalurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2020&pages=368-370&author=D.+Wuauthor=X.+O.+Yang&title=TH17+responses+in+cytokine+storm+of+COVID-19%3A+an+emerging+target+of+JAK2+inhibitor+Fedratinib&doi=10.1016%2Fj.jmii.2020.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib</span></div><div class="casAuthors">Wu, Dandan; Yang, Xuexian O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Microbiology, Immunology and Infection</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">368-370</span>CODEN:
                <span class="NLM_cas:coden">JMIIFG</span>;
        ISSN:<span class="NLM_cas:issn">1995-9133</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Taiwan LLC</span>)
        </div><div class="casAbstract">COVID-19 emerges as a pandemic disease with high mortality.  Development of effective prevention and treatment is an urgent need.  We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxQUfWxGcfQbVg90H21EOLACvtfcHk0ljL1EseZjc1QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsFalurc%253D&md5=bab4a2496a1381dd062fbaf5349baf57</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.jmii.2020.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmii.2020.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DX.%2BO.%26atitle%3DTH17%2520responses%2520in%2520cytokine%2520storm%2520of%2520COVID-19%253A%2520an%2520emerging%2520target%2520of%2520JAK2%2520inhibitor%2520Fedratinib%26jtitle%3DJ.%2520Microbiol.%252C%2520Immunol.%2520Infect.%26date%3D2020%26volume%3D53%26spage%3D368%26epage%3D370%26doi%3D10.1016%2Fj.jmii.2020.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sebastian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrin-Biroulet, L.</span></span> <span> </span><span class="NLM_article-title">Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD</span>. <i>J. Crohn’s Colitis</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1632</span>– <span class="NLM_lpage">1643</span>, <span class="refDoi"> DOI: 10.1093/ecco-jcc/jjaa120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1093%2Fecco-jcc%2Fjjaa120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=32520312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A280%3ADC%252BB38rotV2itw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2020&pages=1632-1643&author=S.+Sebastianauthor=H.+A.+Gonzalezauthor=L.+Peyrin-Biroulet&title=Safety+of+drugs+during+previous+and+current+coronavirus+pandemics%3A+Lessons+for+IBD&doi=10.1093%2Fecco-jcc%2Fjjaa120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of Drugs During Previous and Current Coronavirus Pandemics: Lessons for Inflammatory Bowel Disease</span></div><div class="casAuthors">Sebastian S; Gonzalez H A; Sebastian S; Peyrin-Biroulet L; Peyrin-Biroulet L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Crohn's & colitis</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1632-1643</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The coronavirus 2019 [COVID-19] pandemic has posed challenges in the routine care of patients with inflammatory bowel disease [IBD].  One of the key challenges is quantification of the risks of immunosuppressive and biological therapies in IBD patients during the pandemic.  The similarities and differences between previous coronavirus outbreaks and the pathobiology of the infections can give useful information in understanding the risks, and perhaps potential beneficial aspects of drugs used in IBD.  Although clinical, immunological and pharmacological data from the experience with previous coronavirus outbreaks cannot be automatically translated to predict the safety of IBD therapies during the COVID-19 pandemic, the signals so far from these outbreaks on IBD patients who are on immunomodulators and biologics are reassuring to patients and clinicians alike.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDxB42mXf9lUbxh97K6Vt6fW6udTcc2eY0lIj-bHYz3bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38rotV2itw%253D%253D&md5=9f378a605ec96870f52825cfd4957696</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1093%2Fecco-jcc%2Fjjaa120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fecco-jcc%252Fjjaa120%26sid%3Dliteratum%253Aachs%26aulast%3DSebastian%26aufirst%3DS.%26aulast%3DGonzalez%26aufirst%3DH.%2BA.%26aulast%3DPeyrin-Biroulet%26aufirst%3DL.%26atitle%3DSafety%2520of%2520drugs%2520during%2520previous%2520and%2520current%2520coronavirus%2520pandemics%253A%2520Lessons%2520for%2520IBD%26jtitle%3DJ.%2520Crohn%25E2%2580%2599s%2520Colitis%26date%3D2020%26volume%3D14%26spage%3D1632%26epage%3D1643%26doi%3D10.1093%2Fecco-jcc%2Fjjaa120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minegishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agematsu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuge, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yachie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessho, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujieda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakiguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abinun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochs, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renner, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belohradsky, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyawaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karasuyama, H.</span></span> <span> </span><span class="NLM_article-title">Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2006.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2Fj.immuni.2006.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=17088085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Gnt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=745-755&author=Y.+Minegishiauthor=M.+Saitoauthor=T.+Morioauthor=K.+Watanabeauthor=K.+Agematsuauthor=S.+Tsuchiyaauthor=H.+Takadaauthor=T.+Haraauthor=N.+Kawamuraauthor=T.+Arigaauthor=H.+Kanekoauthor=N.+Kondoauthor=I.+Tsugeauthor=A.+Yachieauthor=Y.+Sakiyamaauthor=T.+Iwataauthor=F.+Besshoauthor=T.+Ohishiauthor=K.+Johauthor=K.+Imaiauthor=K.+Kogawaauthor=M.+Shinoharaauthor=M.+Fujiedaauthor=H.+Wakiguchiauthor=S.+Pasicauthor=M.+Abinunauthor=H.+D.+Ochsauthor=E.+D.+Rennerauthor=A.+Janssonauthor=B.+H.+Belohradskyauthor=A.+Metinauthor=N.+Shimizuauthor=S.+Mizutaniauthor=T.+Miyawakiauthor=S.+Nonoyamaauthor=H.+Karasuyama&title=Human+tyrosine+kinase+2+deficiency+reveals+its+requisite+roles+in+multiple+cytokine+signals+involved+in+innate+and+acquired+immunity&doi=10.1016%2Fj.immuni.2006.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity</span></div><div class="casAuthors">Minegishi, Yoshiyuki; Saito, Masako; Morio, Tomohiro; Watanabe, Ken; Agematsu, Kazunaga; Tsuchiya, Shigeru; Takada, Hidetoshi; Hara, Toshiro; Kawamura, Nobuaki; Ariga, Tadashi; Kaneko, Hideo; Kondo, Naomi; Tsuge, Ikuya; Yachie, Akihiro; Sakiyama, Yukio; Iwata, Tsutomu; Bessho, Fumio; Ohishi, Tsutomu; Joh, Kosuke; Imai, Kohsuke; Kogawa, Kazuhiro; Shinohara, Miwa; Fujieda, Mikiya; Wakiguchi, Hiroshi; Pasic, Srdjan; Abinun, Mario; Ochs, Hans D.; Renner, Eleonore D.; Jansson, Annette; Belohradsky, Bernd H.; Metin, Ayse; Shimizu, Norio; Mizutani, Shuki; Miyawaki, Toshio; Nonoyama, Shigeaki; Karasuyama, Hajime</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">745-755</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tyrosine kinase 2 (Tyk2) is a nonreceptor tyrosine kinase that belongs to the Janus kinase (Jak) family.  Here we identified a homozygous Tyk2 mutation in a patient who had been clin. diagnosed with hyper-IgE syndrome.  This patient showed unusual susceptibility to various microorganisms including virus, fungi, and mycobacteria and suffered from atopic dermatitis with elevated serum IgE.  The patient's cells displayed defects in multiple cytokine signaling pathways including those for type I interferon (IFN), interleukin (IL)-6, IL-10, IL-12, and IL-23.  The cytokine signals were successfully restored by transducing the intact Tyk2 gene.  Thus, the Tyk2 deficiency is likely to account for the patient's complex clin. manifestations, including the phenotype of impaired T helper 1 (Th1) differentiation and accelerated Th2 differentiation.  This study identifies human Tyk2 deficiency and demonstrates that Tyk2 plays obligatory roles in multiple cytokine signals involved in innate and acquired immunity of humans, which differs substantially from Tyk2 function in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TTbAIzXM-bVg90H21EOLACvtfcHk0liHhfoXPuSsPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Gnt7zI&md5=debec30b44a7e1dc111d7cfb1c92f7dd</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2006.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2006.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DMinegishi%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DMorio%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DAgematsu%26aufirst%3DK.%26aulast%3DTsuchiya%26aufirst%3DS.%26aulast%3DTakada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DT.%26aulast%3DKawamura%26aufirst%3DN.%26aulast%3DAriga%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DKondo%26aufirst%3DN.%26aulast%3DTsuge%26aufirst%3DI.%26aulast%3DYachie%26aufirst%3DA.%26aulast%3DSakiyama%26aufirst%3DY.%26aulast%3DIwata%26aufirst%3DT.%26aulast%3DBessho%26aufirst%3DF.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DJoh%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DK.%26aulast%3DKogawa%26aufirst%3DK.%26aulast%3DShinohara%26aufirst%3DM.%26aulast%3DFujieda%26aufirst%3DM.%26aulast%3DWakiguchi%26aufirst%3DH.%26aulast%3DPasic%26aufirst%3DS.%26aulast%3DAbinun%26aufirst%3DM.%26aulast%3DOchs%26aufirst%3DH.%2BD.%26aulast%3DRenner%26aufirst%3DE.%2BD.%26aulast%3DJansson%26aufirst%3DA.%26aulast%3DBelohradsky%26aufirst%3DB.%2BH.%26aulast%3DMetin%26aufirst%3DA.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DMizutani%26aufirst%3DS.%26aulast%3DMiyawaki%26aufirst%3DT.%26aulast%3DNonoyama%26aufirst%3DS.%26aulast%3DKarasuyama%26aufirst%3DH.%26atitle%3DHuman%2520tyrosine%2520kinase%25202%2520deficiency%2520reveals%2520its%2520requisite%2520roles%2520in%2520multiple%2520cytokine%2520signals%2520involved%2520in%2520innate%2520and%2520acquired%2520immunity%26jtitle%3DImmunity%26date%3D2006%26volume%3D25%26spage%3D745%26epage%3D755%26doi%3D10.1016%2Fj.immuni.2006.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishizaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muromoto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohshiro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oritani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, T.</span></span> <span> </span><span class="NLM_article-title">Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1003244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.4049%2Fjimmunol.1003244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=21606247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvVamu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2011&pages=181-189&author=M.+Ishizakiauthor=T.+Akimotoauthor=R.+Muromotoauthor=M.+Yokoyamaauthor=Y.+Ohshiroauthor=Y.+Sekineauthor=H.+Maedaauthor=K.+Shimodaauthor=K.+Oritaniauthor=T.+Matsuda&title=Involvement+of+tyrosine+kinase-2+in+both+the+IL-12%2FTh1+and+IL-23%2FTh17+axes+in+vivo&doi=10.4049%2Fjimmunol.1003244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of Tyrosine Kinase-2 in Both the IL-12/Th1 and IL-23/Th17 Axes In Vivo</span></div><div class="casAuthors">Ishizaki, Masayuki; Akimoto, Toshihiko; Muromoto, Ryuta; Yokoyama, Mika; Ohshiro, Yuya; Sekine, Yuichi; Maeda, Hiroaki; Shimoda, Kazuya; Oritani, Kenji; Matsuda, Tadashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">181-189</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Tyrosine kinase-2 (Tyk2), a member of the Jak family of kinases, mediates the signals triggered by various cytokines, including type I IFNs, IL-12, and IL-23.  In the current study, we investigated the in vivo involvement of Tyk2 in several IL-12/Th1- and IL-23/Th17-mediated models of exptl. diseases, including methylated BSA injection-induced footpad thickness, imiquimod-induced psoriasis-like skin inflammation, and dextran sulfate sodium- or 2,4,6-trinitrobenzene sulfonic acid-induced colitis.  In these disease models, Tyk2 deficiency influenced the phenotypes in immunity and/or inflammation.  Our findings demonstrate a somewhat broader contribution of Tyk2 to immune systems than previously expected and suggest that Tyk2 may represent an important candidate for drug development by targeting both the IL-12/Th1 and IL-23/Th17 axes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSwc2RH-qGwbVg90H21EOLACvtfcHk0liHhfoXPuSsPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvVamu74%253D&md5=35663a32341c05258a1ddfb7fe9482a2</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1003244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1003244%26sid%3Dliteratum%253Aachs%26aulast%3DIshizaki%26aufirst%3DM.%26aulast%3DAkimoto%26aufirst%3DT.%26aulast%3DMuromoto%26aufirst%3DR.%26aulast%3DYokoyama%26aufirst%3DM.%26aulast%3DOhshiro%26aufirst%3DY.%26aulast%3DSekine%26aufirst%3DY.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DShimoda%26aufirst%3DK.%26aulast%3DOritani%26aufirst%3DK.%26aulast%3DMatsuda%26aufirst%3DT.%26atitle%3DInvolvement%2520of%2520tyrosine%2520kinase-2%2520in%2520both%2520the%2520IL-12%252FTh1%2520and%2520IL-23%252FTh17%2520axes%2520in%2520vivo%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D187%26spage%3D181%26epage%3D189%26doi%3D10.4049%2Fjimmunol.1003244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansoul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolae, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duerr, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioux, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brant, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverberg, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barmada, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dassopoulos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datta, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kistner, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murtha, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumm, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhart, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Targan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consortium, N. I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libioulle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lathrop, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belaiche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewit, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laukens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutgeerts, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Gossum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenika, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchimont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hugot, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belgian-French, I. B. D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellcome Trust Case Control, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardon, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimmo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescott, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onnie, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghori, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumpstead, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gwilliam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremelling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deloukas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satsangi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, M. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Genome-wide association defines more than 30 distinct susceptibility loci for crohn’s disease</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">955</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.1038/ng.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1038%2Fng.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=18587394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptFSqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=955-962&author=J.+C.+Barrettauthor=S.+Hansoulauthor=D.+L.+Nicolaeauthor=J.+H.+Choauthor=R.+H.+Duerrauthor=J.+D.+Riouxauthor=S.+R.+Brantauthor=M.+S.+Silverbergauthor=K.+D.+Taylorauthor=M.+M.+Barmadaauthor=A.+Bittonauthor=T.+Dassopoulosauthor=L.+W.+Dattaauthor=T.+Greenauthor=A.+M.+Griffithsauthor=E.+O.+Kistnerauthor=M.+T.+Murthaauthor=M.+D.+Regueiroauthor=J.+I.+Rotterauthor=L.+P.+Schummauthor=A.+H.+Steinhartauthor=S.+R.+Targanauthor=R.+J.+Xavierauthor=N.+I.+G.+Consortiumauthor=C.+Libioulleauthor=C.+Sandorauthor=M.+Lathropauthor=J.+Belaicheauthor=O.+Dewitauthor=I.+Gutauthor=S.+Heathauthor=D.+Laukensauthor=M.+Mniauthor=P.+Rutgeertsauthor=A.+Van+Gossumauthor=D.+Zelenikaauthor=D.+Franchimontauthor=J.+P.+Hugotauthor=M.+de+Vosauthor=S.+Vermeireauthor=E.+Louisauthor=I.+B.+D.+C.+Belgian-Frenchauthor=C.+Wellcome+Trust+Case+Controlauthor=L.+R.+Cardonauthor=C.+A.+Andersonauthor=H.+Drummondauthor=E.+Nimmoauthor=T.+Ahmadauthor=N.+J.+Prescottauthor=C.+M.+Onnieauthor=S.+A.+Fisherauthor=J.+Marchiniauthor=J.+Ghoriauthor=S.+Bumpsteadauthor=R.+Gwilliamauthor=M.+Tremellingauthor=P.+Deloukasauthor=J.+Mansfieldauthor=D.+Jewellauthor=J.+Satsangiauthor=C.+G.+Mathewauthor=M.+Parkesauthor=M.+Georgesauthor=M.+J.+Daly&title=Genome-wide+association+defines+more+than+30+distinct+susceptibility+loci+for+crohn%E2%80%99s+disease&doi=10.1038%2Fng.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease</span></div><div class="casAuthors">Barrett, Jeffrey C.; Hansoul, Sarah; Nicolae, Dan L.; Cho, Judy H.; Duerr, Richard H.; Rioux, John D.; Brant, Steven R.; Silverberg, Mark S.; Taylor, Kent D.; Barmada, M. Michael; Bitton, Alain; Dassopoulos, Themistocles; Datta, Lisa Wu; Green, Todd; Griffiths, Anne M.; Kistner, Emily O.; Murtha, Michael T.; Regueiro, Miguel D.; Rotter, Jerome I.; Schumm, L. Philip; Steinhart, A. Hillary; Targan, Stephan R.; Xavier, Ramnik J.; Libioulle, Cecile; Sandor, Cynthia; Lathrop, Mark; Belaiche, Jacques; Dewit, Olivier; Gut, Ivo; Heath, Simon; Laukens, Debby; Mni, Myriam; Rutgeerts, Paul; Van Gossum, Andre; Zelenika, Diana; Franchimont, Denis; Hugot, Jean-Pierre; de Vos, Martine; Vermeire, Severine; Louis, Edouard; Cardon, Lon R.; Anderson, Carl A.; Drummond, Hazel; Nimmo, Elaine; Ahmad, Tariq; Prescott, Natalie J.; Onnie, Clive M.; Fisher, Sheila A.; Marchini, Jonathan; Ghori, Jilur; Bumpstead, Suzannah; Gwilliam, Rhian; Tremelling, Mark; Deloukas, Panos; Mansfield, John; Jewell, Derek; Satsangi, Jack; Mathew, Christopher G.; Parkes, Miles; Georges, Michel; Daly, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">955-962</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mark Daly and colleagues present results of a combined anal. of data from three recent genome-wide assocn. studies for Crohn's disease, followed by replication in a large independent sample collection.  Their results confirm 11 previously reported risk loci and provide genome-wide significant evidence for 21 new loci assocd. with the disease.  Mark Daly and colleagues present results of a combined anal. of data from three recent genome-wide assocn. studies for Crohn's disease, followed by replication in a large independent sample collection.  Their results confirm 11 previously reported risk loci and provide genome-wide significant evidence for 21 new loci assocd. with the disease.  Several risk factors for Crohn's disease have been identified in recent genome-wide assocn. studies.  To advance gene discovery further, we combined data from three studies on Crohn's disease (a total of 3,230 cases and 4,829 controls) and carried out replication in 3,664 independent cases with a mixt. of population-based and family-based controls.  The results strongly confirm 11 previously reported loci and provide genome-wide significant evidence for 21 addnl. loci, including the regions contg. STAT3, JAK2, ICOSLG, CDKAL1 and ITLN1.  The expanded mol. understanding of the basis of this disease offers promise for informed therapeutic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXvOZmM6KfrLVg90H21EOLACvtfcHk0lh3RUcksVW09Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptFSqs7k%253D&md5=c2f2805316b115765c02aa1dc503626b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fng.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.175%26sid%3Dliteratum%253Aachs%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DHansoul%26aufirst%3DS.%26aulast%3DNicolae%26aufirst%3DD.%2BL.%26aulast%3DCho%26aufirst%3DJ.%2BH.%26aulast%3DDuerr%26aufirst%3DR.%2BH.%26aulast%3DRioux%26aufirst%3DJ.%2BD.%26aulast%3DBrant%26aufirst%3DS.%2BR.%26aulast%3DSilverberg%26aufirst%3DM.%2BS.%26aulast%3DTaylor%26aufirst%3DK.%2BD.%26aulast%3DBarmada%26aufirst%3DM.%2BM.%26aulast%3DBitton%26aufirst%3DA.%26aulast%3DDassopoulos%26aufirst%3DT.%26aulast%3DDatta%26aufirst%3DL.%2BW.%26aulast%3DGreen%26aufirst%3DT.%26aulast%3DGriffiths%26aufirst%3DA.%2BM.%26aulast%3DKistner%26aufirst%3DE.%2BO.%26aulast%3DMurtha%26aufirst%3DM.%2BT.%26aulast%3DRegueiro%26aufirst%3DM.%2BD.%26aulast%3DRotter%26aufirst%3DJ.%2BI.%26aulast%3DSchumm%26aufirst%3DL.%2BP.%26aulast%3DSteinhart%26aufirst%3DA.%2BH.%26aulast%3DTargan%26aufirst%3DS.%2BR.%26aulast%3DXavier%26aufirst%3DR.%2BJ.%26aulast%3DConsortium%26aufirst%3DN.%2BI.%2BG.%26aulast%3DLibioulle%26aufirst%3DC.%26aulast%3DSandor%26aufirst%3DC.%26aulast%3DLathrop%26aufirst%3DM.%26aulast%3DBelaiche%26aufirst%3DJ.%26aulast%3DDewit%26aufirst%3DO.%26aulast%3DGut%26aufirst%3DI.%26aulast%3DHeath%26aufirst%3DS.%26aulast%3DLaukens%26aufirst%3DD.%26aulast%3DMni%26aufirst%3DM.%26aulast%3DRutgeerts%26aufirst%3DP.%26aulast%3DVan%2BGossum%26aufirst%3DA.%26aulast%3DZelenika%26aufirst%3DD.%26aulast%3DFranchimont%26aufirst%3DD.%26aulast%3DHugot%26aufirst%3DJ.%2BP.%26aulast%3Dde%2BVos%26aufirst%3DM.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DLouis%26aufirst%3DE.%26aulast%3DBelgian-French%26aufirst%3DI.%2BB.%2BD.%2BC.%26aulast%3DWellcome%2BTrust%2BCase%2BControl%26aufirst%3DC.%26aulast%3DCardon%26aufirst%3DL.%2BR.%26aulast%3DAnderson%26aufirst%3DC.%2BA.%26aulast%3DDrummond%26aufirst%3DH.%26aulast%3DNimmo%26aufirst%3DE.%26aulast%3DAhmad%26aufirst%3DT.%26aulast%3DPrescott%26aufirst%3DN.%2BJ.%26aulast%3DOnnie%26aufirst%3DC.%2BM.%26aulast%3DFisher%26aufirst%3DS.%2BA.%26aulast%3DMarchini%26aufirst%3DJ.%26aulast%3DGhori%26aufirst%3DJ.%26aulast%3DBumpstead%26aufirst%3DS.%26aulast%3DGwilliam%26aufirst%3DR.%26aulast%3DTremelling%26aufirst%3DM.%26aulast%3DDeloukas%26aufirst%3DP.%26aulast%3DMansfield%26aufirst%3DJ.%26aulast%3DJewell%26aufirst%3DD.%26aulast%3DSatsangi%26aufirst%3DJ.%26aulast%3DMathew%26aufirst%3DC.%2BG.%26aulast%3DParkes%26aufirst%3DM.%26aulast%3DGeorges%26aufirst%3DM.%26aulast%3DDaly%26aufirst%3DM.%2BJ.%26atitle%3DGenome-wide%2520association%2520defines%2520more%2520than%252030%2520distinct%2520susceptibility%2520loci%2520for%2520crohn%25E2%2580%2599s%2520disease%26jtitle%3DNat.%2520Genet.%26date%3D2008%26volume%3D40%26spage%3D955%26epage%3D962%26doi%3D10.1038%2Fng.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jethwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowness, P.</span></span> <span> </span><span class="NLM_article-title">The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1111/cei.12670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1111%2Fcei.12670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=26080615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitV2nt73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2016&pages=30-36&author=H.+Jethwaauthor=P.+Bowness&title=The+interleukin+%28IL%29-23%2FIL-17+axis+in+ankylosing+spondylitis%3A+new+advances+and+potentials+for+treatment&doi=10.1111%2Fcei.12670"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment</span></div><div class="casAuthors">Jethwa, H.; Bowness, P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-36</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary: Ankylosing spondylitis (AS), the most common form of spondyloarthropathy, is a chronic, progressive multi-system inflammatory disorder characteristically affecting the sacroiliac joints and axial skeleton.  Although the exact mechanisms underlying the pathogenesis of AS remain to be elucidated, the presence of human leukocyte antigen (HLA)-B27 is known to markedly increase its risk of development.  Current treatments include non-steroidal anti-inflammatory drugs (NSAIDs) and tumor necrosis factor (TNF) blockers.  In recent years, the interleukin (IL)-23/IL-17 pathway has been shown to have significance in the pathogenesis of AS and treatment modalities targeting this pathway have been shown to be beneficial in various other inflammatory conditions.  This review provides an overview of the IL-23/IL-17 pathway in the pathogenesis of AS and summarizes new potential treatments for AS and related inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruAOqPQQ_7Q7Vg90H21EOLACvtfcHk0lh3RUcksVW09Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitV2nt73J&md5=6cf15c9a1171f925f2324373b1aa506d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fcei.12670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcei.12670%26sid%3Dliteratum%253Aachs%26aulast%3DJethwa%26aufirst%3DH.%26aulast%3DBowness%26aufirst%3DP.%26atitle%3DThe%2520interleukin%2520%2528IL%2529-23%252FIL-17%2520axis%2520in%2520ankylosing%2520spondylitis%253A%2520new%2520advances%2520and%2520potentials%2520for%2520treatment%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D2016%26volume%3D183%26spage%3D30%26epage%3D36%26doi%3D10.1111%2Fcei.12670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moschen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raine, T.</span></span> <span> </span><span class="NLM_article-title">IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting</span>. <i>Nat. Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1038/s41575-018-0084-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1038%2Fs41575-018-0084-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=30478416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlWnu7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=185-196&author=A.+R.+Moschenauthor=H.+Tilgauthor=T.+Raine&title=IL-12%2C+IL-23+and+IL-17+in+IBD%3A+immunobiology+and+therapeutic+targeting&doi=10.1038%2Fs41575-018-0084-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting</span></div><div class="casAuthors">Moschen, Alexander R.; Tilg, Herbert; Raine, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">185-196</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  IL-12 and IL-23 are closely related cytokines with important roles in the regulation of tissue inflammation.  Converging evidence from studies in mice, human observational studies and population genetics supports the importance of these cytokines in the regulation of mucosal inflammation in the gut in particular.  Ustekinumab, a therapeutic antibody targeting both cytokines is now widely licensed for the treatment of Crohn's disease, including in Europe, the USA, Canada and Japan, while agents targeting IL-23 specifically are in late-phase clin. trials.  We review the emerging understanding of the biol. of IL-12 and IL-23, as well as that of their major downstream cytokines, including IL-17.  In particular, we discuss how their biol. has influenced the development of clin. trials and therapeutic strategies in IBD, as well as how findings from clin. trials, at times surprising, have in turn refocused our understanding of the underlying biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOpNxAUthv_rVg90H21EOLACvtfcHk0lgPq-m4-pDMSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlWnu7%252FE&md5=b1f23bb392012256b005f303341d8cc1</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fs41575-018-0084-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41575-018-0084-8%26sid%3Dliteratum%253Aachs%26aulast%3DMoschen%26aufirst%3DA.%2BR.%26aulast%3DTilg%26aufirst%3DH.%26aulast%3DRaine%26aufirst%3DT.%26atitle%3DIL-12%252C%2520IL-23%2520and%2520IL-17%2520in%2520IBD%253A%2520immunobiology%2520and%2520therapeutic%2520targeting%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2019%26volume%3D16%26spage%3D185%26epage%3D196%26doi%3D10.1038%2Fs41575-018-0084-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">JAK/STAT signal transduction: promising attractive targets for immune, inflammatory and hematopoietic diseases</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.2174/1389450117666161207163054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.2174%2F1389450117666161207163054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=27928945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=487-500&author=Q.+Gaoauthor=X.+Liangauthor=A.+S.+Shaikhauthor=J.+Zangauthor=W.+Xuauthor=Y.+Zhang&title=JAK%2FSTAT+signal+transduction%3A+promising+attractive+targets+for+immune%2C+inflammatory+and+hematopoietic+diseases&doi=10.2174%2F1389450117666161207163054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases</span></div><div class="casAuthors">Gao, Qianwen; Liang, Xuewu; Shaikh, Abdul Sami; Zang, Jie; Xu, Wenfang; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">487-500</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: JAK/STAT signal pathway, a requisite part in the signaling process of growth factors and cytokines, has become attractive targets for numerous immune, inflammatory and hematopoietic diseases.  Objective: Herein, we present a review of the JAK/STAT signal pathway, the structure, biol. function, mechanism of the JAKs and STATs along with a summary of the up-to-date clin. or approved JAK inhibitors which are involved in the treatment of various kinds of tumors and other immunity indications.  Moreover, kinds of recently discovered JAKs inhibitors with potent activity or promising selectivity are also briefly discussed.  Conclusion: Research and development of isoform selective JAK inhibitors has become a hot topic in this field.  With the assistance of high throughput screening and rational drug design, more and more JAK inhibitors with improved selective profiles will be discovered as biol. probes and even therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquIztpln8iw7Vg90H21EOLACvtfcHk0lgPq-m4-pDMSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCktLk%253D&md5=03eea4fedd3cf02d3a6450e42309527f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F1389450117666161207163054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450117666161207163054%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DShaikh%26aufirst%3DA.%2BS.%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DJAK%252FSTAT%2520signal%2520transduction%253A%2520promising%2520attractive%2520targets%2520for%2520immune%252C%2520inflammatory%2520and%2520hematopoietic%2520diseases%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2018%26volume%3D19%26spage%3D487%26epage%3D500%26doi%3D10.2174%2F1389450117666161207163054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and orally effective dual janus kinase 2/FLT3 Inhibitors for the treatment of acute myelogenous leukemia and myeloproliferative neoplasms</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10305</span>– <span class="NLM_lpage">10320</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01348</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01348" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVOhtrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10305-10320&author=T.+Yangauthor=M.+Huauthor=W.+Qiauthor=Z.+Yangauthor=M.+Tangauthor=J.+Heauthor=Y.+Chenauthor=P.+Baiauthor=X.+Yuanauthor=C.+Zhangauthor=K.+Liuauthor=Y.+Luauthor=M.+Xiangauthor=L.+Chen&title=Discovery+of+potent+and+orally+effective+dual+janus+kinase+2%2FFLT3+Inhibitors+for+the+treatment+of+acute+myelogenous+leukemia+and+myeloproliferative+neoplasms&doi=10.1021%2Facs.jmedchem.9b01348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms</span></div><div class="casAuthors">Yang, Tao; Hu, Mengshi; Qi, Wenyan; Yang, Zhuang; Tang, Minghai; He, Jun; Chen, Yong; Bai, Peng; Yuan, Xue; Zhang, Chufeng; Liu, Kongjun; Lu, Yulin; Xiang, Mingli; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10305-10320</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, the design, synthesis, and structure-activity relationships of a series of unique 4-(1H-pyrazol-4-yl)-pyrimidin-2-amine derivs. that selectively inhibit Janus kinase 2 (JAK2) and FLT3 kinases is described.  These screening cascades revealed that I was a preferred compd. with IC50 values of 0.7 and 4 nM for JAK2 and FLT3, resp.  Moreover, I was a potent JAK2 inhibitor with 37-fold and 56-fold selectivity over JAK1 and JAK3, resp., and possessed an excellent selectivity profile over the other 100 representative kinases.  In a series of cytokine-stimulated cell-based assays, I exhibited a higher JAK2 selectivity over other JAK isoforms.  The oral administration of 60 mg/kg of I could significantly inhibit tumor growth, with a tumor growth inhibition rate of 93 and 85% in MV4-11 and SET-2 xenograft models, resp.  Addnl., I showed an excellent bioavailability (F = 58%), a suitable half-life time (T1/2 = 4.1 h), a satisfactory metabolic stability, and a weak CYP3A4 inhibitory activity, suggesting that I might be a potential drug candidate for JAK2-driven myeloproliferative neoplasms and FLT3-internal tandem duplication-driven acute myelogenous leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHnNcuajGNcLVg90H21EOLACvtfcHk0likO4NtQj-rsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVOhtrvE&md5=86c811cf77a95a7250996456cd29e6dc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01348%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DP.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520orally%2520effective%2520dual%2520janus%2520kinase%25202%252FFLT3%2520Inhibitors%2520for%2520the%2520treatment%2520of%2520acute%2520myelogenous%2520leukemia%2520and%2520myeloproliferative%2520neoplasms%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10305%26epage%3D10320%26doi%3D10.1021%2Facs.jmedchem.9b01348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PatnyAlicea-Velázquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korniski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmons, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommers, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenbrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasselli, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, T. E.</span></span> <span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>400</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2010.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+PatnyAlicea-Vel%C3%A1zquezauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.+C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6&doi=10.1016%2Fj.jmb.2010.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0likO4NtQj-rsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatnyAlicea-Vel%25C3%25A1zquez%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433%26doi%3D10.1016%2Fj.jmb.2010.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alicea-Velázquez, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span> <span> </span><span class="NLM_article-title">The use of structural biology in janus kinase targeted drug discovery</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">546</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.2174/138945011794751528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.2174%2F138945011794751528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=21126226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVOkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=546-555&author=N.+L.+Alicea-Vel%C3%A1zquezauthor=T.+J.+Boggon&title=The+use+of+structural+biology+in+janus+kinase+targeted+drug+discovery&doi=10.2174%2F138945011794751528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The use of structural biology in Janus kinase targeted drug discovery</span></div><div class="casAuthors">Alicea-Velazquez, Nilda L.; Boggon, Titus J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">546-555</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (or Jak kinases) mediate cytokine and growth factor signal transduction.  Acquired or inherited Jak mutations can result in dysregulation of Jak-mediated signal transduction and can be crit. to disease acquisition in neoplasias including acute myeloid, acute lymphoblastic and acute megakaryoblastic leukemias, and in rare X-linked severe combined immunodeficiency.  The discovery of an acquired Jak2 point mutation, V617F, in significant nos. of patients with classical myeloproliferative disorders has increased the interest in development of Jak2-specific tyrosine kinase inhibitors and consequently there are now over 20 publically available structures of Jak kinase domains that describe all four family members, Jak1, Jak2, Jak3, and Tyk2.  Here we review the recent advances in understanding the druggable structure and function of the Jak family, with a focus on the structural biol. of the Jak kinase domain.  We will discuss how these advances impact the development of Jak-targeted therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJwEtMK-lOu7Vg90H21EOLACvtfcHk0ljN1gAFBUEGZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVOkurg%253D&md5=5e76fc7eda3ffe580dc4e28044a88c2c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2174%2F138945011794751528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945011794751528%26sid%3Dliteratum%253Aachs%26aulast%3DAlicea-Vel%25C3%25A1zquez%26aufirst%3DN.%2BL.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520use%2520of%2520structural%2520biology%2520in%2520janus%2520kinase%2520targeted%2520drug%2520discovery%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2011%26volume%3D12%26spage%3D546%26epage%3D555%26doi%3D10.2174%2F138945011794751528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Argiriadi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedken, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borhani, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burchat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overmeyer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pivorunas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadhukhan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, N. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talanian, R. V.</span></span> <span> </span><span class="NLM_article-title">Enabling structure-based drug design of TYK2 through co-crystallization with a stabilizing aminoindazole inhibitor</span>. <i>BMC Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">22</span>, <span class="refDoi"> DOI: 10.1186/1472-6807-12-22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1186%2F1472-6807-12-22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=22995073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKjtLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=22&author=M.+A.+Argiriadiauthor=E.+R.+Goedkenauthor=D.+Banachauthor=D.+W.+Borhaniauthor=A.+Burchatauthor=R.+W.+Dixonauthor=D.+Marcotteauthor=G.+Overmeyerauthor=V.+Pivorunasauthor=R.+Sadhukhanauthor=S.+Sousaauthor=N.+S.+J.+Mooreauthor=M.+Tomlinsonauthor=J.+Vossauthor=L.+Wangauthor=N.+Wishartauthor=K.+Wollerauthor=R.+V.+Talanian&title=Enabling+structure-based+drug+design+of+TYK2+through+co-crystallization+with+a+stabilizing+aminoindazole+inhibitor&doi=10.1186%2F1472-6807-12-22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor</span></div><div class="casAuthors">Argiriadi, Maria A.; Goedken, Eric R.; Banach, David; Borhani, David W.; Burchat, Andrew; Dixon, Richard W.; Marcotte, Doug; Overmeyer, Gary; Pivorunas, Valerie; Sadhukhan, Ramkrishna; Sousa, Silvino; Moore, Nigel St. John; Tomlinson, Medha; Voss, Jeffrey; Wang, Lu; Wishart, Neil; Woller, Kevin; Talanian, Robert V.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Structural Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22</span>CODEN:
                <span class="NLM_cas:coden">BSBMBB</span>;
        ISSN:<span class="NLM_cas:issn">1472-6807</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Structure-based drug design (SBDD) can accelerate inhibitor lead design and optimization, and efficient methods including protein purifn., characterization, crystn., and high-resoln. diffraction are all needed for rapid, iterative structure detn.  Janus kinases are important targets that are amenable to structure-based drug design.  Here we present the first mouse Tyk2 crystal structures, which are complexed to 3-aminoindazole compds.  Results: A comprehensive construct design effort included N- and C-terminal variations, kinase-inactive mutations, and multiple species orthologs.  High-throughput cloning and expression methods were coupled with an abbreviated purifn. protocol to optimize protein soly. and stability.  In total, 50 Tyk2 constructs were generated.  Many displayed poor expression, inadequate soly., or incomplete affinity tag processing.  One kinase-inactive murine Tyk2 construct, complexed with an ATP-competitive 3-aminoindazole inhibitor, provided crystals that diffracted to 2.5-2.6 Å resoln.  This structure revealed initial "hot-spot" regions for SBDD, and provided a robust platform for ligand soaking expts.  Compared to previously reported human Tyk2 inhibitor crystal structures, our structures revealed a key difference in the glycine-rich loop conformation that is induced by the inhibitor.  Ligand binding also conferred resistance to proteolytic degrdn. by thermolysin.  As crystals could not be obtained with the unliganded enzyme, this enhanced stability is likely important for successful crystn. and inhibitor soaking methods.  Conclusions: Practical criteria for construct performance and prioritization, the optimization of purifn. protocols to enhance protein yields and stability, and use of high-throughput construct exploration enable structure detn. methods early in the drug discovery process.  Addnl., specific ligands stabilize Tyk2 protein and may thereby enable crystn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkojfkSrTvvrVg90H21EOLACvtfcHk0ljN1gAFBUEGZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKjtLnK&md5=193891188ca3f7ce8b07e5c7aa94215c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1186%2F1472-6807-12-22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6807-12-22%26sid%3Dliteratum%253Aachs%26aulast%3DArgiriadi%26aufirst%3DM.%2BA.%26aulast%3DGoedken%26aufirst%3DE.%2BR.%26aulast%3DBanach%26aufirst%3DD.%26aulast%3DBorhani%26aufirst%3DD.%2BW.%26aulast%3DBurchat%26aufirst%3DA.%26aulast%3DDixon%26aufirst%3DR.%2BW.%26aulast%3DMarcotte%26aufirst%3DD.%26aulast%3DOvermeyer%26aufirst%3DG.%26aulast%3DPivorunas%26aufirst%3DV.%26aulast%3DSadhukhan%26aufirst%3DR.%26aulast%3DSousa%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DN.%2BS.%2BJ.%26aulast%3DTomlinson%26aufirst%3DM.%26aulast%3DVoss%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWishart%26aufirst%3DN.%26aulast%3DWoller%26aufirst%3DK.%26aulast%3DTalanian%26aufirst%3DR.%2BV.%26atitle%3DEnabling%2520structure-based%2520drug%2520design%2520of%2520TYK2%2520through%2520co-crystallization%2520with%2520a%2520stabilizing%2520aminoindazole%2520inhibitor%26jtitle%3DBMC%2520Struct.%2520Biol.%26date%3D2012%26volume%3D12%26spage%3D22%26doi%3D10.1186%2F1472-6807-12-22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravikumar, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shook, B. C.</span></span> <span> </span><span class="NLM_article-title">Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7902</span>– <span class="NLM_lpage">7917</span>, <span class="refDoi"> DOI: 10.1021/jm100762r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100762r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2kurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7902-7917&author=F.+F.+Flemingauthor=L.+Yaoauthor=P.+C.+Ravikumarauthor=L.+Funkauthor=B.+C.+Shook&title=Nitrile-containing+pharmaceuticals%3A+efficacious+roles+of+the+nitrile+pharmacophore&doi=10.1021%2Fjm100762r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore</span></div><div class="casAuthors">Fleming, Fraser F.; Yao, Lihua; Ravikumar, P. C.; Funk, Lee; Shook, Brian C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7902-7917</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review is structured according to the nature of the nitrile-bearing substituent.  As the no. of nitrile-contg. drug leads is vast, the review has focused on launched nitrile-contg. pharmaceuticals and currently active clin. candidates.  Most nitrile-contg. pharmaceuticals are aroms. with aliph.-, alkene-, and nitrogen-bearing nitriles being progressively less frequent.  Within each class, the bioactive nitriles are collated according to common structural elements and mode of action.  The hope is that this survey will allow greater deployment of this versatile functionality within drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR6kPPdWVuvLVg90H21EOLACvtfcHk0ljcBRsIziwWpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2kurvP&md5=040bbaebd9e8c9999d195b9a22221fea</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm100762r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100762r%26sid%3Dliteratum%253Aachs%26aulast%3DFleming%26aufirst%3DF.%2BF.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DRavikumar%26aufirst%3DP.%2BC.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DShook%26aufirst%3DB.%2BC.%26atitle%3DNitrile-containing%2520pharmaceuticals%253A%2520efficacious%2520roles%2520of%2520the%2520nitrile%2520pharmacophore%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7902%26epage%3D7917%26doi%3D10.1021%2Fjm100762r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, M.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vensel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beresford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashwell, M. A.</span></span> <span> </span><span class="NLM_article-title">The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1709</span>– <span class="NLM_lpage">1712</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.01.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2Fj.bmcl.2004.01.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=15026055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFCis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1709-1712&author=M.+Tandonauthor=M.-M.+O%E2%80%99Donnellauthor=A.+Porteauthor=D.+Venselauthor=D.+Yangauthor=R.+Palmaauthor=A.+Beresfordauthor=M.+A.+Ashwell&title=The+design+and+preparation+of+metabolically+protected+new+arylpiperazine+5-HT1A+ligands&doi=10.1016%2Fj.bmcl.2004.01.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands</span></div><div class="casAuthors">Tandon, Manish; O'Donnell, Mary-Margaret; Porte, Alex; Vensel, David; Yang, Donglai; Palma, Rocio; Beresford, Alan; Ashwell, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1709-1712</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">New arylpiperazines related to buspirone, gepirone and NAN-190 were designed and screened in silico for their 5-HT1A affinity and potential sites of metab. by human cytochrome P 450 (CYP3A4).  Modifications to these structures were assessed in silico for their influence on both 5HT1A affinity and metab.  Selected new mols. were synthesized and purified in a parallel chem. approach to det. structure activity relationships.  The resulting mols. were assessed in vitro for their 5HT1A affinity and half-life in a heterologously expressed human CYP3A4 assay.  Mol. features responsible for 5-HT1A affinity and CYP3A4 stability are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnE6c-cxXRkrVg90H21EOLACvtfcHk0ljcBRsIziwWpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFCis70%253D&md5=5853a5db1b3e29c8e7e266d814f2504d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.01.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.01.045%26sid%3Dliteratum%253Aachs%26aulast%3DTandon%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.-M.%26aulast%3DPorte%26aufirst%3DA.%26aulast%3DVensel%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DPalma%26aufirst%3DR.%26aulast%3DBeresford%26aufirst%3DA.%26aulast%3DAshwell%26aufirst%3DM.%2BA.%26atitle%3DThe%2520design%2520and%2520preparation%2520of%2520metabolically%2520protected%2520new%2520arylpiperazine%25205-HT1A%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D1709%26epage%3D1712%26doi%3D10.1016%2Fj.bmcl.2004.01.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamert, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walden, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilks, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossjohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucet, I. S.</span></span> <span> </span><span class="NLM_article-title">Dissecting specificity in the janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2009.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+janus+kinases%3A+the+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains&doi=10.1016%2Fj.jmb.2009.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0ljcBRsIziwWpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520janus%2520kinases%253A%2520the%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232%26doi%3D10.1016%2Fj.jmb.2009.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Serine/Threonine protein kinase STK16</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1760</span>, <span class="refDoi"> DOI: 10.3390/ijms20071760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.3390%2Fijms20071760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1760&author=J.+Wangauthor=X.+Jiauthor=J.+Liuauthor=X.+Zhang&title=Serine%2FThreonine+protein+kinase+STK16&doi=10.3390%2Fijms20071760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Serine/threonine protein kinase STK16</span></div><div class="casAuthors">Wang, Junjun; Ji, Xinmiao; Liu, Juanjuan; Zhang, Xin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1760</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  STK16 (Ser/Thr kinase 16, also known as Krct/PKL12/MPSK1/TSF-1) is a myristoylated and palmitoylated Ser/Thr protein kinase that is ubiquitously expressed and conserved among all eukaryotes.  STK16 is distantly related to the other kinases and belongs to the NAK kinase family that has an atypical activation loop architecture.  As a membrane-assocd. protein that is primarily localized to the Golgi, STK16 has been shown to participate in the TGF-β signaling pathway, TGN protein secretion and sorting, as well as cell cycle and Golgi assembly regulation.  This review aims to provide a comprehensive summary of the progress made in recent research about STK16, ranging from its distribution, mol. characterization, post-translational modification (fatty acylation and phosphorylation), interactors (GlcNAcK/DRG1/MAL2/Actin/WDR1), and related functions.  As a relatively underexplored kinase, more studies are encouraged to unravel its regulation mechanisms and cellular functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi_DpWPQ2-HrVg90H21EOLACvtfcHk0lggePZqc6HN2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGmu7g%253D&md5=30340e00a109a16d389c52af3f429147</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3390%2Fijms20071760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20071760%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DSerine%252FThreonine%2520protein%2520kinase%2520STK16%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1760%26doi%3D10.3390%2Fijms20071760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eberl, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muelbaier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span> <span> </span><span class="NLM_article-title">Chemical proteomics reveals target selectivity of clinical JAK inhibitors in human primary cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">14159</span> <span class="refDoi"> DOI: 10.1038/s41598-019-50335-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1038%2Fs41598-019-50335-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=31578349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A280%3ADC%252BB3MnksVKrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&author=H.+C.+Eberlauthor=T.+Wernerauthor=F.+B.+Reinhardauthor=S.+Lehmannauthor=D.+Thomsonauthor=P.+Chenauthor=C.+Zhangauthor=C.+Rauauthor=M.+Muelbaierauthor=G.+Drewesauthor=D.+Drewryauthor=M.+Bantscheff&title=Chemical+proteomics+reveals+target+selectivity+of+clinical+JAK+inhibitors+in+human+primary+cells&doi=10.1038%2Fs41598-019-50335-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells</span></div><div class="casAuthors">Eberl H Christian; Werner Thilo; Reinhard Friedrich B; Lehmann Stephanie; Thomson Douglas; Rau Christina; Muelbaier Marcel; Drewes Gerard; Bantscheff Marcus; Chen Peiling; Zhang Cunyu; Drewry David; Drewry David</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14159</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Kinobeads are a set of promiscuous kinase inhibitors immobilized on sepharose beads for the comprehensive enrichment of endogenously expressed protein kinases from cell lines and tissues.  These beads enable chemoproteomics profiling of kinase inhibitors of interest in dose-dependent competition studies in combination with quantitative mass spectrometry.  We present improved bead matrices that capture more than 350 protein kinases and 15 lipid kinases from human cell lysates, respectively.  A multiplexing strategy is suggested that enables determination of apparent dissociation constants in a single mass spectrometry experiment.  Miniaturization of the procedure enabled determining the target selectivity of the clinical BCR-ABL inhibitor dasatinib in peripheral blood mononuclear cell (PBMC) lysates from individual donors.  Profiling of a set of Jak kinase inhibitors revealed kinase off-targets from nearly all kinase families underpinning the need to profile kinase inhibitors against the kinome.  Potently bound off-targets of clinical inhibitors suggest polypharmacology, e.g. through MRCK alpha and beta, which bind to decernotinib with nanomolar affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-dkv-Tn26AS6Ufuk_1xoTfW6udTcc2eaEK6odhrhSx7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnksVKrug%253D%253D&md5=2c25adec8f1b19cc3d3e259c30016f36</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-50335-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-50335-5%26sid%3Dliteratum%253Aachs%26aulast%3DEberl%26aufirst%3DH.%2BC.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DReinhard%26aufirst%3DF.%2BB.%26aulast%3DLehmann%26aufirst%3DS.%26aulast%3DThomson%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DRau%26aufirst%3DC.%26aulast%3DMuelbaier%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DDrewry%26aufirst%3DD.%26aulast%3DBantscheff%26aufirst%3DM.%26atitle%3DChemical%2520proteomics%2520reveals%2520target%2520selectivity%2520of%2520clinical%2520JAK%2520inhibitors%2520in%2520human%2520primary%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26doi%3D10.1038%2Fs41598-019-50335-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorrell, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szklarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Azeez, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Family-wide structural analysis of human numb-associated protein kinases</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1016/j.str.2015.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2Fj.str.2015.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=26853940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=401-411&author=F.+J.+Sorrellauthor=M.+Szklarzauthor=K.+R.+Abdul+Azeezauthor=J.+M.+Elkinsauthor=S.+Knapp&title=Family-wide+structural+analysis+of+human+numb-associated+protein+kinases&doi=10.1016%2Fj.str.2015.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Family-wide Structural Analysis of Human Numb-Associated Protein Kinases</span></div><div class="casAuthors">Sorrell, Fiona J.; Szklarz, Marta; Abdul Azeez, Kamal R.; Elkins, Jon M.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">401-411</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The highly diverse Numb-assocd. kinase (NAK) family has been linked to broad cellular functions including receptor-mediated endocytosis, Notch pathway modulation, osteoblast differentiation, and dendrite morphogenesis.  Consequently, NAK kinases play a key role in a diverse range of diseases from Parkinson's and prostate cancer to HIV.  Due to the plasticity of this kinase family, NAK kinases are often inhibited by approved or investigational drugs and have been assocd. with side effects, but they are also potential drug targets.  The presence of cysteine residues in some NAK family members provides the possibility for selective targeting via covalent inhibition.  Here we report the first high-resoln. structures of kinases AAK1 and BIKE in complex with two drug candidates.  The presented data allow a comprehensive structural characterization of the NAK kinase family and provide the basis for rational design of selective NAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryZi0QmT8YH7Vg90H21EOLACvtfcHk0liGpeLvTbeKNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCktLY%253D&md5=6a353c993ec9f2b7152e459d72bab9d3</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2015.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2015.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DSzklarz%26aufirst%3DM.%26aulast%3DAbdul%2BAzeez%26aufirst%3DK.%2BR.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DFamily-wide%2520structural%2520analysis%2520of%2520human%2520numb-associated%2520protein%2520kinases%26jtitle%3DStructure%26date%3D2016%26volume%3D24%26spage%3D401%26epage%3D411%26doi%3D10.1016%2Fj.str.2015.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorarensen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juba, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span> <span> </span><span class="NLM_article-title">ATP-Mediated kinome selectivity: The missing link in understanding the contribution of individual JAK kinase isoforms to cellular signaling</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1552</span>– <span class="NLM_lpage">1558</span>, <span class="refDoi"> DOI: 10.1021/cb5002125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5002125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1552-1558&author=A.+Thorarensenauthor=M.+E.+Bankerauthor=A.+Fensomeauthor=J.-B.+Telliezauthor=B.+Jubaauthor=F.+Vincentauthor=R.+M.+Czerwinskiauthor=A.+Casimiro-Garcia&title=ATP-Mediated+kinome+selectivity%3A+The+missing+link+in+understanding+the+contribution+of+individual+JAK+kinase+isoforms+to+cellular+signaling&doi=10.1021%2Fcb5002125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling</span></div><div class="casAuthors">Thorarensen, Atli; Banker, Mary Ellen; Fensome, Andrew; Telliez, Jean-Baptiste; Juba, Brian; Vincent, Fabien; Czerwinski, Robert M.; Casimiro-Garcia, Agustin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1552-1558</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases constitute an important class of therapeutic targets being explored both by academia and the pharmaceutical industry.  The major focus of this effort was directed toward the identification of ATP competitive inhibitors.  Although it has long been recognized that the intracellular concn. of ATP is very different from the concns. utilized in biochem. enzyme assays, little thought has been devoted to incorporating this discrepancy into our understanding of translation from enzyme inhibition to cellular function.  Significant work has been dedicated to the discovery of JAK kinase inhibitors; however, a disconnect between enzyme and cellular function is prominently displayed in the literature for this class of inhibitors.  Herein, we demonstrate utilizing the four JAK family members (JAK1, JAK2, JAK3, and TYK2) that the difference in the ATP Km of each individual kinase has a significant impact on the enzyme to cell inhibition translation.  We evaluated a large no. of JAK inhibitors in enzymic assays utilizing either 1 mM ATP or Km ATP for the four isoforms as well as in primary cell assays.  This data set provided the opportunity to examine individual kinase contributions to the heterodimeric kinase complexes mediating cellular signaling.  In contrast to a recent study, we demonstrate that for IL-15 cytokine signaling it is sufficient to inhibit either JAK1 or JAK3 to fully inhibit downstream STAT5 phosphorylation.  This addnl. data thus provides a crit. piece of information explaining why JAK1 has incorrectly been thought to have a dominant role over JAK3.  Beyond enabling a deeper understanding of JAK signaling, conducting similar analyses for other kinases by taking into account potency at high ATP rather than Km ATP may provide crucial insights into a compd.'s activity and selectivity in cellular contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYiMVl7OpPFLVg90H21EOLACvtfcHk0liGpeLvTbeKNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D&md5=c87874cb1748e13eef2aa241ecef3e79</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fcb5002125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5002125%26sid%3Dliteratum%253Aachs%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DJuba%26aufirst%3DB.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26atitle%3DATP-Mediated%2520kinome%2520selectivity%253A%2520The%2520missing%2520link%2520in%2520understanding%2520the%2520contribution%2520of%2520individual%2520JAK%2520kinase%2520isoforms%2520to%2520cellular%2520signaling%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1552%26epage%3D1558%26doi%3D10.1021%2Fcb5002125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faqua, C. F.</span>; <span class="NLM_string-name">Akomeah, R.</span>; <span class="NLM_string-name">Adunyah, S. E.</span></span> <span> </span><span class="NLM_article-title">IL-21 signaling and induction of cytokine expression in human leukemia cells and monocytes</span>. In  <i>Cytokines</i>, <span class="NLM_edition">1</span>st ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Behzadi, P.</span></span>, Ed.; <span class="NLM_publisher-name">IntechOpen</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_year">2020</span>; pp  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">132</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.5772%2Fintechopen.93004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=129-132&author=C.+F.+Faqua&author=R.+Akomeah&author=S.+E.+Adunyahauthor=P.+Behzadi&title=Cytokines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.5772%2Fintechopen.93004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.5772%252Fintechopen.93004%26sid%3Dliteratum%253Aachs%26aulast%3DFaqua%26aufirst%3DC.%2BF.%26atitle%3DIL-21%2520signaling%2520and%2520induction%2520of%2520cytokine%2520expression%2520in%2520human%2520leukemia%2520cells%2520and%2520monocytes%26btitle%3DCytokines%26aulast%3DBehzadi%26aufirst%3DP.%26pub%3DIntechOpen%26date%3D2020%26spage%3D129%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parisinos, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serghiou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsoulis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemingway, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hingorani, A. D.</span></span> <span> </span><span class="NLM_article-title">Variation in interleukin 6 receptor gene associates with risk of crohn’s disease and ulcerative colitis</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">306</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2018.05.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1053%2Fj.gastro.2018.05.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=29775600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSqurvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=303-306&author=C.+A.+Parisinosauthor=S.+Serghiouauthor=M.+Katsoulisauthor=M.+J.+Georgeauthor=R.+S.+Patelauthor=H.+Hemingwayauthor=A.+D.+Hingorani&title=Variation+in+interleukin+6+receptor+gene+associates+with+risk+of+crohn%E2%80%99s+disease+and+ulcerative+colitis&doi=10.1053%2Fj.gastro.2018.05.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Variation in Interleukin 6 Receptor Gene Associates With Risk of Crohn's Disease and Ulcerative Colitis</span></div><div class="casAuthors">Parisinos, Constantinos A.; Serghiou, Stylianos; Katsoulis, Michail; George, Marc Jonathan; Patel, Riyaz S.; Hemingway, Harry; Hingorani, Aroon D.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">303-306.e2</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Interleukin 6 (IL6) is an inflammatory cytokine; signaling via its receptor (IL6R) is believed to contribute to development of inflammatory bowel diseases (IBD).  The single nucleotide polymorphism rs2228145 in IL6R assocs. with increased levels of sol. IL6R (s-IL6R), as well as reduced IL6R signaling and risk of inflammatory disorders; its effects are similar to those of a therapeutic monoclonal antibody that blocks IL6R signaling.  We used the effect of rs2228145 on s-IL6R level as an indirect marker to investigate whether reduced IL6R signaling assocs. with risk of ulcerative colitis (UC) or Crohn's disease (CD).  In a genome-wide meta-anal. of 20,550 patients with CD, 17,647 patients with UC, and more than 40,000 individuals without IBD (controls), we found that rs2228145 (scaled to a 2-fold increase in s-IL6R) was assocd. with reduced risk of CD (odds ratio 0.876; 95% confidence interval 0.822-0.933; P = .00003) or UC (odds ratio 0.932; 95% confidence interval 0.875-0.996; P = .036).  These findings indicate that therapeutics designed to block IL6R signaling might be effective in treatment of IBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY9_9ewOfFbLVg90H21EOLACvtfcHk0lhkqSlvdg9d7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSqurvO&md5=eb69ffa02f9dfcbcd6f34e6aa2d16aaf</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2018.05.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2018.05.022%26sid%3Dliteratum%253Aachs%26aulast%3DParisinos%26aufirst%3DC.%2BA.%26aulast%3DSerghiou%26aufirst%3DS.%26aulast%3DKatsoulis%26aufirst%3DM.%26aulast%3DGeorge%26aufirst%3DM.%2BJ.%26aulast%3DPatel%26aufirst%3DR.%2BS.%26aulast%3DHemingway%26aufirst%3DH.%26aulast%3DHingorani%26aufirst%3DA.%2BD.%26atitle%3DVariation%2520in%2520interleukin%25206%2520receptor%2520gene%2520associates%2520with%2520risk%2520of%2520crohn%25E2%2580%2599s%2520disease%2520and%2520ulcerative%2520colitis%26jtitle%3DGastroenterology%26date%3D2018%26volume%3D155%26spage%3D303%26epage%3D306%26doi%3D10.1053%2Fj.gastro.2018.05.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">IL-10 and IL-10 receptor mutations in very early onset inflammatory bowel disease</span>. <i>Gastroenterol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.14740/gr740w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.14740%2Fgr740w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=28496525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Ojs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=65-69&author=L.+Zhuauthor=T.+Shiauthor=C.+Zhongauthor=Y.+Wangauthor=M.+Changauthor=X.+Liu&title=IL-10+and+IL-10+receptor+mutations+in+very+early+onset+inflammatory+bowel+disease&doi=10.14740%2Fgr740w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">IL-10 and IL-10 receptor mutations in very early onset inflammatory bowel disease</span></div><div class="casAuthors">Zhu, Lei; Shi, Tingting; Zhong, Chengdi; Wang, Yingde; Chang, Michael; Liu, Xiuli</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">65-69</span>CODEN:
                <span class="NLM_cas:coden">GRAECV</span>;
        ISSN:<span class="NLM_cas:issn">1918-2805</span>.
    
            (<span class="NLM_cas:orgname">Elmer Press</span>)
        </div><div class="casAbstract">Very early onset inflammatory bowel disease (VEO-IBD) is a unique disease entity with a complex genetic susceptibility in affected patients.  Next-generation gene sequencing techniques have revealed various monogenetic mutations contributing to the pathogenesis of VEO-IBD, including interleukin 10 (IL-10) and IL-10 receptor (IL- 10R) mutations.  In this article, we reviewed the features of and effective therapeutic options for VEO-IBD with IL-10 and/or IL-10R mutations.  The IL-10 signal pathway inhibits the release of several key cytokines and thereby has a significant anti-inflammatory effect in the gastrointestinal tract.  Mutations of the genes encoding IL-10 and/or IL-10R have been detected in VEO-IBD patients among myriad populations throughout the world.  VEO-IBD patients with IL-10 or IL-10R mutations often present with repeated bouts of bloody diarrhea, marked wt. loss, growth retardation, and recurrent perianal problems, including abscesses, fistulas, and significant fissures.  Moreover, some patients may have folliculitis and present with pulmonary infections.  While the therapeutic efficacy of immunosuppressants is typically poor in these patients, allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to improve symptoms significantly.  However, the long-term prognosis of VEO-IBD patients with IL-10 or IL-10R gene mutations treated with HSCT requires further exploration to verify the efficacy and safety of this treatment.  We concluded that clinicians should recognize the clin. phenotype of VEO-IBD, as mutational anal. of the IL-10 pathway can support the diagnosis and prompt early treatment of this complicated disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRL9LKTgHLPrVg90H21EOLACvtfcHk0lhkqSlvdg9d7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Ojs7c%253D&md5=ed0aac3ed2d43694363fb1fffd77f609</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.14740%2Fgr740w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14740%252Fgr740w%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DT.%26aulast%3DZhong%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DIL-10%2520and%2520IL-10%2520receptor%2520mutations%2520in%2520very%2520early%2520onset%2520inflammatory%2520bowel%2520disease%26jtitle%3DGastroenterol.%2520Res.%26date%3D2017%26volume%3D10%26spage%3D65%26epage%3D69%26doi%3D10.14740%2Fgr740w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Clinical development of JAK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Docking results of <b>11e</b> in the (A) TYK2 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GJ3">4GJ3</a>) and (B) JAK2 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Predicted binding conformation of <b>14l</b> with (A) TYK2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GJ3">4GJ3</a>) and (B) JAK2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a>). (C) Surface electrostatic potential of <b>14l</b> and TYK2 docking result and (D) surface electrostatic potential of<b>14l</b> and JAK2 docking result. Blue color represents the positive electrostatic potential and red the negative electrostatic potential.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Kinome-wide selectivity profiling of <b>14l</b> at 0.1 μM. Green circles denote <75% inhibition. Red circles denote >75% inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>14l</b> inhibited IL-6-, IFN-α-, GM-CSF-, and IL-4-induced phosphorylation of STAT in vitro. (A) IL-6-activated JAK1/JAK2/TYK2-dependent STAT3 phosphorylation in TF-1 cells. (B) IFN-α-activated JAK1/TYK2-dependent STAT1 phosphorylation in H9 cells. (C) GM-CSF-activated JAK2-dependent STAT5 phosphorylation in TF-1 cells. (D) IL-4-activated JAK1/JAK3-dependent STAT6 phosphorylation in THP-1 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Therapeutic efficacy of <b>14l</b> in the acute mice colitis model. (A) Disease activity index (DAI = weight loss score + mice status + stool consistency score + bleeding score) of C57BL/6 mice treated with <b>14l</b> (10 or 20 mg/kg), oral administration (p.o.), twice a day (bid.). *<i>P</i> < 0.05; **<i>P</i> < 0.01 versus vehicle group. (B) Record of the initial weight from day 0 to day 12. *<i>P</i> < 0.05; **<i>P</i> < 0.01 versus vehicle group. (C) Gross views of the colons in the different experimental groups at the end of administration. (D) Lengths of colons in each group. <sup>#</sup><i>P</i> < 0.05; <sup>##</sup><i>P</i> < 0.01; <sup>###</sup><i>P</i> < 0.001 versus normal group. *<i>P</i> < 0.05, <sup>**</sup><i>P</i> < 0.01, <sup>***</sup><i>P</i> < 0.001 versus vehicle group, <i>n</i> = 8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of <b>14l</b> on histopathology in DSS-induced colitis. (A) Representative photomicrographs of colon tissue sections stained with hematoxylin and eosin (H&E) (magnifications, ×100 and ×200). Arrows indicate crypt abscess (black), inflammatory cell infiltration (white), epithelium surface erosion (blue), submucosal edema (yellow), and crypts/regeneration of crypts (green) (B). Histopathological score of each group after microscopic analysis of tissue sections. *<i>P</i> < 0.05 versus vehicle group, <i>n</i> = 8. Histopathological score = inflammation + mucosal damage + crypt damage + range of lesions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <b>14l</b> suppressed the secretion of IL-6 and TNF-α and promoted the IL-10. Levels of IL-6 (A), IL-10 (B), and TNF-α (C) in the colon tissue. Levels of IL-6 (D), IL-10 (E), and TNF-α (F) in serum. *<i>P</i> < 0.05, <sup>**</sup><i>P</i> < 0.01, <sup>***</sup><i>P</i> < 0.001 versus vehicle group, <i>n</i> = 8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Preparation of Compound <b>16a–16u</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf), 1,4-dioxane/H<sub>2</sub>O, 98 °C, 3–4 h.</p></p></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Preparation of Compounds <b>11a–11s, 12a–12g, 13a–13l, 14a</b>, and <b>14e–14j</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) di-<i>tert</i>-butyl dicarbonate, 4-dimethylaminopyridine (4-DMAP), tetrahydrofuran (THF), 60 °C, 3 h; (b) H<sub>2</sub>, Pd/C, EtOH, rt, 12 h; (c) Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 110 °C, 4 h; (d) trifluoroacetic acid (TFA), dichloromethane (DCM), rt., 4 h; (e) (i) HATU, DIEA, DMF or (ii) DIEA, DCM, 0 °C;</p></p></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/medium/jm0c01468_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Preparation of Compound <b>14b–14d, 14k–14o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01468/20210218/images/large/jm0c01468_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01468&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 110 °C, 4 h; (b) K<sub>2</sub>CO<sub>3</sub>, MeOH/H<sub>2</sub>O, 100 °C, 4 h; (c) DIEA, DCM, 0 °C; (d) NaH, dry DMF; (e) H<sub>2</sub>, Pd/C, EtOH, rt, 12 h;</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i114">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43228" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43228" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 41 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alatab, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepanlou, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikuta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahedi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisignano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeghi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abolhassani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alipour, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almadi, M. A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almasi-Hashiani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anushiravani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arabloo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atique, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badawi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baig, A. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhala, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bijani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzì, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daryani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eftekhari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haj-Mirzaian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haj-Mirzaian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasanzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashemian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Househ, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilesanmi, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafari Balalami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kengne, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malekzadeh, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meretoja, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestrovic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirrakhimov, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzaei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammad, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokdad, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monasta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negoi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourshams, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poustchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramezanzadeh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawaf, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawaf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezaei, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronfani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepehrimanesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharafi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siabani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sima, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soheili, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotoudehmanesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suleria, H. A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesfay, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsoi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wondmieneh, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarghi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirac, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malekzadeh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naghavi, M.</span></span> <span> </span><span class="NLM_article-title">The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017</span>. <i>Lancet Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1016/S2468-1253(19)30333-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2FS2468-1253%2819%2930333-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=31648971" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&pages=17-30&author=S.+Alatabauthor=S.+G.+Sepanlouauthor=K.+Ikutaauthor=H.+Vahediauthor=C.+Bisignanoauthor=S.+Safiriauthor=A.+Sadeghiauthor=M.+R.+Nixonauthor=A.+Abdoliauthor=H.+Abolhassaniauthor=V.+Alipourauthor=M.+A.+H.+Almadiauthor=A.+Almasi-Hashianiauthor=A.+Anushiravaniauthor=J.+Arablooauthor=S.+Atiqueauthor=A.+Awasthiauthor=A.+Badawiauthor=A.+A.+A.+Baigauthor=N.+Bhalaauthor=A.+Bijaniauthor=A.+Biondiauthor=A.+M.+Borz%C3%ACauthor=K.+E.+Burkeauthor=F.+Carvalhoauthor=A.+Daryaniauthor=M.+Dubeyauthor=A.+Eftekhariauthor=E.+Fernandesauthor=J.+C.+Fernandesauthor=F.+Fischerauthor=A.+Haj-Mirzaianauthor=A.+Haj-Mirzaianauthor=A.+Hasanzadehauthor=M.+Hashemianauthor=S.+I.+Hayauthor=C.+L.+Hoangauthor=M.+Househauthor=O.+S.+Ilesanmiauthor=N.+Jafari+Balalamiauthor=S.+L.+Jamesauthor=A.+P.+Kengneauthor=M.+M.+Malekzadehauthor=S.+Meratauthor=T.+J.+Meretojaauthor=T.+Mestrovicauthor=E.+M.+Mirrakhimovauthor=H.+Mirzaeiauthor=K.+A.+Mohammadauthor=A.+H.+Mokdadauthor=L.+Monastaauthor=I.+Negoiauthor=T.+H.+Nguyenauthor=C.+T.+Nguyenauthor=A.+Pourshamsauthor=H.+Poustchiauthor=M.+Rabieeauthor=N.+Rabieeauthor=K.+Ramezanzadehauthor=D.+L.+Rawafauthor=S.+Rawafauthor=N.+Rezaeiauthor=S.+R.+Robinsonauthor=L.+Ronfaniauthor=S.+Saxenaauthor=M.+Sepehrimaneshauthor=M.+A.+Shaikhauthor=Z.+Sharafiauthor=M.+Sharifauthor=S.+Siabaniauthor=A.+R.+Simaauthor=J.+A.+Singhauthor=A.+Soheiliauthor=R.+Sotoudehmaneshauthor=H.+A.+R.+Suleriaauthor=B.+E.+Tesfayauthor=B.+Tranauthor=D.+Tsoiauthor=M.+Vacanteauthor=A.+B.+Wondmienehauthor=A.+Zarghiauthor=Z.-J.+Zhangauthor=M.+Diracauthor=R.+Malekzadehauthor=M.+Naghavi&title=The+global%2C+regional%2C+and+national+burden+of+inflammatory+bowel+disease+in+195+countries+and+territories%2C+1990%E2%80%932017%3A+a+systematic+analysis+for+the+global+burden+of+disease+study+2017&doi=10.1016%2FS2468-1253%2819%2930333-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS2468-1253%2819%2930333-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2468-1253%252819%252930333-4%26sid%3Dliteratum%253Aachs%26aulast%3DAlatab%26aufirst%3DS.%26aulast%3DSepanlou%26aufirst%3DS.%2BG.%26aulast%3DIkuta%26aufirst%3DK.%26aulast%3DVahedi%26aufirst%3DH.%26aulast%3DBisignano%26aufirst%3DC.%26aulast%3DSafiri%26aufirst%3DS.%26aulast%3DSadeghi%26aufirst%3DA.%26aulast%3DNixon%26aufirst%3DM.%2BR.%26aulast%3DAbdoli%26aufirst%3DA.%26aulast%3DAbolhassani%26aufirst%3DH.%26aulast%3DAlipour%26aufirst%3DV.%26aulast%3DAlmadi%26aufirst%3DM.%2BA.%2BH.%26aulast%3DAlmasi-Hashiani%26aufirst%3DA.%26aulast%3DAnushiravani%26aufirst%3DA.%26aulast%3DArabloo%26aufirst%3DJ.%26aulast%3DAtique%26aufirst%3DS.%26aulast%3DAwasthi%26aufirst%3DA.%26aulast%3DBadawi%26aufirst%3DA.%26aulast%3DBaig%26aufirst%3DA.%2BA.%2BA.%26aulast%3DBhala%26aufirst%3DN.%26aulast%3DBijani%26aufirst%3DA.%26aulast%3DBiondi%26aufirst%3DA.%26aulast%3DBorz%25C3%25AC%26aufirst%3DA.%2BM.%26aulast%3DBurke%26aufirst%3DK.%2BE.%26aulast%3DCarvalho%26aufirst%3DF.%26aulast%3DDaryani%26aufirst%3DA.%26aulast%3DDubey%26aufirst%3DM.%26aulast%3DEftekhari%26aufirst%3DA.%26aulast%3DFernandes%26aufirst%3DE.%26aulast%3DFernandes%26aufirst%3DJ.%2BC.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DHaj-Mirzaian%26aufirst%3DA.%26aulast%3DHaj-Mirzaian%26aufirst%3DA.%26aulast%3DHasanzadeh%26aufirst%3DA.%26aulast%3DHashemian%26aufirst%3DM.%26aulast%3DHay%26aufirst%3DS.%2BI.%26aulast%3DHoang%26aufirst%3DC.%2BL.%26aulast%3DHouseh%26aufirst%3DM.%26aulast%3DIlesanmi%26aufirst%3DO.%2BS.%26aulast%3DJafari%2BBalalami%26aufirst%3DN.%26aulast%3DJames%26aufirst%3DS.%2BL.%26aulast%3DKengne%26aufirst%3DA.%2BP.%26aulast%3DMalekzadeh%26aufirst%3DM.%2BM.%26aulast%3DMerat%26aufirst%3DS.%26aulast%3DMeretoja%26aufirst%3DT.%2BJ.%26aulast%3DMestrovic%26aufirst%3DT.%26aulast%3DMirrakhimov%26aufirst%3DE.%2BM.%26aulast%3DMirzaei%26aufirst%3DH.%26aulast%3DMohammad%26aufirst%3DK.%2BA.%26aulast%3DMokdad%26aufirst%3DA.%2BH.%26aulast%3DMonasta%26aufirst%3DL.%26aulast%3DNegoi%26aufirst%3DI.%26aulast%3DNguyen%26aufirst%3DT.%2BH.%26aulast%3DNguyen%26aufirst%3DC.%2BT.%26aulast%3DPourshams%26aufirst%3DA.%26aulast%3DPoustchi%26aufirst%3DH.%26aulast%3DRabiee%26aufirst%3DM.%26aulast%3DRabiee%26aufirst%3DN.%26aulast%3DRamezanzadeh%26aufirst%3DK.%26aulast%3DRawaf%26aufirst%3DD.%2BL.%26aulast%3DRawaf%26aufirst%3DS.%26aulast%3DRezaei%26aufirst%3DN.%26aulast%3DRobinson%26aufirst%3DS.%2BR.%26aulast%3DRonfani%26aufirst%3DL.%26aulast%3DSaxena%26aufirst%3DS.%26aulast%3DSepehrimanesh%26aufirst%3DM.%26aulast%3DShaikh%26aufirst%3DM.%2BA.%26aulast%3DSharafi%26aufirst%3DZ.%26aulast%3DSharif%26aufirst%3DM.%26aulast%3DSiabani%26aufirst%3DS.%26aulast%3DSima%26aufirst%3DA.%2BR.%26aulast%3DSingh%26aufirst%3DJ.%2BA.%26aulast%3DSoheili%26aufirst%3DA.%26aulast%3DSotoudehmanesh%26aufirst%3DR.%26aulast%3DSuleria%26aufirst%3DH.%2BA.%2BR.%26aulast%3DTesfay%26aufirst%3DB.%2BE.%26aulast%3DTran%26aufirst%3DB.%26aulast%3DTsoi%26aufirst%3DD.%26aulast%3DVacante%26aufirst%3DM.%26aulast%3DWondmieneh%26aufirst%3DA.%2BB.%26aulast%3DZarghi%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DZ.-J.%26aulast%3DDirac%26aufirst%3DM.%26aulast%3DMalekzadeh%26aufirst%3DR.%26aulast%3DNaghavi%26aufirst%3DM.%26atitle%3DThe%2520global%252C%2520regional%252C%2520and%2520national%2520burden%2520of%2520inflammatory%2520bowel%2520disease%2520in%2520195%2520countries%2520and%2520territories%252C%25201990%25E2%2580%25932017%253A%2520a%2520systematic%2520analysis%2520for%2520the%2520global%2520burden%2520of%2520disease%2520study%25202017%26jtitle%3DLancet%2520Gastroenterol.%2520Hepatol.%26date%3D2020%26volume%3D5%26spage%3D17%26epage%3D30%26doi%3D10.1016%2FS2468-1253%2819%2930333-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mizoguchi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, T.</span></span> <span> </span><span class="NLM_article-title">Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models</span>. <i>Intest. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.5217/ir.2019.09154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.5217%2Fir.2019.09154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=32326669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A280%3ADC%252BB38zovVantQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2020&pages=151-167&author=E.+Mizoguchiauthor=D.+Lowauthor=Y.+Ezakiauthor=T.+Okada&title=Recent+updates+on+the+basic+mechanisms+and+pathogenesis+of+inflammatory+bowel+diseases+in+experimental+animal+models&doi=10.5217%2Fir.2019.09154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models</span></div><div class="casAuthors">Mizoguchi Emiko; Ezaki Yui; Okada Toshiyuki; Mizoguchi Emiko; Low Daren</div><div class="citationInfo"><span class="NLM_cas:title">Intestinal research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-167</span>
        ISSN:<span class="NLM_cas:issn">1598-9100</span>.
    </div><div class="casAbstract">The specific pathogenesis underlining inflammatory bowel disease (IBD) is very complicated, and it is further more difficult to clearly explain the pathophysiology of 2 major forms of IBD, Crohn's disease (CD) and ulcerative colitis (UC), and both disorders affect individuals throughout life.  Despite every extensive effort, the interplay among genetic factors, immunological factors, environmental factors and intestinal microbes is still completely unrevealed.  Animal models are indispensable to find out mechanistic details that will facilitate better preclinical setting to target specific components involved in the pathogenesis of IBD.  Based on many recent reports, dysbiosis of the commensal microbiota is implicated in the pathogenesis of several diseases, not only IBD but also colon cancer, obesity, psoriasis as well as allergic disorders, in both human and animal models.  Advanced technologies including cell-specific and inducible knockout systems, which are recently employed to mouse IBD models, have further enhanced the ability of developing new therapeutic strategies for IBD.  Furthermore, data from these mouse models highlight the critical involvement of dysregulated immune responses and impaired colonic epithelial defense system in the pathogenesis of IBD.  In this review, we will explain from the history of animal models of IBD to the recent reports of the latest compounds, therapeutic strategies, and approaches tested on IBD animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxW8KR0DOSZ5PlX7E30qdzfW6udTcc2eYl7ovUQCnRxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zovVantQ%253D%253D&md5=fc6c235570b7aa72bab2365db1370e84</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.5217%2Fir.2019.09154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5217%252Fir.2019.09154%26sid%3Dliteratum%253Aachs%26aulast%3DMizoguchi%26aufirst%3DE.%26aulast%3DLow%26aufirst%3DD.%26aulast%3DEzaki%26aufirst%3DY.%26aulast%3DOkada%26aufirst%3DT.%26atitle%3DRecent%2520updates%2520on%2520the%2520basic%2520mechanisms%2520and%2520pathogenesis%2520of%2520inflammatory%2520bowel%2520diseases%2520in%2520experimental%2520animal%2520models%26jtitle%3DIntest.%2520Res.%26date%3D2020%26volume%3D18%26spage%3D151%26epage%3D167%26doi%3D10.5217%2Fir.2019.09154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panés, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span> <span> </span><span class="NLM_article-title">JAK Inhibitors: back to small molecules for the treatment of IBD</span>. <i>J. Crohn’s Colitis</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">S711</span>– <span class="NLM_lpage">S712</span>, <span class="refDoi"> DOI: 10.1093/ecco-jcc/jjaa109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1093%2Fecco-jcc%2Fjjaa109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=32737980" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2020&pages=S711-S712&author=J.+Pan%C3%A9sauthor=S.+Vermeire&title=JAK+Inhibitors%3A+back+to+small+molecules+for+the+treatment+of+IBD&doi=10.1093%2Fecco-jcc%2Fjjaa109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fecco-jcc%2Fjjaa109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fecco-jcc%252Fjjaa109%26sid%3Dliteratum%253Aachs%26aulast%3DPan%25C3%25A9s%26aufirst%3DJ.%26aulast%3DVermeire%26aufirst%3DS.%26atitle%3DJAK%2520Inhibitors%253A%2520back%2520to%2520small%2520molecules%2520for%2520the%2520treatment%2520of%2520IBD%26jtitle%3DJ.%2520Crohn%25E2%2580%2599s%2520Colitis%26date%3D2020%26volume%3D14%26spage%3DS711%26epage%3DS712%26doi%3D10.1093%2Fecco-jcc%2Fjjaa109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Rocha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duijvestein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faubion, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGovern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetrano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vande Casteele, N.</span></span> <span> </span><span class="NLM_article-title">JAK–STAT pathway targeting for the treatment of inflammatory bowel disease</span>. <i>Nat. Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1038/s41575-020-0273-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1038%2Fs41575-020-0273-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=32203403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A280%3ADC%252BB383msFGruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=323-337&author=A.+Salasauthor=C.+Hernandez-Rochaauthor=M.+Duijvesteinauthor=W.+Faubionauthor=D.+McGovernauthor=S.+Vermeireauthor=S.+Vetranoauthor=N.+Vande+Casteele&title=JAK%E2%80%93STAT+pathway+targeting+for+the+treatment+of+inflammatory+bowel+disease&doi=10.1038%2Fs41575-020-0273-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">JAK-STAT pathway targeting for the treatment of inflammatory bowel disease</span></div><div class="casAuthors">Salas Azucena; Salas Azucena; Hernandez-Rocha Cristian; Duijvestein Marjolijn; Faubion William; McGovern Dermot; Vermeire Severine; Vetrano Stefania; Vetrano Stefania; Vande Casteele Niels; Vande Casteele Niels</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Gastroenterology & hepatology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">323-337</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cytokines are involved in intestinal homeostasis and pathological processes associated with inflammatory bowel disease (IBD).  The biological effects of cytokines, including several involved in the pathology of Crohn's disease and ulcerative colitis, occur as a result of receptor-mediated signalling through the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) DNA-binding families of proteins.  Although therapies targeting cytokines have revolutionized IBD therapy, they have historically targeted individual cytokines, and an unmet medical need exists for patients who do not respond to or lose response to these treatments.  Several small-molecule inhibitors of JAKs that have the potential to affect multiple pro-inflammatory cytokine-dependent pathways are in clinical development for the treatment of IBD, with one agent, tofacitinib, already approved for ulcerative colitis and several other agents with demonstrated efficacy in early phase trials.  This Review describes the current understanding of JAK-STAT signalling in intestinal homeostasis and disease and the rationale for targeting this pathway as a treatment for IBD.  The available evidence for the efficacy, safety and pharmacokinetics of JAK inhibitors in IBD as well as the potential approaches to optimize treatment with these agents, such as localized delivery or combination therapy, are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSno5DPCW-EPx0LsK7uFuY7fW6udTcc2eaVlG9L9b-C3rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383msFGruw%253D%253D&md5=5d99314904b35088e90dfb6b0861016d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fs41575-020-0273-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41575-020-0273-0%26sid%3Dliteratum%253Aachs%26aulast%3DSalas%26aufirst%3DA.%26aulast%3DHernandez-Rocha%26aufirst%3DC.%26aulast%3DDuijvestein%26aufirst%3DM.%26aulast%3DFaubion%26aufirst%3DW.%26aulast%3DMcGovern%26aufirst%3DD.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DVetrano%26aufirst%3DS.%26aulast%3DVande%2BCasteele%26aufirst%3DN.%26atitle%3DJAK%25E2%2580%2593STAT%2520pathway%2520targeting%2520for%2520the%2520treatment%2520of%2520inflammatory%2520bowel%2520disease%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2020%26volume%3D17%26spage%3D323%26epage%3D337%26doi%3D10.1038%2Fs41575-020-0273-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1038%2Fnrd.2017.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=29104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=843-862&author=D.+M.+Schwartzauthor=Y.+Kannoauthor=A.+Villarinoauthor=M.+Wardauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=JAK+inhibition+as+a+therapeutic+strategy+for+immune+and+inflammatory+diseases&doi=10.1038%2Fnrd.2017.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Kanno, Yuka; Villarino, Alejandro; Ward, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-862</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their assocd. signalling pathways.  Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-mol. inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.  Building on the clin. success of first-generation jakinibs, second-generation compds. that claim to be more selective are currently undergoing development and proceeding to clin. trials.  However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs.  This Review discusses the biol. of jakinibs from a translational perspective, focusing on recent insights from clin. trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TNpGT01l8rVg90H21EOLACvtfcHk0lhUDJAgk3MyEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO&md5=4607422f83f94c0c7194935d6d460c31</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DVillarino%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAK%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520immune%2520and%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D843%26epage%3D862%26doi%3D10.1038%2Fnrd.2017.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2015.167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1038%2Fnrrheum.2015.167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=26633291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=25-36&author=D.+M.+Schwartzauthor=M.+Bonelliauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=Type+I%2FII+cytokines%2C+JAKs%2C+and+new+strategies+for+treating+autoimmune+diseases&doi=10.1038%2Fnrrheum.2015.167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Bonelli, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-36</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cytokines are major drivers of autoimmunity, and biol. agents targeting cytokines have revolutionized the treatment of immune-mediated diseases.  Despite the effectiveness of these drugs, they do not induce complete remission in all patients, prompting the development of alternative strategies - including targeting of intracellular signal transduction pathways downstream of cytokines.  Many cytokines that bind type I and type II cytokine receptors are crit. regulators of immune-mediated diseases and employ the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway to exert their effect.  Pharmacol. inhibition of JAKs blocks the actions of type I/II cytokines, and within the past 3 years therapeutic JAK inhibitors, or Jakinibs, have become available to rheumatologists.  Jakinibs have proven effective for the treatment of rheumatoid arthritis and other inflammatory diseases.  Adverse effects of these agents are largely related to their mode of action and include infections and hyperlipidemia.  Jakinibs are currently being investigated for a no. of new indications, and second-generation selective Jakinibs are being developed and tested.  Targeting STATs could be a future avenue for the treatment of rheumatol. diseases, although substantial challenges remain.  Nonetheless, the ability to therapeutically target intracellular signalling pathways has already created a new paradigm for the treatment of rheumatol. disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUdr1Dh92dnLVg90H21EOLACvtfcHk0lhUDJAgk3MyEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ&md5=e06f7ab6424f1fbdbf481c75fa9ebd23</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2015.167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2015.167%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DBonelli%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DType%2520I%252FII%2520cytokines%252C%2520JAKs%252C%2520and%2520new%2520strategies%2520for%2520treating%2520autoimmune%2520diseases%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2016%26volume%3D12%26spage%3D25%26epage%3D36%26doi%3D10.1038%2Fnrrheum.2015.167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Vries, L. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildenberg, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonge, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Haens, G. R.</span></span> <span> </span><span class="NLM_article-title">The future of janus kinase inhibitors in inflammatory bowel disease</span>. <i>J. Crohn’s Colitis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">893</span>, <span class="refDoi"> DOI: 10.1093/ecco-jcc/jjx003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1093%2Fecco-jcc%2Fjjx003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=28158411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A280%3ADC%252BC1c3ivVejsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=885-893&author=L.+C.+S.+De%0AVriesauthor=M.+E.+Wildenbergauthor=W.+J.+De+Jongeauthor=G.+R.+D%E2%80%99Haens&title=The+future+of+janus+kinase+inhibitors+in+inflammatory+bowel+disease&doi=10.1093%2Fecco-jcc%2Fjjx003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease</span></div><div class="casAuthors">De Vries L C S; Wildenberg M E; De Jonge W J; De Vries L C S; Wildenberg M E; D'Haens G R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Crohn's & colitis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">885-893</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease, are disabling conditions characterised by chronic, relapsing inflammation of the gastrointestinal tract.  Current treatments are not universally effective or, in the case of therapeutic antibodies, are hampered by immune responses.  Janus kinase inhibitors are orally delivered small molecules that target cytokine signalling by preventing phosphorylation of Janus kinases associated with the cytokine receptor.  Subsequently, phosphorylation of signal transducers and activators of transcription that relay Janus kinase signalling and transcription of cytokines in the nucleus will be diminished.  Key cytokines in the pathogenesis of inflammatory bowel diseases are targeted by Janus kinase inhibitors.  Several Janus kinase inhibitors are in development for the treatment of inflammatory bowel diseases.  Tofacitinib, inhibiting signalling via all Janus kinase family members, was effective in phase 2 and 3 trials in moderate-severe ulcerative colitis.  GSK2586184, a Janus kinase 1 selective inhibitor, induced clinical and endoscopic response in ulcerative colitis; however, the study was discontinued at an early stage due to liver toxicity observed in systemic lupus patients receiving the drug.  Filgotinib, a Janus kinase 1 selective inhibitor investigated in treatment of Crohn's disease, was superior to placebo.  As adverse events associated with the broad immunological effect of these agents have been reported, the future application of these drugs is potentially limited.  We will discuss the treatment efficacy of Janus kinase inhibition in inflammatory bowel diseases, how current Janus kinase inhibitors available target immune responses relevant in inflammatory bowel disease, and whether more specific kinase inhibition could be effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9MSlSyh0K8d1QT_1O5WBYfW6udTcc2eYly3WzPwc5Erntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3ivVejsw%253D%253D&md5=0185380438c0f04885828160a8d1d512</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fecco-jcc%2Fjjx003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fecco-jcc%252Fjjx003%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BVries%26aufirst%3DL.%2BC.%2BS.%26aulast%3DWildenberg%26aufirst%3DM.%2BE.%26aulast%3DDe%2BJonge%26aufirst%3DW.%2BJ.%26aulast%3DD%25E2%2580%2599Haens%26aufirst%3DG.%2BR.%26atitle%3DThe%2520future%2520of%2520janus%2520kinase%2520inhibitors%2520in%2520inflammatory%2520bowel%2520disease%26jtitle%3DJ.%2520Crohn%25E2%2580%2599s%2520Colitis%26date%3D2017%26volume%3D11%26spage%3D885%26epage%3D893%26doi%3D10.1093%2Fecco-jcc%2Fjjx003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span> <span> </span><span class="NLM_article-title">Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1038</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1038%2Fleu.2017.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=28119526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC2sXislyms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=1023-1038&author=E.+Leroyauthor=S.+N.+Constantinescu&title=Rethinking+JAK2+inhibition%3A+towards+novel+strategies+of+more+specific+and+versatile+janus+kinase+inhibition&doi=10.1038%2Fleu.2017.43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition</span></div><div class="casAuthors">Leroy, E.; Constantinescu, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1023-1038</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are required for cytokine receptor signaling.  Since the discovery of the highly prevalent JAK2 V617F mutation in myeloproliferative neoplasms (MPNs), JAK2 became a prime target for inhibition.  Only one approved JAK2 inhibitor exists, with pos., but not curative effects in MPNs, and promising effects in autoimmune diseases and cancer.  On the basis of recent advances in the structural features regulating both normal and mutant JAKs, as well as in small-mol. targeting, we review the current state of JAK2 inhibitor development and present novel avenues of selecting JAK2 inhibitors, with broad and narrow specificities and extend these approaches to other JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLVJS8PwHOlbVg90H21EOLACvtfcHk0lg_jA_BuyDYag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXislyms7w%253D&md5=0dc333d94e27daad1d32110dee26e637</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.43%26sid%3Dliteratum%253Aachs%26aulast%3DLeroy%26aufirst%3DE.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26atitle%3DRethinking%2520JAK2%2520inhibition%253A%2520towards%2520novel%2520strategies%2520of%2520more%2520specific%2520and%2520versatile%2520janus%2520kinase%2520inhibition%26jtitle%3DLeukemia%26date%3D2017%26volume%3D31%26spage%3D1023%26epage%3D1038%26doi%3D10.1038%2Fleu.2017.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Actis, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagoonee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribaldone, D. G.</span></span> <span> </span><span class="NLM_article-title">History of inflammatory bowel diseases</span>. <i>J. Clin. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1970</span>, <span class="refDoi"> DOI: 10.3390/jcm8111970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.3390%2Fjcm8111970" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsl2htbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=1970&author=G.+C.+Actisauthor=R.+Pellicanoauthor=S.+Fagooneeauthor=D.+G.+Ribaldone&title=History+of+inflammatory+bowel+diseases&doi=10.3390%2Fjcm8111970"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">History of inflammatory bowel diseases</span></div><div class="casAuthors">Actis, Giovanni Clemente; Pellicano, Rinaldo; Fagoonee, Sharmila; Ribaldone, Davide Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1970</span>CODEN:
                <span class="NLM_cas:coden">JCMOHK</span>;
        ISSN:<span class="NLM_cas:issn">2077-0383</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the intestinal mucosa and unknown etiol.  In this review, we identified three main eras in the IBD history.  Between the 19th and the 20th century, the primary task had been the definition of the diagnostic criteria in order to differentiate the new entity from intestinal tuberculosis.  In the 20th century, an intense and prolific therapeutic research prevailed, culminating in the introduction of biol. drugs in the clin. setting.  Since the beginning of the 21st century, traditional definition criteria have been challenged by holistic criteria in an effort to seek a still unattained cure.  Centuries of worldwide efforts on IBD etiol. and therapy search have culminated in this novel strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3acTnsmLXSrVg90H21EOLACvtfcHk0lg_jA_BuyDYag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsl2htbo%253D&md5=d2c5b67d7ae268253b1f51d203d5a901</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3390%2Fjcm8111970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fjcm8111970%26sid%3Dliteratum%253Aachs%26aulast%3DActis%26aufirst%3DG.%2BC.%26aulast%3DPellicano%26aufirst%3DR.%26aulast%3DFagoonee%26aufirst%3DS.%26aulast%3DRibaldone%26aufirst%3DD.%2BG.%26atitle%3DHistory%2520of%2520inflammatory%2520bowel%2520diseases%26jtitle%3DJ.%2520Clin.%2520Med.%26date%3D2019%26volume%3D8%26spage%3D1970%26doi%3D10.3390%2Fjcm8111970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monaghan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fateen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, G. W.</span></span> <span> </span><span class="NLM_article-title">Review article: novel oral-targeted therapies in inflammatory bowel disease</span>. <i>Aliment. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1610</span>– <span class="NLM_lpage">1622</span>, <span class="refDoi"> DOI: 10.1111/apt.14669</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1111%2Fapt.14669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=29672874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A280%3ADC%252BC1MjksVCktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2018&pages=1610-1622&author=J.+R.+Whiteauthor=F.+Phillipsauthor=T.+Monaghanauthor=W.+Fateenauthor=S.+Samuelauthor=S.+Ghoshauthor=G.+W.+Moran&title=Review+article%3A+novel+oral-targeted+therapies+in+inflammatory+bowel+disease&doi=10.1111%2Fapt.14669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Review article: novel oral-targeted therapies in inflammatory bowel disease</span></div><div class="casAuthors">White J R; Phillips F; Monaghan T; Fateen W; Samuel S; Moran G W; Ghosh S</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary pharmacology & therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1610-1622</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  There is a great unmet clinical need for efficacious, tolerable, economical and orally administrated drugs for the treatment of inflammatory bowel disease (IBD).  New therapeutic avenues have become possible including the development of medications that target specific genetic pathways found to be relevant in other immune mediated diseases.  AIMS:  To provide an overview of recent clinical trials for new generation oral targeted medications that may have a future role in IBD management.  METHODS:  Pubmed and Medline searches were performed up to 1 March 2018 using keywords: "IBD", "UC", "CD", "inflammatory bowel disease" "ulcerative colitis", "Crohn's disease" in combination with "phase", "study", "trial" and "oral".  A manual search of the clinical trial register, article reference lists, abstracts from meetings of Digestive Disease Week, United European Gastroenterology Week and ECCO congress were also conducted.  RESULTS:  In randomised controlled trials primary efficacy endpoints were met for tofacitinib (JAK 1/3 inhibitor-phase III), upadacitinib (JAK 1 inhibitor-phase II) and AJM300 (α4-integrin antagonist-phase II) in ulcerative colitis.  Ozanimod (S1P receptor agonist-phase II) also demonstrated clinical remission.  For Crohn's disease, filgotinib (JAK1 inhibitor-phase II) met primary endpoints and laquinimod (quinolone-3-carboxide small molecule-phase II) was also efficacious.  Trials using mongersen (SMAD7 inhibitor) and vidofludimus (dihydroorotate dehydrogenase inhibitor) have been halted.  CONCLUSIONS:  This is potentially the start of an exciting new era in which multiple therapeutic options are at the disposal of physicians to treat IBD on an individualised basis.  Head-to-head studies with existing treatments and longer term safety data are needed for this to be possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTA18heQeJUy7FU0A1HOshhfW6udTcc2eZZLLFALlknjrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjksVCktA%253D%253D&md5=f5d12f9a01fd3b4969781ff2acec454a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fapt.14669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fapt.14669%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%2BR.%26aulast%3DPhillips%26aufirst%3DF.%26aulast%3DMonaghan%26aufirst%3DT.%26aulast%3DFateen%26aufirst%3DW.%26aulast%3DSamuel%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DMoran%26aufirst%3DG.%2BW.%26atitle%3DReview%2520article%253A%2520novel%2520oral-targeted%2520therapies%2520in%2520inflammatory%2520bowel%2520disease%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2018%26volume%3D47%26spage%3D1610%26epage%3D1622%26doi%3D10.1111%2Fapt.14669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintás-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caulder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waeltz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3109</span>– <span class="NLM_lpage">3117</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-04-214957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1182%2Fblood-2009-04-214957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=20130243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3109-3117&author=A.+Quint%C3%A1s-Cardamaauthor=K.+Vaddiauthor=P.+Liuauthor=T.+Manshouriauthor=J.+Liauthor=P.+A.+Scherleauthor=E.+Caulderauthor=X.+Wenauthor=Y.+Liauthor=P.+Waeltzauthor=M.+Ruparauthor=T.+Burnauthor=Y.+Loauthor=J.+Kelleyauthor=M.+Covingtonauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=P.+Haleyauthor=H.+Kantarjianauthor=J.+S.+Fridmanauthor=S.+Verstovsek&title=Preclinical+characterization+of+the+selective+JAK1%2F2+inhibitor+INCB018424%3A+therapeutic+implications+for+the+treatment+of+myeloproliferative+neoplasms&doi=10.1182%2Fblood-2009-04-214957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Vaddi, Kris; Liu, Phillip; Manshouri, Taghi; Li, Jun; Scherle, Peggy A.; Caulder, Eian; Wen, Xiaoming; Li, Yanlong; Waeltz, Paul; Rupar, Mark; Burn, Timothy; Lo, Yvonne; Kelley, Jennifer; Covington, Maryanne; Shepard, Stacey; Rodgers, James D.; Haley, Patrick; Kantarjian, Hagop; Fridman, Jordan S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3109-3117</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN) phenotypes in mice, establishing JAK2 inhibition as a potential therapeutic strategy.  Although most polycythemia vera patients carry the JAK2V617F mutation, half of those with essential thrombocythemia or primary myelofibrosis do not, suggesting alternative mechanisms for constitutive JAK-STAT signaling in MPNs.  Most patients with primary myelofibrosis have elevated levels of JAK-dependent proinflammatory cytokines (eg, interleukin-6) consistent with our observation of JAK1 hyperactivation.  Accordingly, we evaluated the effectiveness of selective JAK1/2 inhibition in exptl. models relevant to MPNs and report on the effects of INCB018424, the first potent, selective, oral JAK1/JAK2 inhibitor to enter the clinic.  INCB018424 inhibited interleukin-6 signaling (50% inhibitory concn. [IC50] = 281nM), and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127nM).  In primary cultures, INCB018424 preferentially suppressed erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67nM) vs. healthy donors (IC50 > 400nM).  In a mouse model of JAK2V617F+ MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects.  Preliminary clin. results support these preclin. data and establish INCB018424 as a promising oral agent for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvKGz1l6Y-CbVg90H21EOLACvtfcHk0ljy2aMDLCcbgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D&md5=cd52b7013d76ed00ca2df22444c45160</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-04-214957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-04-214957%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCaulder%26aufirst%3DE.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWaeltz%26aufirst%3DP.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DY.%26aulast%3DKelley%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520selective%2520JAK1%252F2%2520inhibitor%2520INCB018424%253A%2520therapeutic%2520implications%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D3109%26epage%3D3117%26doi%3D10.1182%2Fblood-2009-04-214957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritomo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span> <span> </span><span class="NLM_article-title">Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4971</span>– <span class="NLM_lpage">4983</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2Fj.bmc.2018.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=30145050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyktrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=4971-4983&author=H.+Hamaguchiauthor=Y.+Amanoauthor=A.+Moritomoauthor=S.+Shirakamiauthor=Y.+Nakajimaauthor=K.+Nakaiauthor=N.+Nomuraauthor=M.+Itoauthor=Y.+Higashiauthor=T.+Inoue&title=Discovery+and+structural+characterization+of+peficitinib+%28ASP015K%29+as+a+novel+and+potent+JAK+inhibitor&doi=10.1016%2Fj.bmc.2018.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor</span></div><div class="casAuthors">Hamaguchi, Hisao; Amano, Yasushi; Moritomo, Ayako; Shirakami, Shohei; Nakajima, Yutaka; Nakai, Kazuo; Nomura, Naoko; Ito, Misato; Higashi, Yasuyuki; Inoue, Takayuki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4971-4983</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are considered promising targets for the treatment of autoimmune diseases including rheumatoid arthritis (RA) due to their important role in multiple cytokine receptor signaling pathways.  Recently, several JAK inhibitors have been developed for the treatment of RA.  Here, the authors describe the identification of the novel orally bioavailable JAK inhibitor 18, peficitinib (also known as ASP015K), which showed moderate selectivity for JAK3 over JAK1, JAK2, and TYK2 in enzyme assays.  Chem. modification at the C4-position of lead compd. 5 led to a large increase in JAK inhibitory activity and metabolic stability in liver microsomes.  Furthermore, the authors detd. the crystal structures of JAK1, JAK2, JAK3, and TYK2 in a complex with peficitinib, and revealed that the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold of peficitinib forms triple hydrogen bonds with the hinge region.  Interestingly, the binding modes of peficitinib in the ATP-binding pockets differed among JAK1, JAK2, JAK3, and TYK2.  WaterMap anal. of the crystal structures suggests that unfavorable water mols. are the likely reason for the difference in orientation of the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold to the hinge region among JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXmtQr-zPJgbVg90H21EOLACvtfcHk0lh2Ndn8fpjxTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyktrnO&md5=ee50230760e7ab2300f9ccb6a42f62a8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DHamaguchi%26aufirst%3DH.%26aulast%3DAmano%26aufirst%3DY.%26aulast%3DMoritomo%26aufirst%3DA.%26aulast%3DShirakami%26aufirst%3DS.%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DNakai%26aufirst%3DK.%26aulast%3DNomura%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DHigashi%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DT.%26atitle%3DDiscovery%2520and%2520structural%2520characterization%2520of%2520peficitinib%2520%2528ASP015K%2529%2520as%2520a%2520novel%2520and%2520potent%2520JAK%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D4971%26epage%3D4983%26doi%3D10.1016%2Fj.bmc.2018.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argiriadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosebraugh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)</span>. <i>BMC Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">23</span> <span class="refDoi"> DOI: 10.1186/s41927-018-0031-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1186%2Fs41927-018-0031-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=30886973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A280%3ADC%252BB3cbls1ymuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2018&author=J.+M.+Parmentierauthor=J.+Vossauthor=C.+Graffauthor=A.+Schwartzauthor=M.+Argiriadiauthor=M.+Friedmanauthor=H.+S.+Campauthor=R.+J.+Padleyauthor=J.+S.+Georgeauthor=D.+Hylandauthor=M.+Rosebraughauthor=N.+Wishartauthor=L.+Olsonauthor=A.+J.+Long&title=In+vitro+and+in+vivo+characterization+of+the+JAK1+selectivity+of+upadacitinib+%28ABT-494%29&doi=10.1186%2Fs41927-018-0031-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)</span></div><div class="casAuthors">Parmentier Julie M; Voss Jeff; Graff Candace; Schwartz Annette; Argiriadi Maria; Friedman Michael; George Jonathan S; Hyland Deborah; Wishart Neil; Olson Lisa; Long Andrew J; Camp Heidi S; Padley Robert J; Rosebraugh Matthew</div><div class="citationInfo"><span class="NLM_cas:title">BMC rheumatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in the pathogenesis of rheumatoid arthritis.  Tofacitinib, a pan-JAK inhibitor, is the first approved JAK inhibitor for the treatment of RA and has been shown to be effective in managing disease.  However, in phase 2 dose-ranging studies tofacitinib was associated with dose-limiting tolerability and safety issues such as anemia.  Upadacitinib (ABT-494) is a selective JAK1 inhibitor that was engineered to address the hypothesis that greater JAK1 selectivity over other JAK family members will translate into a more favorable benefit:risk profile.  Upadacitinib selectively targets JAK1 dependent disease drivers such as IL-6 and IFNγ, while reducing effects on reticulocytes and natural killer (NK) cells, which potentially contributed to the tolerability issues of tofacitinib.  Methods:  Structure-based hypotheses were used to design the JAK1 selective inhibitor upadacitinib.  JAK family selectivity was defined with in vitro assays including biochemical assessments, engineered cell lines, and cytokine stimulation.  In vivo selectivity was defined by the efficacy of upadacitinib and tofacitinib in a rat adjuvant induced arthritis model, activity on reticulocyte deployment, and effect on circulating NK cells.  The translation of the preclinical JAK1 selectivity was assessed in healthy volunteers using ex vivo stimulation with JAK-dependent cytokines.  Results:  Here, we show the structural basis for the JAK1 selectivity of upadacitinib, along with the in vitro JAK family selectivity profile and subsequent in vivo physiological consequences.  Upadacitinib is ~ 60 fold selective for JAK1 over JAK2, and > 100 fold selective over JAK3 in cellular assays.  While both upadacitinib and tofacitinib demonstrated efficacy in a rat model of arthritis, the increased selectivity of upadacitinib for JAK1 resulted in a reduced effect on reticulocyte deployment and NK cell depletion relative to efficacy.  Ex vivo pharmacodynamic data obtained from Phase I healthy volunteers confirmed the JAK1 selectivity of upadactinib in a clinical setting.  Conclusions:  The data presented here highlight the JAK1 selectivity of upadacinitinib and supports its use as an effective therapy for the treatment of RA with the potential for an improved benefit:risk profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTVFFxllNWaxfKb6ELK8t0fW6udTcc2eb4R_rLpqtXybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbls1ymuw%253D%253D&md5=5ca2dcb18a98362567d2193e858cc800</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1186%2Fs41927-018-0031-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs41927-018-0031-x%26sid%3Dliteratum%253Aachs%26aulast%3DParmentier%26aufirst%3DJ.%2BM.%26aulast%3DVoss%26aufirst%3DJ.%26aulast%3DGraff%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DA.%26aulast%3DArgiriadi%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DM.%26aulast%3DCamp%26aufirst%3DH.%2BS.%26aulast%3DPadley%26aufirst%3DR.%2BJ.%26aulast%3DGeorge%26aufirst%3DJ.%2BS.%26aulast%3DHyland%26aufirst%3DD.%26aulast%3DRosebraugh%26aufirst%3DM.%26aulast%3DWishart%26aufirst%3DN.%26aulast%3DOlson%26aufirst%3DL.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520the%2520JAK1%2520selectivity%2520of%2520upadacitinib%2520%2528ABT-494%2529%26jtitle%3DBMC%2520Rheumatol.%26date%3D2018%26volume%3D2%26doi%3D10.1186%2Fs41927-018-0031-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8597</span>– <span class="NLM_lpage">8612</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8597-8612&author=A.+Fensomeauthor=C.+M.+Amblerauthor=E.+Arnoldauthor=M.+E.+Bankerauthor=M.+F.+Brownauthor=J.+Chrencikauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=I.+V.+Efremovauthor=A.+Flickauthor=B.+S.+Gerstenbergerauthor=A.+Gopalsamyauthor=M.+M.+Haywardauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+Jussifauthor=J.+D.+Knafelsauthor=D.+C.+Limburgauthor=D.+Linauthor=T.+H.+Linauthor=B.+S.+Pierceauthor=E.+Saiahauthor=R.+Sharmaauthor=P.+T.+Symanowiczauthor=J.+B.+Telliezauthor=J.+I.+Trujilloauthor=F.+F.+Vajdosauthor=F.+Vincentauthor=Z.+K.+Wanauthor=L.+Xingauthor=X.+Yangauthor=X.+Yangauthor=L.+Zhang&title=Dual+inhibition+of+TYK2+and+JAK1+for+the+treatment+of+autoimmune+diseases%3A+discovery+of+%28%28S%29-2%2C2-Difluorocyclopropyl%29%28%281+R%2C5+S%29-3-%282-%28%281-methyl-1+H-pyrazol-4-yl%29amino%29pyrimidin-4-yl%29-3%2C8-diazabicyclo%5B3.2.1%5Doctan-8-yl%29methanone+%28PF-06700841%29&doi=10.1021%2Facs.jmedchem.8b00917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span></div><div class="casAuthors">Fensome, Andrew; Ambler, Catherine M.; Arnold, Eric; Banker, Mary Ellen; Brown, Matthew F.; Chrencik, Jill; Clark, James D.; Dowty, Martin E.; Efremov, Ivan V.; Flick, Andrew; Gerstenberger, Brian S.; Gopalsamy, Ariamala; Hayward, Matthew M.; Hegen, Martin; Hollingshead, Brett D.; Jussif, Jason; Knafels, John D.; Limburg, David C.; Lin, David; Lin, Tsung H.; Pierce, Betsy S.; Saiah, Eddine; Sharma, Raman; Symanowicz, Peter T.; Telliez, Jean-Baptiste; Trujillo, John I.; Vajdos, Felix F.; Vincent, Fabien; Wan, Zhao-Kui; Xing, Li; Yang, Xiaojing; Yang, Xin; Zhang, Liying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8597-8612</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytokine signaling is an important characteristic of autoimmune diseases.  Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway.  JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6 and type-I interferon (IFN) family, while TYK2 in addn. to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling.  Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease and rheumatoid arthritis studies, leading to multiple drug approvals.  It is hypothesized that a dual JAK1/TYK2 inhibitor will provide addnl. efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes.  Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compd. 23), which is in Phase II clin. development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNhVkNWDMq7Vg90H21EOLACvtfcHk0lgpRMldsF_ESg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI&md5=c321512f524560cba445d070b9639e55</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00917%26sid%3Dliteratum%253Aachs%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChrencik%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DFlick%26aufirst%3DA.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DZ.%2BK.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDual%2520inhibition%2520of%2520TYK2%2520and%2520JAK1%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%253A%2520discovery%2520of%2520%2528%2528S%2529-2%252C2-Difluorocyclopropyl%2529%2528%25281%2520R%252C5%2520S%2529-3-%25282-%2528%25281-methyl-1%2520H-pyrazol-4-yl%2529amino%2529pyrimidin-4-yl%2529-3%252C8-diazabicyclo%255B3.2.1%255Doctan-8-yl%2529methanone%2520%2528PF-06700841%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8597%26epage%3D8612%26doi%3D10.1021%2Facs.jmedchem.8b00917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F. D. A.</span>; <span class="NLM_string-name">Fensome, A.</span>; <span class="NLM_string-name">Gerstenberger, B. S.</span>; <span class="NLM_string-name">Hayward, M. M.</span>; <span class="NLM_string-name">Owen, D. R.</span>; <span class="NLM_string-name">Wright, S. W.</span>; <span class="NLM_string-name">Xing, L. H.</span>; <span class="NLM_string-name">Yang, X.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[l,5-a]pyrazin-4-yl derivatives</span>. U.S. Patent <span class="NLM_patent">US2017/0240552A1</span>, Feb 21, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+F.+D.+A.+Brown&author=A.+Fensome&author=B.+S.+Gerstenberger&author=M.+M.+Hayward&author=D.+R.+Owen&author=S.+W.+Wright&author=L.+H.+Xing&author=X.+Yang&title=Pyrazolo%5Bl%2C5-a%5Dpyrazin-4-yl+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DM.%2BF.%2BD.%2BA.%26atitle%3DPyrazolo%255Bl%252C5-a%255Dpyrazin-4-yl%2520derivatives%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimalakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8973</span>– <span class="NLM_lpage">8995</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00444</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00444" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8973-8995&author=S.+T.+Wrobleskiauthor=R.+Moslinauthor=S.+Linauthor=Y.+Zhangauthor=S.+Spergelauthor=J.+Kempsonauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=D.+Shusterauthor=K.+Gilloolyauthor=X.+Yangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=C.+Chaudhryauthor=J.+Khanauthor=M.+Ruzanovauthor=J.+Tredupauthor=D.+Mulliganauthor=D.+Xieauthor=H.+Sunauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=N.+Aranibarauthor=M.+Chineyauthor=A.+Chimalakondaauthor=W.+J.+Pittsauthor=L.+Lombardoauthor=P.+H.+Carterauthor=J.+R.+Burkeauthor=D.+S.+Weinstein&title=Highly+selective+inhibition+of+tyrosine+kinase+2+%28TYK2%29+for+the+treatment+of+autoimmune+diseases%3A+discovery+of+the+allosteric+inhibitor+BMS-986165&doi=10.1021%2Facs.jmedchem.9b00444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165</span></div><div class="casAuthors">Wrobleski, Stephen T.; Moslin, Ryan; Lin, Shuqun; Zhang, Yanlei; Spergel, Steven; Kempson, James; Tokarski, John S.; Strnad, Joann; Zupa-Fernandez, Adriana; Cheng, Lihong; Shuster, David; Gillooly, Kathleen; Yang, Xiaoxia; Heimrich, Elizabeth; McIntyre, Kim W.; Chaudhry, Charu; Khan, Javed; Ruzanov, Max; Tredup, Jeffrey; Mulligan, Dawn; Xie, Dianlin; Sun, Huadong; Huang, Christine; D'Arienzo, Celia; Aranibar, Nelly; Chiney, Manoj; Chimalakonda, Anjaneya; Pitts, William J.; Lombardo, Louis; Carter, Percy H.; Burke, James R.; Weinstein, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8973-8995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases.  The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formidable challenge.  Our strategy to achieve high selectivity for TYK2 relies on targeting the TYK2 pseudokinase (JH2) domain.  Herein we report the late stage optimization efforts including a structure-guided design and water displacement strategy that led to the discovery of BMS-986165 (11, I) as a high affinity JH2 ligand and potent allosteric inhibitor of TYK2.  In addn. to unprecedented JAK isoform and kinome selectivity, I shows excellent pharmacokinetic properties with minimal profiling liabilities and is efficacious in several murine models of autoimmune disease.  On the basis of these findings, I appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clin. development as an oral treatment for autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmA75TJmytlrVg90H21EOLACvtfcHk0ljKNBFDfzvvdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP&md5=ca161c470df002b0bdd2bf6b19920ada</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00444%26sid%3Dliteratum%253Aachs%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DKempson%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DShuster%26aufirst%3DD.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DMulligan%26aufirst%3DD.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DChiney%26aufirst%3DM.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DLombardo%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DHighly%2520selective%2520inhibition%2520of%2520tyrosine%2520kinase%25202%2520%2528TYK2%2529%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%253A%2520discovery%2520of%2520the%2520allosteric%2520inhibitor%2520BMS-986165%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8973%26epage%3D8995%26doi%3D10.1021%2Facs.jmedchem.9b00444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, M. T.</span></span> <span> </span><span class="NLM_article-title">TYK2 inhibition shows promise</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">668</span>, <span class="refDoi"> DOI: 10.1038/d41573-019-00134-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1038%2Fd41573-019-00134-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=31477862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs12nsrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=668&author=M.+T.+Villanueva&title=TYK2+inhibition+shows+promise&doi=10.1038%2Fd41573-019-00134-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">TYK2 inhibition shows promise</span></div><div class="casAuthors">Villanueva, M. Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">668</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq49wp9oc5jSLVg90H21EOLACvtfcHk0ljKNBFDfzvvdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs12nsrvP&md5=066a2dcb6b91ef52fd7608b894f4e166</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fd41573-019-00134-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41573-019-00134-4%26sid%3Dliteratum%253Aachs%26aulast%3DVillanueva%26aufirst%3DM.%2BT.%26atitle%3DTYK2%2520inhibition%2520shows%2520promise%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D668%26doi%3D10.1038%2Fd41573-019-00134-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">784</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2Fj.phrs.2016.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=27473820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12jurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=784-803&author=R.+Roskoski&title=Janus+kinase+%28JAK%29+inhibitors+in+the+treatment+of+inflammatory+and+neoplastic+diseases&doi=10.1016%2Fj.phrs.2016.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases</span></div><div class="casAuthors">Roskoski, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">784-803</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinase (JAK) family of non-receptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (tyrosine kinase-2).  Each of these proteins contains a JAK homol. pseudokinase (JH2) domain that regulates the adjacent protein kinase domain (JH1).  JAK1/2 and TYK2 are ubiquitously expressed whereas JAK3 is found predominantly in hematopoietic cells.  The Janus kinase family is regulated by numerous cytokines including interleukins, interferons, and hormones such as erythropoietin, thrombopoietin, and growth hormone.  Ligand binding to cytokine and hormone receptors leads to the activation of assocd. Janus kinases, which then mediate the phosphorylation of the receptors.  The SH2 domain of STATs (signal transducers and activators of transcription) binds to the receptor phosphotyrosines thereby promoting STAT phosphorylation by the Janus kinases and consequent activation.  STAT dimers are translocated to the nucleus where they participate in the regulation of the expression of thousands of proteins.  JAK-STAT dysregulation results in autoimmune disorders such as rheumatoid arthritis, ulcerative colitis, and Crohn disease.  JAK-STAT dysregulation also plays a role in the pathogenesis of myelofibrosis, polycythemia vera, and other myeloproliferative illnesses.  An activating JAK2 V617F mutation occurs in 95% of people with polycythemia vera and in a lower percentage of people with other neoplasms.  JAK1/3 signaling participates in the pathogenesis of inflammatory afflictions while JAK1/2 signaling participates in the development of several malignancies including leukemias and lymphomas as well as myeloproliferative neoplasms.  Tofacitinib is a pan-JAK inhibitor that is approved by the FDA for the treatment of rheumatoid arthritis and ruxolitinib is a JAK1/2 inhibitor that is approved for the treatment of polycythemia vera and myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov32m4UjOrv7Vg90H21EOLACvtfcHk0ljKNBFDfzvvdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12jurzJ&md5=a45fba1bb110eff4d5c1b31b78c1b3ac</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DJanus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520in%2520the%2520treatment%2520of%2520inflammatory%2520and%2520neoplastic%2520diseases%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D784%26epage%3D803%26doi%3D10.1016%2Fj.phrs.2016.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotival, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, S.</span></span> <span> </span><span class="NLM_article-title">Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>, <span class="NLM_elocation-id">e0225289</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0225289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1371%2Fjournal.pone.0225289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=31961910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFCru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&author=Z.+Liauthor=M.+Rotivalauthor=E.+Patinauthor=F.+Michelauthor=S.+Pellegrini&title=Two+common+disease-associated+TYK2+variants+impact+exon+splicing+and+TYK2+dosage&doi=10.1371%2Fjournal.pone.0225289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage</span></div><div class="casAuthors">Li, Zhi; Rotival, Maxime; Patin, Etienne; Michel, Frederique; Pellegrini, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0225289</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">TYK2 belongs to the JAK protein tyrosine kinase family and mediates signaling of numerous antiviral and immunoregulatory cytokines (type I and type III IFNs, IL-10, IL-12, IL-22, IL-23) in immune and non-immune cells.  After many years of genetic assocn. studies, TYK2 is recognized as a susceptibility gene for some inflammatory and autoimmune diseases (AID).  Seven TYK2 variants have been assocd. with AIDs in Europeans, and establishing their causality remains challenging.  Previous work showed that a protective variant (P1104A) is hypomorphic and also a risk allele for mycobacterial infection.  Here, we have studied two AID-assocd. common TYK2 variants: rs12720270 located in intron 7 and rs2304256, a non-synonymous variant in exon 8 that causes a valine to phenylalanine substitution (c.1084 G > T, Val362Phe).  We found that this amino acid substitution does not alter TYK2 expression, catalytic activity or ability to relay signaling in EBV-B cell lines or in reconstituted TYK2-null cells.  Based on in silico predictions that these variants may impact splicing of exon 8, we: (i) analyzed TYK2 transcripts in genotyped EBV-B cells and in CRISPR/Cas9-edited cells, (ii) measured splicing using minigene assays, and (iii) performed eQTL (expression quant. trait locus) anal. of TYK2 transcripts in primary monocytes and whole blood cells.  Our results reveal that the two variants promote the inclusion of exon 8, which, we demonstrate, is essential for TYK2 binding to cognate receptors.  In addn. and in line with GTEx (Genetic Tissue Expression) data, our eQTL results show that rs2304256 mildly enhances TYK2 expression in whole blood.  In all, these findings suggest that these TYK2 variants are not neutral but instead have a potential impact in AID.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS_S2jEHTx4bVg90H21EOLACvtfcHk0liRG_LvFuQTFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFCru7g%253D&md5=0de778b5c248a6a88a08e33c791f8255</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0225289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0225289%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DRotival%26aufirst%3DM.%26aulast%3DPatin%26aufirst%3DE.%26aulast%3DMichel%26aufirst%3DF.%26aulast%3DPellegrini%26aufirst%3DS.%26atitle%3DTwo%2520common%2520disease-associated%2520TYK2%2520variants%2520impact%2520exon%2520splicing%2520and%2520TYK2%2520dosage%26jtitle%3DPLoS%2520One%26date%3D2020%26volume%3D15%26doi%3D10.1371%2Fjournal.pone.0225289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. O.</span></span> <span> </span><span class="NLM_article-title">TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib</span>. <i>J. Microbiol., Immunol. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">368</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1016/j.jmii.2020.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2Fj.jmii.2020.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=32205092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsFalurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2020&pages=368-370&author=D.+Wuauthor=X.+O.+Yang&title=TH17+responses+in+cytokine+storm+of+COVID-19%3A+an+emerging+target+of+JAK2+inhibitor+Fedratinib&doi=10.1016%2Fj.jmii.2020.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib</span></div><div class="casAuthors">Wu, Dandan; Yang, Xuexian O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Microbiology, Immunology and Infection</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">368-370</span>CODEN:
                <span class="NLM_cas:coden">JMIIFG</span>;
        ISSN:<span class="NLM_cas:issn">1995-9133</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Taiwan LLC</span>)
        </div><div class="casAbstract">COVID-19 emerges as a pandemic disease with high mortality.  Development of effective prevention and treatment is an urgent need.  We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxQUfWxGcfQbVg90H21EOLACvtfcHk0liRG_LvFuQTFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsFalurc%253D&md5=bab4a2496a1381dd062fbaf5349baf57</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.jmii.2020.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmii.2020.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DX.%2BO.%26atitle%3DTH17%2520responses%2520in%2520cytokine%2520storm%2520of%2520COVID-19%253A%2520an%2520emerging%2520target%2520of%2520JAK2%2520inhibitor%2520Fedratinib%26jtitle%3DJ.%2520Microbiol.%252C%2520Immunol.%2520Infect.%26date%3D2020%26volume%3D53%26spage%3D368%26epage%3D370%26doi%3D10.1016%2Fj.jmii.2020.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sebastian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrin-Biroulet, L.</span></span> <span> </span><span class="NLM_article-title">Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD</span>. <i>J. Crohn’s Colitis</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1632</span>– <span class="NLM_lpage">1643</span>, <span class="refDoi"> DOI: 10.1093/ecco-jcc/jjaa120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1093%2Fecco-jcc%2Fjjaa120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=32520312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A280%3ADC%252BB38rotV2itw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2020&pages=1632-1643&author=S.+Sebastianauthor=H.+A.+Gonzalezauthor=L.+Peyrin-Biroulet&title=Safety+of+drugs+during+previous+and+current+coronavirus+pandemics%3A+Lessons+for+IBD&doi=10.1093%2Fecco-jcc%2Fjjaa120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of Drugs During Previous and Current Coronavirus Pandemics: Lessons for Inflammatory Bowel Disease</span></div><div class="casAuthors">Sebastian S; Gonzalez H A; Sebastian S; Peyrin-Biroulet L; Peyrin-Biroulet L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Crohn's & colitis</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1632-1643</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The coronavirus 2019 [COVID-19] pandemic has posed challenges in the routine care of patients with inflammatory bowel disease [IBD].  One of the key challenges is quantification of the risks of immunosuppressive and biological therapies in IBD patients during the pandemic.  The similarities and differences between previous coronavirus outbreaks and the pathobiology of the infections can give useful information in understanding the risks, and perhaps potential beneficial aspects of drugs used in IBD.  Although clinical, immunological and pharmacological data from the experience with previous coronavirus outbreaks cannot be automatically translated to predict the safety of IBD therapies during the COVID-19 pandemic, the signals so far from these outbreaks on IBD patients who are on immunomodulators and biologics are reassuring to patients and clinicians alike.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDxB42mXf9lUbxh97K6Vt6fW6udTcc2ebn0Mw1jOMZqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38rotV2itw%253D%253D&md5=9f378a605ec96870f52825cfd4957696</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1093%2Fecco-jcc%2Fjjaa120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fecco-jcc%252Fjjaa120%26sid%3Dliteratum%253Aachs%26aulast%3DSebastian%26aufirst%3DS.%26aulast%3DGonzalez%26aufirst%3DH.%2BA.%26aulast%3DPeyrin-Biroulet%26aufirst%3DL.%26atitle%3DSafety%2520of%2520drugs%2520during%2520previous%2520and%2520current%2520coronavirus%2520pandemics%253A%2520Lessons%2520for%2520IBD%26jtitle%3DJ.%2520Crohn%25E2%2580%2599s%2520Colitis%26date%3D2020%26volume%3D14%26spage%3D1632%26epage%3D1643%26doi%3D10.1093%2Fecco-jcc%2Fjjaa120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minegishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agematsu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuge, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yachie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessho, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujieda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakiguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abinun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochs, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renner, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belohradsky, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyawaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karasuyama, H.</span></span> <span> </span><span class="NLM_article-title">Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2006.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2Fj.immuni.2006.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=17088085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Gnt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=745-755&author=Y.+Minegishiauthor=M.+Saitoauthor=T.+Morioauthor=K.+Watanabeauthor=K.+Agematsuauthor=S.+Tsuchiyaauthor=H.+Takadaauthor=T.+Haraauthor=N.+Kawamuraauthor=T.+Arigaauthor=H.+Kanekoauthor=N.+Kondoauthor=I.+Tsugeauthor=A.+Yachieauthor=Y.+Sakiyamaauthor=T.+Iwataauthor=F.+Besshoauthor=T.+Ohishiauthor=K.+Johauthor=K.+Imaiauthor=K.+Kogawaauthor=M.+Shinoharaauthor=M.+Fujiedaauthor=H.+Wakiguchiauthor=S.+Pasicauthor=M.+Abinunauthor=H.+D.+Ochsauthor=E.+D.+Rennerauthor=A.+Janssonauthor=B.+H.+Belohradskyauthor=A.+Metinauthor=N.+Shimizuauthor=S.+Mizutaniauthor=T.+Miyawakiauthor=S.+Nonoyamaauthor=H.+Karasuyama&title=Human+tyrosine+kinase+2+deficiency+reveals+its+requisite+roles+in+multiple+cytokine+signals+involved+in+innate+and+acquired+immunity&doi=10.1016%2Fj.immuni.2006.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity</span></div><div class="casAuthors">Minegishi, Yoshiyuki; Saito, Masako; Morio, Tomohiro; Watanabe, Ken; Agematsu, Kazunaga; Tsuchiya, Shigeru; Takada, Hidetoshi; Hara, Toshiro; Kawamura, Nobuaki; Ariga, Tadashi; Kaneko, Hideo; Kondo, Naomi; Tsuge, Ikuya; Yachie, Akihiro; Sakiyama, Yukio; Iwata, Tsutomu; Bessho, Fumio; Ohishi, Tsutomu; Joh, Kosuke; Imai, Kohsuke; Kogawa, Kazuhiro; Shinohara, Miwa; Fujieda, Mikiya; Wakiguchi, Hiroshi; Pasic, Srdjan; Abinun, Mario; Ochs, Hans D.; Renner, Eleonore D.; Jansson, Annette; Belohradsky, Bernd H.; Metin, Ayse; Shimizu, Norio; Mizutani, Shuki; Miyawaki, Toshio; Nonoyama, Shigeaki; Karasuyama, Hajime</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">745-755</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tyrosine kinase 2 (Tyk2) is a nonreceptor tyrosine kinase that belongs to the Janus kinase (Jak) family.  Here we identified a homozygous Tyk2 mutation in a patient who had been clin. diagnosed with hyper-IgE syndrome.  This patient showed unusual susceptibility to various microorganisms including virus, fungi, and mycobacteria and suffered from atopic dermatitis with elevated serum IgE.  The patient's cells displayed defects in multiple cytokine signaling pathways including those for type I interferon (IFN), interleukin (IL)-6, IL-10, IL-12, and IL-23.  The cytokine signals were successfully restored by transducing the intact Tyk2 gene.  Thus, the Tyk2 deficiency is likely to account for the patient's complex clin. manifestations, including the phenotype of impaired T helper 1 (Th1) differentiation and accelerated Th2 differentiation.  This study identifies human Tyk2 deficiency and demonstrates that Tyk2 plays obligatory roles in multiple cytokine signals involved in innate and acquired immunity of humans, which differs substantially from Tyk2 function in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TTbAIzXM-bVg90H21EOLACvtfcHk0ljlO5HOwk0lWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Gnt7zI&md5=debec30b44a7e1dc111d7cfb1c92f7dd</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2006.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2006.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DMinegishi%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DMorio%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DAgematsu%26aufirst%3DK.%26aulast%3DTsuchiya%26aufirst%3DS.%26aulast%3DTakada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DT.%26aulast%3DKawamura%26aufirst%3DN.%26aulast%3DAriga%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DKondo%26aufirst%3DN.%26aulast%3DTsuge%26aufirst%3DI.%26aulast%3DYachie%26aufirst%3DA.%26aulast%3DSakiyama%26aufirst%3DY.%26aulast%3DIwata%26aufirst%3DT.%26aulast%3DBessho%26aufirst%3DF.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DJoh%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DK.%26aulast%3DKogawa%26aufirst%3DK.%26aulast%3DShinohara%26aufirst%3DM.%26aulast%3DFujieda%26aufirst%3DM.%26aulast%3DWakiguchi%26aufirst%3DH.%26aulast%3DPasic%26aufirst%3DS.%26aulast%3DAbinun%26aufirst%3DM.%26aulast%3DOchs%26aufirst%3DH.%2BD.%26aulast%3DRenner%26aufirst%3DE.%2BD.%26aulast%3DJansson%26aufirst%3DA.%26aulast%3DBelohradsky%26aufirst%3DB.%2BH.%26aulast%3DMetin%26aufirst%3DA.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DMizutani%26aufirst%3DS.%26aulast%3DMiyawaki%26aufirst%3DT.%26aulast%3DNonoyama%26aufirst%3DS.%26aulast%3DKarasuyama%26aufirst%3DH.%26atitle%3DHuman%2520tyrosine%2520kinase%25202%2520deficiency%2520reveals%2520its%2520requisite%2520roles%2520in%2520multiple%2520cytokine%2520signals%2520involved%2520in%2520innate%2520and%2520acquired%2520immunity%26jtitle%3DImmunity%26date%3D2006%26volume%3D25%26spage%3D745%26epage%3D755%26doi%3D10.1016%2Fj.immuni.2006.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishizaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muromoto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohshiro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oritani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, T.</span></span> <span> </span><span class="NLM_article-title">Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1003244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.4049%2Fjimmunol.1003244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=21606247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvVamu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2011&pages=181-189&author=M.+Ishizakiauthor=T.+Akimotoauthor=R.+Muromotoauthor=M.+Yokoyamaauthor=Y.+Ohshiroauthor=Y.+Sekineauthor=H.+Maedaauthor=K.+Shimodaauthor=K.+Oritaniauthor=T.+Matsuda&title=Involvement+of+tyrosine+kinase-2+in+both+the+IL-12%2FTh1+and+IL-23%2FTh17+axes+in+vivo&doi=10.4049%2Fjimmunol.1003244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of Tyrosine Kinase-2 in Both the IL-12/Th1 and IL-23/Th17 Axes In Vivo</span></div><div class="casAuthors">Ishizaki, Masayuki; Akimoto, Toshihiko; Muromoto, Ryuta; Yokoyama, Mika; Ohshiro, Yuya; Sekine, Yuichi; Maeda, Hiroaki; Shimoda, Kazuya; Oritani, Kenji; Matsuda, Tadashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">181-189</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Tyrosine kinase-2 (Tyk2), a member of the Jak family of kinases, mediates the signals triggered by various cytokines, including type I IFNs, IL-12, and IL-23.  In the current study, we investigated the in vivo involvement of Tyk2 in several IL-12/Th1- and IL-23/Th17-mediated models of exptl. diseases, including methylated BSA injection-induced footpad thickness, imiquimod-induced psoriasis-like skin inflammation, and dextran sulfate sodium- or 2,4,6-trinitrobenzene sulfonic acid-induced colitis.  In these disease models, Tyk2 deficiency influenced the phenotypes in immunity and/or inflammation.  Our findings demonstrate a somewhat broader contribution of Tyk2 to immune systems than previously expected and suggest that Tyk2 may represent an important candidate for drug development by targeting both the IL-12/Th1 and IL-23/Th17 axes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSwc2RH-qGwbVg90H21EOLACvtfcHk0lgO9UjoSuluuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvVamu74%253D&md5=35663a32341c05258a1ddfb7fe9482a2</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1003244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1003244%26sid%3Dliteratum%253Aachs%26aulast%3DIshizaki%26aufirst%3DM.%26aulast%3DAkimoto%26aufirst%3DT.%26aulast%3DMuromoto%26aufirst%3DR.%26aulast%3DYokoyama%26aufirst%3DM.%26aulast%3DOhshiro%26aufirst%3DY.%26aulast%3DSekine%26aufirst%3DY.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DShimoda%26aufirst%3DK.%26aulast%3DOritani%26aufirst%3DK.%26aulast%3DMatsuda%26aufirst%3DT.%26atitle%3DInvolvement%2520of%2520tyrosine%2520kinase-2%2520in%2520both%2520the%2520IL-12%252FTh1%2520and%2520IL-23%252FTh17%2520axes%2520in%2520vivo%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D187%26spage%3D181%26epage%3D189%26doi%3D10.4049%2Fjimmunol.1003244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansoul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolae, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duerr, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioux, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brant, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverberg, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barmada, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dassopoulos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datta, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kistner, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murtha, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumm, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhart, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Targan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consortium, N. I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libioulle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lathrop, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belaiche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewit, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laukens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutgeerts, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Gossum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenika, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchimont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hugot, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belgian-French, I. B. D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellcome Trust Case Control, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardon, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimmo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescott, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onnie, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghori, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumpstead, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gwilliam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremelling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deloukas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satsangi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, M. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Genome-wide association defines more than 30 distinct susceptibility loci for crohn’s disease</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">955</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.1038/ng.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1038%2Fng.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=18587394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptFSqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=955-962&author=J.+C.+Barrettauthor=S.+Hansoulauthor=D.+L.+Nicolaeauthor=J.+H.+Choauthor=R.+H.+Duerrauthor=J.+D.+Riouxauthor=S.+R.+Brantauthor=M.+S.+Silverbergauthor=K.+D.+Taylorauthor=M.+M.+Barmadaauthor=A.+Bittonauthor=T.+Dassopoulosauthor=L.+W.+Dattaauthor=T.+Greenauthor=A.+M.+Griffithsauthor=E.+O.+Kistnerauthor=M.+T.+Murthaauthor=M.+D.+Regueiroauthor=J.+I.+Rotterauthor=L.+P.+Schummauthor=A.+H.+Steinhartauthor=S.+R.+Targanauthor=R.+J.+Xavierauthor=N.+I.+G.+Consortiumauthor=C.+Libioulleauthor=C.+Sandorauthor=M.+Lathropauthor=J.+Belaicheauthor=O.+Dewitauthor=I.+Gutauthor=S.+Heathauthor=D.+Laukensauthor=M.+Mniauthor=P.+Rutgeertsauthor=A.+Van+Gossumauthor=D.+Zelenikaauthor=D.+Franchimontauthor=J.+P.+Hugotauthor=M.+de+Vosauthor=S.+Vermeireauthor=E.+Louisauthor=I.+B.+D.+C.+Belgian-Frenchauthor=C.+Wellcome+Trust+Case+Controlauthor=L.+R.+Cardonauthor=C.+A.+Andersonauthor=H.+Drummondauthor=E.+Nimmoauthor=T.+Ahmadauthor=N.+J.+Prescottauthor=C.+M.+Onnieauthor=S.+A.+Fisherauthor=J.+Marchiniauthor=J.+Ghoriauthor=S.+Bumpsteadauthor=R.+Gwilliamauthor=M.+Tremellingauthor=P.+Deloukasauthor=J.+Mansfieldauthor=D.+Jewellauthor=J.+Satsangiauthor=C.+G.+Mathewauthor=M.+Parkesauthor=M.+Georgesauthor=M.+J.+Daly&title=Genome-wide+association+defines+more+than+30+distinct+susceptibility+loci+for+crohn%E2%80%99s+disease&doi=10.1038%2Fng.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease</span></div><div class="casAuthors">Barrett, Jeffrey C.; Hansoul, Sarah; Nicolae, Dan L.; Cho, Judy H.; Duerr, Richard H.; Rioux, John D.; Brant, Steven R.; Silverberg, Mark S.; Taylor, Kent D.; Barmada, M. Michael; Bitton, Alain; Dassopoulos, Themistocles; Datta, Lisa Wu; Green, Todd; Griffiths, Anne M.; Kistner, Emily O.; Murtha, Michael T.; Regueiro, Miguel D.; Rotter, Jerome I.; Schumm, L. Philip; Steinhart, A. Hillary; Targan, Stephan R.; Xavier, Ramnik J.; Libioulle, Cecile; Sandor, Cynthia; Lathrop, Mark; Belaiche, Jacques; Dewit, Olivier; Gut, Ivo; Heath, Simon; Laukens, Debby; Mni, Myriam; Rutgeerts, Paul; Van Gossum, Andre; Zelenika, Diana; Franchimont, Denis; Hugot, Jean-Pierre; de Vos, Martine; Vermeire, Severine; Louis, Edouard; Cardon, Lon R.; Anderson, Carl A.; Drummond, Hazel; Nimmo, Elaine; Ahmad, Tariq; Prescott, Natalie J.; Onnie, Clive M.; Fisher, Sheila A.; Marchini, Jonathan; Ghori, Jilur; Bumpstead, Suzannah; Gwilliam, Rhian; Tremelling, Mark; Deloukas, Panos; Mansfield, John; Jewell, Derek; Satsangi, Jack; Mathew, Christopher G.; Parkes, Miles; Georges, Michel; Daly, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">955-962</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mark Daly and colleagues present results of a combined anal. of data from three recent genome-wide assocn. studies for Crohn's disease, followed by replication in a large independent sample collection.  Their results confirm 11 previously reported risk loci and provide genome-wide significant evidence for 21 new loci assocd. with the disease.  Mark Daly and colleagues present results of a combined anal. of data from three recent genome-wide assocn. studies for Crohn's disease, followed by replication in a large independent sample collection.  Their results confirm 11 previously reported risk loci and provide genome-wide significant evidence for 21 new loci assocd. with the disease.  Several risk factors for Crohn's disease have been identified in recent genome-wide assocn. studies.  To advance gene discovery further, we combined data from three studies on Crohn's disease (a total of 3,230 cases and 4,829 controls) and carried out replication in 3,664 independent cases with a mixt. of population-based and family-based controls.  The results strongly confirm 11 previously reported loci and provide genome-wide significant evidence for 21 addnl. loci, including the regions contg. STAT3, JAK2, ICOSLG, CDKAL1 and ITLN1.  The expanded mol. understanding of the basis of this disease offers promise for informed therapeutic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXvOZmM6KfrLVg90H21EOLACvtfcHk0lgO9UjoSuluuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptFSqs7k%253D&md5=c2f2805316b115765c02aa1dc503626b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fng.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.175%26sid%3Dliteratum%253Aachs%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DHansoul%26aufirst%3DS.%26aulast%3DNicolae%26aufirst%3DD.%2BL.%26aulast%3DCho%26aufirst%3DJ.%2BH.%26aulast%3DDuerr%26aufirst%3DR.%2BH.%26aulast%3DRioux%26aufirst%3DJ.%2BD.%26aulast%3DBrant%26aufirst%3DS.%2BR.%26aulast%3DSilverberg%26aufirst%3DM.%2BS.%26aulast%3DTaylor%26aufirst%3DK.%2BD.%26aulast%3DBarmada%26aufirst%3DM.%2BM.%26aulast%3DBitton%26aufirst%3DA.%26aulast%3DDassopoulos%26aufirst%3DT.%26aulast%3DDatta%26aufirst%3DL.%2BW.%26aulast%3DGreen%26aufirst%3DT.%26aulast%3DGriffiths%26aufirst%3DA.%2BM.%26aulast%3DKistner%26aufirst%3DE.%2BO.%26aulast%3DMurtha%26aufirst%3DM.%2BT.%26aulast%3DRegueiro%26aufirst%3DM.%2BD.%26aulast%3DRotter%26aufirst%3DJ.%2BI.%26aulast%3DSchumm%26aufirst%3DL.%2BP.%26aulast%3DSteinhart%26aufirst%3DA.%2BH.%26aulast%3DTargan%26aufirst%3DS.%2BR.%26aulast%3DXavier%26aufirst%3DR.%2BJ.%26aulast%3DConsortium%26aufirst%3DN.%2BI.%2BG.%26aulast%3DLibioulle%26aufirst%3DC.%26aulast%3DSandor%26aufirst%3DC.%26aulast%3DLathrop%26aufirst%3DM.%26aulast%3DBelaiche%26aufirst%3DJ.%26aulast%3DDewit%26aufirst%3DO.%26aulast%3DGut%26aufirst%3DI.%26aulast%3DHeath%26aufirst%3DS.%26aulast%3DLaukens%26aufirst%3DD.%26aulast%3DMni%26aufirst%3DM.%26aulast%3DRutgeerts%26aufirst%3DP.%26aulast%3DVan%2BGossum%26aufirst%3DA.%26aulast%3DZelenika%26aufirst%3DD.%26aulast%3DFranchimont%26aufirst%3DD.%26aulast%3DHugot%26aufirst%3DJ.%2BP.%26aulast%3Dde%2BVos%26aufirst%3DM.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DLouis%26aufirst%3DE.%26aulast%3DBelgian-French%26aufirst%3DI.%2BB.%2BD.%2BC.%26aulast%3DWellcome%2BTrust%2BCase%2BControl%26aufirst%3DC.%26aulast%3DCardon%26aufirst%3DL.%2BR.%26aulast%3DAnderson%26aufirst%3DC.%2BA.%26aulast%3DDrummond%26aufirst%3DH.%26aulast%3DNimmo%26aufirst%3DE.%26aulast%3DAhmad%26aufirst%3DT.%26aulast%3DPrescott%26aufirst%3DN.%2BJ.%26aulast%3DOnnie%26aufirst%3DC.%2BM.%26aulast%3DFisher%26aufirst%3DS.%2BA.%26aulast%3DMarchini%26aufirst%3DJ.%26aulast%3DGhori%26aufirst%3DJ.%26aulast%3DBumpstead%26aufirst%3DS.%26aulast%3DGwilliam%26aufirst%3DR.%26aulast%3DTremelling%26aufirst%3DM.%26aulast%3DDeloukas%26aufirst%3DP.%26aulast%3DMansfield%26aufirst%3DJ.%26aulast%3DJewell%26aufirst%3DD.%26aulast%3DSatsangi%26aufirst%3DJ.%26aulast%3DMathew%26aufirst%3DC.%2BG.%26aulast%3DParkes%26aufirst%3DM.%26aulast%3DGeorges%26aufirst%3DM.%26aulast%3DDaly%26aufirst%3DM.%2BJ.%26atitle%3DGenome-wide%2520association%2520defines%2520more%2520than%252030%2520distinct%2520susceptibility%2520loci%2520for%2520crohn%25E2%2580%2599s%2520disease%26jtitle%3DNat.%2520Genet.%26date%3D2008%26volume%3D40%26spage%3D955%26epage%3D962%26doi%3D10.1038%2Fng.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jethwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowness, P.</span></span> <span> </span><span class="NLM_article-title">The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1111/cei.12670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1111%2Fcei.12670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=26080615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitV2nt73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2016&pages=30-36&author=H.+Jethwaauthor=P.+Bowness&title=The+interleukin+%28IL%29-23%2FIL-17+axis+in+ankylosing+spondylitis%3A+new+advances+and+potentials+for+treatment&doi=10.1111%2Fcei.12670"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment</span></div><div class="casAuthors">Jethwa, H.; Bowness, P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-36</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary: Ankylosing spondylitis (AS), the most common form of spondyloarthropathy, is a chronic, progressive multi-system inflammatory disorder characteristically affecting the sacroiliac joints and axial skeleton.  Although the exact mechanisms underlying the pathogenesis of AS remain to be elucidated, the presence of human leukocyte antigen (HLA)-B27 is known to markedly increase its risk of development.  Current treatments include non-steroidal anti-inflammatory drugs (NSAIDs) and tumor necrosis factor (TNF) blockers.  In recent years, the interleukin (IL)-23/IL-17 pathway has been shown to have significance in the pathogenesis of AS and treatment modalities targeting this pathway have been shown to be beneficial in various other inflammatory conditions.  This review provides an overview of the IL-23/IL-17 pathway in the pathogenesis of AS and summarizes new potential treatments for AS and related inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruAOqPQQ_7Q7Vg90H21EOLACvtfcHk0lhkoXtfOUhLyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitV2nt73J&md5=6cf15c9a1171f925f2324373b1aa506d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fcei.12670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcei.12670%26sid%3Dliteratum%253Aachs%26aulast%3DJethwa%26aufirst%3DH.%26aulast%3DBowness%26aufirst%3DP.%26atitle%3DThe%2520interleukin%2520%2528IL%2529-23%252FIL-17%2520axis%2520in%2520ankylosing%2520spondylitis%253A%2520new%2520advances%2520and%2520potentials%2520for%2520treatment%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D2016%26volume%3D183%26spage%3D30%26epage%3D36%26doi%3D10.1111%2Fcei.12670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moschen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raine, T.</span></span> <span> </span><span class="NLM_article-title">IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting</span>. <i>Nat. Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1038/s41575-018-0084-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1038%2Fs41575-018-0084-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=30478416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlWnu7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=185-196&author=A.+R.+Moschenauthor=H.+Tilgauthor=T.+Raine&title=IL-12%2C+IL-23+and+IL-17+in+IBD%3A+immunobiology+and+therapeutic+targeting&doi=10.1038%2Fs41575-018-0084-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting</span></div><div class="casAuthors">Moschen, Alexander R.; Tilg, Herbert; Raine, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">185-196</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  IL-12 and IL-23 are closely related cytokines with important roles in the regulation of tissue inflammation.  Converging evidence from studies in mice, human observational studies and population genetics supports the importance of these cytokines in the regulation of mucosal inflammation in the gut in particular.  Ustekinumab, a therapeutic antibody targeting both cytokines is now widely licensed for the treatment of Crohn's disease, including in Europe, the USA, Canada and Japan, while agents targeting IL-23 specifically are in late-phase clin. trials.  We review the emerging understanding of the biol. of IL-12 and IL-23, as well as that of their major downstream cytokines, including IL-17.  In particular, we discuss how their biol. has influenced the development of clin. trials and therapeutic strategies in IBD, as well as how findings from clin. trials, at times surprising, have in turn refocused our understanding of the underlying biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOpNxAUthv_rVg90H21EOLACvtfcHk0lhkoXtfOUhLyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlWnu7%252FE&md5=b1f23bb392012256b005f303341d8cc1</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fs41575-018-0084-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41575-018-0084-8%26sid%3Dliteratum%253Aachs%26aulast%3DMoschen%26aufirst%3DA.%2BR.%26aulast%3DTilg%26aufirst%3DH.%26aulast%3DRaine%26aufirst%3DT.%26atitle%3DIL-12%252C%2520IL-23%2520and%2520IL-17%2520in%2520IBD%253A%2520immunobiology%2520and%2520therapeutic%2520targeting%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2019%26volume%3D16%26spage%3D185%26epage%3D196%26doi%3D10.1038%2Fs41575-018-0084-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">JAK/STAT signal transduction: promising attractive targets for immune, inflammatory and hematopoietic diseases</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.2174/1389450117666161207163054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.2174%2F1389450117666161207163054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=27928945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=487-500&author=Q.+Gaoauthor=X.+Liangauthor=A.+S.+Shaikhauthor=J.+Zangauthor=W.+Xuauthor=Y.+Zhang&title=JAK%2FSTAT+signal+transduction%3A+promising+attractive+targets+for+immune%2C+inflammatory+and+hematopoietic+diseases&doi=10.2174%2F1389450117666161207163054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases</span></div><div class="casAuthors">Gao, Qianwen; Liang, Xuewu; Shaikh, Abdul Sami; Zang, Jie; Xu, Wenfang; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">487-500</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: JAK/STAT signal pathway, a requisite part in the signaling process of growth factors and cytokines, has become attractive targets for numerous immune, inflammatory and hematopoietic diseases.  Objective: Herein, we present a review of the JAK/STAT signal pathway, the structure, biol. function, mechanism of the JAKs and STATs along with a summary of the up-to-date clin. or approved JAK inhibitors which are involved in the treatment of various kinds of tumors and other immunity indications.  Moreover, kinds of recently discovered JAKs inhibitors with potent activity or promising selectivity are also briefly discussed.  Conclusion: Research and development of isoform selective JAK inhibitors has become a hot topic in this field.  With the assistance of high throughput screening and rational drug design, more and more JAK inhibitors with improved selective profiles will be discovered as biol. probes and even therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquIztpln8iw7Vg90H21EOLACvtfcHk0lgzbERAA-jGEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCktLk%253D&md5=03eea4fedd3cf02d3a6450e42309527f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F1389450117666161207163054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450117666161207163054%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DShaikh%26aufirst%3DA.%2BS.%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DJAK%252FSTAT%2520signal%2520transduction%253A%2520promising%2520attractive%2520targets%2520for%2520immune%252C%2520inflammatory%2520and%2520hematopoietic%2520diseases%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2018%26volume%3D19%26spage%3D487%26epage%3D500%26doi%3D10.2174%2F1389450117666161207163054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and orally effective dual janus kinase 2/FLT3 Inhibitors for the treatment of acute myelogenous leukemia and myeloproliferative neoplasms</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10305</span>– <span class="NLM_lpage">10320</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01348</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01348" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVOhtrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10305-10320&author=T.+Yangauthor=M.+Huauthor=W.+Qiauthor=Z.+Yangauthor=M.+Tangauthor=J.+Heauthor=Y.+Chenauthor=P.+Baiauthor=X.+Yuanauthor=C.+Zhangauthor=K.+Liuauthor=Y.+Luauthor=M.+Xiangauthor=L.+Chen&title=Discovery+of+potent+and+orally+effective+dual+janus+kinase+2%2FFLT3+Inhibitors+for+the+treatment+of+acute+myelogenous+leukemia+and+myeloproliferative+neoplasms&doi=10.1021%2Facs.jmedchem.9b01348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms</span></div><div class="casAuthors">Yang, Tao; Hu, Mengshi; Qi, Wenyan; Yang, Zhuang; Tang, Minghai; He, Jun; Chen, Yong; Bai, Peng; Yuan, Xue; Zhang, Chufeng; Liu, Kongjun; Lu, Yulin; Xiang, Mingli; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10305-10320</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, the design, synthesis, and structure-activity relationships of a series of unique 4-(1H-pyrazol-4-yl)-pyrimidin-2-amine derivs. that selectively inhibit Janus kinase 2 (JAK2) and FLT3 kinases is described.  These screening cascades revealed that I was a preferred compd. with IC50 values of 0.7 and 4 nM for JAK2 and FLT3, resp.  Moreover, I was a potent JAK2 inhibitor with 37-fold and 56-fold selectivity over JAK1 and JAK3, resp., and possessed an excellent selectivity profile over the other 100 representative kinases.  In a series of cytokine-stimulated cell-based assays, I exhibited a higher JAK2 selectivity over other JAK isoforms.  The oral administration of 60 mg/kg of I could significantly inhibit tumor growth, with a tumor growth inhibition rate of 93 and 85% in MV4-11 and SET-2 xenograft models, resp.  Addnl., I showed an excellent bioavailability (F = 58%), a suitable half-life time (T1/2 = 4.1 h), a satisfactory metabolic stability, and a weak CYP3A4 inhibitory activity, suggesting that I might be a potential drug candidate for JAK2-driven myeloproliferative neoplasms and FLT3-internal tandem duplication-driven acute myelogenous leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHnNcuajGNcLVg90H21EOLACvtfcHk0lgzbERAA-jGEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVOhtrvE&md5=86c811cf77a95a7250996456cd29e6dc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01348%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DP.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520orally%2520effective%2520dual%2520janus%2520kinase%25202%252FFLT3%2520Inhibitors%2520for%2520the%2520treatment%2520of%2520acute%2520myelogenous%2520leukemia%2520and%2520myeloproliferative%2520neoplasms%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10305%26epage%3D10320%26doi%3D10.1021%2Facs.jmedchem.9b01348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PatnyAlicea-Velázquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korniski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmons, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommers, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenbrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasselli, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, T. E.</span></span> <span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>400</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2010.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+PatnyAlicea-Vel%C3%A1zquezauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.+C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6&doi=10.1016%2Fj.jmb.2010.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0lhY3ezus52CzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatnyAlicea-Vel%25C3%25A1zquez%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433%26doi%3D10.1016%2Fj.jmb.2010.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alicea-Velázquez, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span> <span> </span><span class="NLM_article-title">The use of structural biology in janus kinase targeted drug discovery</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">546</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.2174/138945011794751528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.2174%2F138945011794751528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=21126226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVOkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=546-555&author=N.+L.+Alicea-Vel%C3%A1zquezauthor=T.+J.+Boggon&title=The+use+of+structural+biology+in+janus+kinase+targeted+drug+discovery&doi=10.2174%2F138945011794751528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The use of structural biology in Janus kinase targeted drug discovery</span></div><div class="casAuthors">Alicea-Velazquez, Nilda L.; Boggon, Titus J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">546-555</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (or Jak kinases) mediate cytokine and growth factor signal transduction.  Acquired or inherited Jak mutations can result in dysregulation of Jak-mediated signal transduction and can be crit. to disease acquisition in neoplasias including acute myeloid, acute lymphoblastic and acute megakaryoblastic leukemias, and in rare X-linked severe combined immunodeficiency.  The discovery of an acquired Jak2 point mutation, V617F, in significant nos. of patients with classical myeloproliferative disorders has increased the interest in development of Jak2-specific tyrosine kinase inhibitors and consequently there are now over 20 publically available structures of Jak kinase domains that describe all four family members, Jak1, Jak2, Jak3, and Tyk2.  Here we review the recent advances in understanding the druggable structure and function of the Jak family, with a focus on the structural biol. of the Jak kinase domain.  We will discuss how these advances impact the development of Jak-targeted therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJwEtMK-lOu7Vg90H21EOLACvtfcHk0liwBqHX7CZhWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVOkurg%253D&md5=5e76fc7eda3ffe580dc4e28044a88c2c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2174%2F138945011794751528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945011794751528%26sid%3Dliteratum%253Aachs%26aulast%3DAlicea-Vel%25C3%25A1zquez%26aufirst%3DN.%2BL.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520use%2520of%2520structural%2520biology%2520in%2520janus%2520kinase%2520targeted%2520drug%2520discovery%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2011%26volume%3D12%26spage%3D546%26epage%3D555%26doi%3D10.2174%2F138945011794751528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Argiriadi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedken, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borhani, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burchat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overmeyer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pivorunas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadhukhan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, N. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talanian, R. V.</span></span> <span> </span><span class="NLM_article-title">Enabling structure-based drug design of TYK2 through co-crystallization with a stabilizing aminoindazole inhibitor</span>. <i>BMC Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">22</span>, <span class="refDoi"> DOI: 10.1186/1472-6807-12-22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1186%2F1472-6807-12-22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=22995073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKjtLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=22&author=M.+A.+Argiriadiauthor=E.+R.+Goedkenauthor=D.+Banachauthor=D.+W.+Borhaniauthor=A.+Burchatauthor=R.+W.+Dixonauthor=D.+Marcotteauthor=G.+Overmeyerauthor=V.+Pivorunasauthor=R.+Sadhukhanauthor=S.+Sousaauthor=N.+S.+J.+Mooreauthor=M.+Tomlinsonauthor=J.+Vossauthor=L.+Wangauthor=N.+Wishartauthor=K.+Wollerauthor=R.+V.+Talanian&title=Enabling+structure-based+drug+design+of+TYK2+through+co-crystallization+with+a+stabilizing+aminoindazole+inhibitor&doi=10.1186%2F1472-6807-12-22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor</span></div><div class="casAuthors">Argiriadi, Maria A.; Goedken, Eric R.; Banach, David; Borhani, David W.; Burchat, Andrew; Dixon, Richard W.; Marcotte, Doug; Overmeyer, Gary; Pivorunas, Valerie; Sadhukhan, Ramkrishna; Sousa, Silvino; Moore, Nigel St. John; Tomlinson, Medha; Voss, Jeffrey; Wang, Lu; Wishart, Neil; Woller, Kevin; Talanian, Robert V.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Structural Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22</span>CODEN:
                <span class="NLM_cas:coden">BSBMBB</span>;
        ISSN:<span class="NLM_cas:issn">1472-6807</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Structure-based drug design (SBDD) can accelerate inhibitor lead design and optimization, and efficient methods including protein purifn., characterization, crystn., and high-resoln. diffraction are all needed for rapid, iterative structure detn.  Janus kinases are important targets that are amenable to structure-based drug design.  Here we present the first mouse Tyk2 crystal structures, which are complexed to 3-aminoindazole compds.  Results: A comprehensive construct design effort included N- and C-terminal variations, kinase-inactive mutations, and multiple species orthologs.  High-throughput cloning and expression methods were coupled with an abbreviated purifn. protocol to optimize protein soly. and stability.  In total, 50 Tyk2 constructs were generated.  Many displayed poor expression, inadequate soly., or incomplete affinity tag processing.  One kinase-inactive murine Tyk2 construct, complexed with an ATP-competitive 3-aminoindazole inhibitor, provided crystals that diffracted to 2.5-2.6 Å resoln.  This structure revealed initial "hot-spot" regions for SBDD, and provided a robust platform for ligand soaking expts.  Compared to previously reported human Tyk2 inhibitor crystal structures, our structures revealed a key difference in the glycine-rich loop conformation that is induced by the inhibitor.  Ligand binding also conferred resistance to proteolytic degrdn. by thermolysin.  As crystals could not be obtained with the unliganded enzyme, this enhanced stability is likely important for successful crystn. and inhibitor soaking methods.  Conclusions: Practical criteria for construct performance and prioritization, the optimization of purifn. protocols to enhance protein yields and stability, and use of high-throughput construct exploration enable structure detn. methods early in the drug discovery process.  Addnl., specific ligands stabilize Tyk2 protein and may thereby enable crystn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkojfkSrTvvrVg90H21EOLACvtfcHk0liwBqHX7CZhWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKjtLnK&md5=193891188ca3f7ce8b07e5c7aa94215c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1186%2F1472-6807-12-22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6807-12-22%26sid%3Dliteratum%253Aachs%26aulast%3DArgiriadi%26aufirst%3DM.%2BA.%26aulast%3DGoedken%26aufirst%3DE.%2BR.%26aulast%3DBanach%26aufirst%3DD.%26aulast%3DBorhani%26aufirst%3DD.%2BW.%26aulast%3DBurchat%26aufirst%3DA.%26aulast%3DDixon%26aufirst%3DR.%2BW.%26aulast%3DMarcotte%26aufirst%3DD.%26aulast%3DOvermeyer%26aufirst%3DG.%26aulast%3DPivorunas%26aufirst%3DV.%26aulast%3DSadhukhan%26aufirst%3DR.%26aulast%3DSousa%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DN.%2BS.%2BJ.%26aulast%3DTomlinson%26aufirst%3DM.%26aulast%3DVoss%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWishart%26aufirst%3DN.%26aulast%3DWoller%26aufirst%3DK.%26aulast%3DTalanian%26aufirst%3DR.%2BV.%26atitle%3DEnabling%2520structure-based%2520drug%2520design%2520of%2520TYK2%2520through%2520co-crystallization%2520with%2520a%2520stabilizing%2520aminoindazole%2520inhibitor%26jtitle%3DBMC%2520Struct.%2520Biol.%26date%3D2012%26volume%3D12%26spage%3D22%26doi%3D10.1186%2F1472-6807-12-22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravikumar, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shook, B. C.</span></span> <span> </span><span class="NLM_article-title">Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7902</span>– <span class="NLM_lpage">7917</span>, <span class="refDoi"> DOI: 10.1021/jm100762r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100762r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2kurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7902-7917&author=F.+F.+Flemingauthor=L.+Yaoauthor=P.+C.+Ravikumarauthor=L.+Funkauthor=B.+C.+Shook&title=Nitrile-containing+pharmaceuticals%3A+efficacious+roles+of+the+nitrile+pharmacophore&doi=10.1021%2Fjm100762r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore</span></div><div class="casAuthors">Fleming, Fraser F.; Yao, Lihua; Ravikumar, P. C.; Funk, Lee; Shook, Brian C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7902-7917</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review is structured according to the nature of the nitrile-bearing substituent.  As the no. of nitrile-contg. drug leads is vast, the review has focused on launched nitrile-contg. pharmaceuticals and currently active clin. candidates.  Most nitrile-contg. pharmaceuticals are aroms. with aliph.-, alkene-, and nitrogen-bearing nitriles being progressively less frequent.  Within each class, the bioactive nitriles are collated according to common structural elements and mode of action.  The hope is that this survey will allow greater deployment of this versatile functionality within drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR6kPPdWVuvLVg90H21EOLACvtfcHk0ljmJcQz6D5qiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2kurvP&md5=040bbaebd9e8c9999d195b9a22221fea</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm100762r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100762r%26sid%3Dliteratum%253Aachs%26aulast%3DFleming%26aufirst%3DF.%2BF.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DRavikumar%26aufirst%3DP.%2BC.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DShook%26aufirst%3DB.%2BC.%26atitle%3DNitrile-containing%2520pharmaceuticals%253A%2520efficacious%2520roles%2520of%2520the%2520nitrile%2520pharmacophore%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7902%26epage%3D7917%26doi%3D10.1021%2Fjm100762r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, M.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vensel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beresford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashwell, M. A.</span></span> <span> </span><span class="NLM_article-title">The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1709</span>– <span class="NLM_lpage">1712</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.01.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2Fj.bmcl.2004.01.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=15026055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFCis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1709-1712&author=M.+Tandonauthor=M.-M.+O%E2%80%99Donnellauthor=A.+Porteauthor=D.+Venselauthor=D.+Yangauthor=R.+Palmaauthor=A.+Beresfordauthor=M.+A.+Ashwell&title=The+design+and+preparation+of+metabolically+protected+new+arylpiperazine+5-HT1A+ligands&doi=10.1016%2Fj.bmcl.2004.01.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands</span></div><div class="casAuthors">Tandon, Manish; O'Donnell, Mary-Margaret; Porte, Alex; Vensel, David; Yang, Donglai; Palma, Rocio; Beresford, Alan; Ashwell, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1709-1712</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">New arylpiperazines related to buspirone, gepirone and NAN-190 were designed and screened in silico for their 5-HT1A affinity and potential sites of metab. by human cytochrome P 450 (CYP3A4).  Modifications to these structures were assessed in silico for their influence on both 5HT1A affinity and metab.  Selected new mols. were synthesized and purified in a parallel chem. approach to det. structure activity relationships.  The resulting mols. were assessed in vitro for their 5HT1A affinity and half-life in a heterologously expressed human CYP3A4 assay.  Mol. features responsible for 5-HT1A affinity and CYP3A4 stability are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnE6c-cxXRkrVg90H21EOLACvtfcHk0ljmJcQz6D5qiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFCis70%253D&md5=5853a5db1b3e29c8e7e266d814f2504d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.01.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.01.045%26sid%3Dliteratum%253Aachs%26aulast%3DTandon%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.-M.%26aulast%3DPorte%26aufirst%3DA.%26aulast%3DVensel%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DPalma%26aufirst%3DR.%26aulast%3DBeresford%26aufirst%3DA.%26aulast%3DAshwell%26aufirst%3DM.%2BA.%26atitle%3DThe%2520design%2520and%2520preparation%2520of%2520metabolically%2520protected%2520new%2520arylpiperazine%25205-HT1A%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D1709%26epage%3D1712%26doi%3D10.1016%2Fj.bmcl.2004.01.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamert, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walden, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilks, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossjohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucet, I. S.</span></span> <span> </span><span class="NLM_article-title">Dissecting specificity in the janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2009.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+janus+kinases%3A+the+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains&doi=10.1016%2Fj.jmb.2009.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0ljap4KP9tspiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520janus%2520kinases%253A%2520the%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232%26doi%3D10.1016%2Fj.jmb.2009.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Serine/Threonine protein kinase STK16</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1760</span>, <span class="refDoi"> DOI: 10.3390/ijms20071760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.3390%2Fijms20071760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1760&author=J.+Wangauthor=X.+Jiauthor=J.+Liuauthor=X.+Zhang&title=Serine%2FThreonine+protein+kinase+STK16&doi=10.3390%2Fijms20071760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Serine/threonine protein kinase STK16</span></div><div class="casAuthors">Wang, Junjun; Ji, Xinmiao; Liu, Juanjuan; Zhang, Xin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1760</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  STK16 (Ser/Thr kinase 16, also known as Krct/PKL12/MPSK1/TSF-1) is a myristoylated and palmitoylated Ser/Thr protein kinase that is ubiquitously expressed and conserved among all eukaryotes.  STK16 is distantly related to the other kinases and belongs to the NAK kinase family that has an atypical activation loop architecture.  As a membrane-assocd. protein that is primarily localized to the Golgi, STK16 has been shown to participate in the TGF-β signaling pathway, TGN protein secretion and sorting, as well as cell cycle and Golgi assembly regulation.  This review aims to provide a comprehensive summary of the progress made in recent research about STK16, ranging from its distribution, mol. characterization, post-translational modification (fatty acylation and phosphorylation), interactors (GlcNAcK/DRG1/MAL2/Actin/WDR1), and related functions.  As a relatively underexplored kinase, more studies are encouraged to unravel its regulation mechanisms and cellular functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi_DpWPQ2-HrVg90H21EOLACvtfcHk0ljap4KP9tspiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGmu7g%253D&md5=30340e00a109a16d389c52af3f429147</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3390%2Fijms20071760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20071760%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DSerine%252FThreonine%2520protein%2520kinase%2520STK16%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1760%26doi%3D10.3390%2Fijms20071760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eberl, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muelbaier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span> <span> </span><span class="NLM_article-title">Chemical proteomics reveals target selectivity of clinical JAK inhibitors in human primary cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">14159</span> <span class="refDoi"> DOI: 10.1038/s41598-019-50335-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1038%2Fs41598-019-50335-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=31578349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A280%3ADC%252BB3MnksVKrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&author=H.+C.+Eberlauthor=T.+Wernerauthor=F.+B.+Reinhardauthor=S.+Lehmannauthor=D.+Thomsonauthor=P.+Chenauthor=C.+Zhangauthor=C.+Rauauthor=M.+Muelbaierauthor=G.+Drewesauthor=D.+Drewryauthor=M.+Bantscheff&title=Chemical+proteomics+reveals+target+selectivity+of+clinical+JAK+inhibitors+in+human+primary+cells&doi=10.1038%2Fs41598-019-50335-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells</span></div><div class="casAuthors">Eberl H Christian; Werner Thilo; Reinhard Friedrich B; Lehmann Stephanie; Thomson Douglas; Rau Christina; Muelbaier Marcel; Drewes Gerard; Bantscheff Marcus; Chen Peiling; Zhang Cunyu; Drewry David; Drewry David</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14159</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Kinobeads are a set of promiscuous kinase inhibitors immobilized on sepharose beads for the comprehensive enrichment of endogenously expressed protein kinases from cell lines and tissues.  These beads enable chemoproteomics profiling of kinase inhibitors of interest in dose-dependent competition studies in combination with quantitative mass spectrometry.  We present improved bead matrices that capture more than 350 protein kinases and 15 lipid kinases from human cell lysates, respectively.  A multiplexing strategy is suggested that enables determination of apparent dissociation constants in a single mass spectrometry experiment.  Miniaturization of the procedure enabled determining the target selectivity of the clinical BCR-ABL inhibitor dasatinib in peripheral blood mononuclear cell (PBMC) lysates from individual donors.  Profiling of a set of Jak kinase inhibitors revealed kinase off-targets from nearly all kinase families underpinning the need to profile kinase inhibitors against the kinome.  Potently bound off-targets of clinical inhibitors suggest polypharmacology, e.g. through MRCK alpha and beta, which bind to decernotinib with nanomolar affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-dkv-Tn26AS6Ufuk_1xoTfW6udTcc2eZ2Zl1qe3Vklbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnksVKrug%253D%253D&md5=2c25adec8f1b19cc3d3e259c30016f36</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-50335-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-50335-5%26sid%3Dliteratum%253Aachs%26aulast%3DEberl%26aufirst%3DH.%2BC.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DReinhard%26aufirst%3DF.%2BB.%26aulast%3DLehmann%26aufirst%3DS.%26aulast%3DThomson%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DRau%26aufirst%3DC.%26aulast%3DMuelbaier%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DDrewry%26aufirst%3DD.%26aulast%3DBantscheff%26aufirst%3DM.%26atitle%3DChemical%2520proteomics%2520reveals%2520target%2520selectivity%2520of%2520clinical%2520JAK%2520inhibitors%2520in%2520human%2520primary%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26doi%3D10.1038%2Fs41598-019-50335-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorrell, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szklarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Azeez, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Family-wide structural analysis of human numb-associated protein kinases</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1016/j.str.2015.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1016%2Fj.str.2015.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=26853940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=401-411&author=F.+J.+Sorrellauthor=M.+Szklarzauthor=K.+R.+Abdul+Azeezauthor=J.+M.+Elkinsauthor=S.+Knapp&title=Family-wide+structural+analysis+of+human+numb-associated+protein+kinases&doi=10.1016%2Fj.str.2015.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Family-wide Structural Analysis of Human Numb-Associated Protein Kinases</span></div><div class="casAuthors">Sorrell, Fiona J.; Szklarz, Marta; Abdul Azeez, Kamal R.; Elkins, Jon M.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">401-411</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The highly diverse Numb-assocd. kinase (NAK) family has been linked to broad cellular functions including receptor-mediated endocytosis, Notch pathway modulation, osteoblast differentiation, and dendrite morphogenesis.  Consequently, NAK kinases play a key role in a diverse range of diseases from Parkinson's and prostate cancer to HIV.  Due to the plasticity of this kinase family, NAK kinases are often inhibited by approved or investigational drugs and have been assocd. with side effects, but they are also potential drug targets.  The presence of cysteine residues in some NAK family members provides the possibility for selective targeting via covalent inhibition.  Here we report the first high-resoln. structures of kinases AAK1 and BIKE in complex with two drug candidates.  The presented data allow a comprehensive structural characterization of the NAK kinase family and provide the basis for rational design of selective NAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryZi0QmT8YH7Vg90H21EOLACvtfcHk0lgdmH9lxjcCxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCktLY%253D&md5=6a353c993ec9f2b7152e459d72bab9d3</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2015.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2015.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DSzklarz%26aufirst%3DM.%26aulast%3DAbdul%2BAzeez%26aufirst%3DK.%2BR.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DFamily-wide%2520structural%2520analysis%2520of%2520human%2520numb-associated%2520protein%2520kinases%26jtitle%3DStructure%26date%3D2016%26volume%3D24%26spage%3D401%26epage%3D411%26doi%3D10.1016%2Fj.str.2015.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorarensen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juba, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span> <span> </span><span class="NLM_article-title">ATP-Mediated kinome selectivity: The missing link in understanding the contribution of individual JAK kinase isoforms to cellular signaling</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1552</span>– <span class="NLM_lpage">1558</span>, <span class="refDoi"> DOI: 10.1021/cb5002125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5002125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1552-1558&author=A.+Thorarensenauthor=M.+E.+Bankerauthor=A.+Fensomeauthor=J.-B.+Telliezauthor=B.+Jubaauthor=F.+Vincentauthor=R.+M.+Czerwinskiauthor=A.+Casimiro-Garcia&title=ATP-Mediated+kinome+selectivity%3A+The+missing+link+in+understanding+the+contribution+of+individual+JAK+kinase+isoforms+to+cellular+signaling&doi=10.1021%2Fcb5002125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling</span></div><div class="casAuthors">Thorarensen, Atli; Banker, Mary Ellen; Fensome, Andrew; Telliez, Jean-Baptiste; Juba, Brian; Vincent, Fabien; Czerwinski, Robert M.; Casimiro-Garcia, Agustin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1552-1558</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases constitute an important class of therapeutic targets being explored both by academia and the pharmaceutical industry.  The major focus of this effort was directed toward the identification of ATP competitive inhibitors.  Although it has long been recognized that the intracellular concn. of ATP is very different from the concns. utilized in biochem. enzyme assays, little thought has been devoted to incorporating this discrepancy into our understanding of translation from enzyme inhibition to cellular function.  Significant work has been dedicated to the discovery of JAK kinase inhibitors; however, a disconnect between enzyme and cellular function is prominently displayed in the literature for this class of inhibitors.  Herein, we demonstrate utilizing the four JAK family members (JAK1, JAK2, JAK3, and TYK2) that the difference in the ATP Km of each individual kinase has a significant impact on the enzyme to cell inhibition translation.  We evaluated a large no. of JAK inhibitors in enzymic assays utilizing either 1 mM ATP or Km ATP for the four isoforms as well as in primary cell assays.  This data set provided the opportunity to examine individual kinase contributions to the heterodimeric kinase complexes mediating cellular signaling.  In contrast to a recent study, we demonstrate that for IL-15 cytokine signaling it is sufficient to inhibit either JAK1 or JAK3 to fully inhibit downstream STAT5 phosphorylation.  This addnl. data thus provides a crit. piece of information explaining why JAK1 has incorrectly been thought to have a dominant role over JAK3.  Beyond enabling a deeper understanding of JAK signaling, conducting similar analyses for other kinases by taking into account potency at high ATP rather than Km ATP may provide crucial insights into a compd.'s activity and selectivity in cellular contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYiMVl7OpPFLVg90H21EOLACvtfcHk0lhhzSRGdrnAcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D&md5=c87874cb1748e13eef2aa241ecef3e79</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fcb5002125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5002125%26sid%3Dliteratum%253Aachs%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DJuba%26aufirst%3DB.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26atitle%3DATP-Mediated%2520kinome%2520selectivity%253A%2520The%2520missing%2520link%2520in%2520understanding%2520the%2520contribution%2520of%2520individual%2520JAK%2520kinase%2520isoforms%2520to%2520cellular%2520signaling%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1552%26epage%3D1558%26doi%3D10.1021%2Fcb5002125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faqua, C. F.</span>; <span class="NLM_string-name">Akomeah, R.</span>; <span class="NLM_string-name">Adunyah, S. E.</span></span> <span> </span><span class="NLM_article-title">IL-21 signaling and induction of cytokine expression in human leukemia cells and monocytes</span>. In  <i>Cytokines</i>, <span class="NLM_edition">1</span>st ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Behzadi, P.</span></span>, Ed.; <span class="NLM_publisher-name">IntechOpen</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_year">2020</span>; pp  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">132</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.5772%2Fintechopen.93004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=129-132&author=C.+F.+Faqua&author=R.+Akomeah&author=S.+E.+Adunyahauthor=P.+Behzadi&title=Cytokines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.5772%2Fintechopen.93004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.5772%252Fintechopen.93004%26sid%3Dliteratum%253Aachs%26aulast%3DFaqua%26aufirst%3DC.%2BF.%26atitle%3DIL-21%2520signaling%2520and%2520induction%2520of%2520cytokine%2520expression%2520in%2520human%2520leukemia%2520cells%2520and%2520monocytes%26btitle%3DCytokines%26aulast%3DBehzadi%26aufirst%3DP.%26pub%3DIntechOpen%26date%3D2020%26spage%3D129%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parisinos, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serghiou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsoulis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemingway, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hingorani, A. D.</span></span> <span> </span><span class="NLM_article-title">Variation in interleukin 6 receptor gene associates with risk of crohn’s disease and ulcerative colitis</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">306</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2018.05.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.1053%2Fj.gastro.2018.05.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=29775600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSqurvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=303-306&author=C.+A.+Parisinosauthor=S.+Serghiouauthor=M.+Katsoulisauthor=M.+J.+Georgeauthor=R.+S.+Patelauthor=H.+Hemingwayauthor=A.+D.+Hingorani&title=Variation+in+interleukin+6+receptor+gene+associates+with+risk+of+crohn%E2%80%99s+disease+and+ulcerative+colitis&doi=10.1053%2Fj.gastro.2018.05.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Variation in Interleukin 6 Receptor Gene Associates With Risk of Crohn's Disease and Ulcerative Colitis</span></div><div class="casAuthors">Parisinos, Constantinos A.; Serghiou, Stylianos; Katsoulis, Michail; George, Marc Jonathan; Patel, Riyaz S.; Hemingway, Harry; Hingorani, Aroon D.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">303-306.e2</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Interleukin 6 (IL6) is an inflammatory cytokine; signaling via its receptor (IL6R) is believed to contribute to development of inflammatory bowel diseases (IBD).  The single nucleotide polymorphism rs2228145 in IL6R assocs. with increased levels of sol. IL6R (s-IL6R), as well as reduced IL6R signaling and risk of inflammatory disorders; its effects are similar to those of a therapeutic monoclonal antibody that blocks IL6R signaling.  We used the effect of rs2228145 on s-IL6R level as an indirect marker to investigate whether reduced IL6R signaling assocs. with risk of ulcerative colitis (UC) or Crohn's disease (CD).  In a genome-wide meta-anal. of 20,550 patients with CD, 17,647 patients with UC, and more than 40,000 individuals without IBD (controls), we found that rs2228145 (scaled to a 2-fold increase in s-IL6R) was assocd. with reduced risk of CD (odds ratio 0.876; 95% confidence interval 0.822-0.933; P = .00003) or UC (odds ratio 0.932; 95% confidence interval 0.875-0.996; P = .036).  These findings indicate that therapeutics designed to block IL6R signaling might be effective in treatment of IBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY9_9ewOfFbLVg90H21EOLACvtfcHk0lhhzSRGdrnAcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSqurvO&md5=eb69ffa02f9dfcbcd6f34e6aa2d16aaf</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2018.05.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2018.05.022%26sid%3Dliteratum%253Aachs%26aulast%3DParisinos%26aufirst%3DC.%2BA.%26aulast%3DSerghiou%26aufirst%3DS.%26aulast%3DKatsoulis%26aufirst%3DM.%26aulast%3DGeorge%26aufirst%3DM.%2BJ.%26aulast%3DPatel%26aufirst%3DR.%2BS.%26aulast%3DHemingway%26aufirst%3DH.%26aulast%3DHingorani%26aufirst%3DA.%2BD.%26atitle%3DVariation%2520in%2520interleukin%25206%2520receptor%2520gene%2520associates%2520with%2520risk%2520of%2520crohn%25E2%2580%2599s%2520disease%2520and%2520ulcerative%2520colitis%26jtitle%3DGastroenterology%26date%3D2018%26volume%3D155%26spage%3D303%26epage%3D306%26doi%3D10.1053%2Fj.gastro.2018.05.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">IL-10 and IL-10 receptor mutations in very early onset inflammatory bowel disease</span>. <i>Gastroenterol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.14740/gr740w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=10.14740%2Fgr740w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=28496525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Ojs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=65-69&author=L.+Zhuauthor=T.+Shiauthor=C.+Zhongauthor=Y.+Wangauthor=M.+Changauthor=X.+Liu&title=IL-10+and+IL-10+receptor+mutations+in+very+early+onset+inflammatory+bowel+disease&doi=10.14740%2Fgr740w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">IL-10 and IL-10 receptor mutations in very early onset inflammatory bowel disease</span></div><div class="casAuthors">Zhu, Lei; Shi, Tingting; Zhong, Chengdi; Wang, Yingde; Chang, Michael; Liu, Xiuli</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">65-69</span>CODEN:
                <span class="NLM_cas:coden">GRAECV</span>;
        ISSN:<span class="NLM_cas:issn">1918-2805</span>.
    
            (<span class="NLM_cas:orgname">Elmer Press</span>)
        </div><div class="casAbstract">Very early onset inflammatory bowel disease (VEO-IBD) is a unique disease entity with a complex genetic susceptibility in affected patients.  Next-generation gene sequencing techniques have revealed various monogenetic mutations contributing to the pathogenesis of VEO-IBD, including interleukin 10 (IL-10) and IL-10 receptor (IL- 10R) mutations.  In this article, we reviewed the features of and effective therapeutic options for VEO-IBD with IL-10 and/or IL-10R mutations.  The IL-10 signal pathway inhibits the release of several key cytokines and thereby has a significant anti-inflammatory effect in the gastrointestinal tract.  Mutations of the genes encoding IL-10 and/or IL-10R have been detected in VEO-IBD patients among myriad populations throughout the world.  VEO-IBD patients with IL-10 or IL-10R mutations often present with repeated bouts of bloody diarrhea, marked wt. loss, growth retardation, and recurrent perianal problems, including abscesses, fistulas, and significant fissures.  Moreover, some patients may have folliculitis and present with pulmonary infections.  While the therapeutic efficacy of immunosuppressants is typically poor in these patients, allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to improve symptoms significantly.  However, the long-term prognosis of VEO-IBD patients with IL-10 or IL-10R gene mutations treated with HSCT requires further exploration to verify the efficacy and safety of this treatment.  We concluded that clinicians should recognize the clin. phenotype of VEO-IBD, as mutational anal. of the IL-10 pathway can support the diagnosis and prompt early treatment of this complicated disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRL9LKTgHLPrVg90H21EOLACvtfcHk0ljL40TOxCl3KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Ojs7c%253D&md5=ed0aac3ed2d43694363fb1fffd77f609</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.14740%2Fgr740w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14740%252Fgr740w%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DT.%26aulast%3DZhong%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DIL-10%2520and%2520IL-10%2520receptor%2520mutations%2520in%2520very%2520early%2520onset%2520inflammatory%2520bowel%2520disease%26jtitle%3DGastroenterol.%2520Res.%26date%3D2017%26volume%3D10%26spage%3D65%26epage%3D69%26doi%3D10.14740%2Fgr740w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GJ3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GJ3','PDB','4GJ3'); return false;">PDB: 4GJ3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4','PDB','2XA4'); return false;">PDB: 2XA4</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i110"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_00340"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01468?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01468</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">11e_in_2XA4_JAK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_001.pdb">PDB</a>)</p></li><li><p class="inline">11e_in_4GJ3_TYK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_002.pdb">PDB</a>)</p></li><li><p class="inline">14l_in_2XA4_JAK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_003.pdb">PDB</a>)</p></li><li><p class="inline">14l_in_4GJ3_TYK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_004.pdb">PDB</a>)</p></li><li><p class="inline">jmcmar_ccc (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_005.xls">XLS</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_006.csv">CSV</a>)</p></li><li><p class="inline">Compounds <b>12a–12g</b> with different hinge binders and their enzymatic potencies (Table S1); enzymatic potencies and the metabolic stability of compounds <b>13a–13l</b> (Table S2); enzymatic potencies and the metabolic stability of compounds <b>14a–14o</b> (Table S3); kinome-wide selectivity profiling of compound <b>14l</b> @ 0.1 μM (Table S4); <sup>1</sup>H NMR, <sup>13</sup>C NMR, and HRMS-ESI of <b>14l</b>, respectively (Figures S1–S3); purity of <b>14l</b> (Figure S4); and biological assay methods (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_007.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_001.pdb">jm0c01468_si_001.pdb (384.97 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_002.pdb">jm0c01468_si_002.pdb (536.79 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_003.pdb">jm0c01468_si_003.pdb (383.25 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_004.pdb">jm0c01468_si_004.pdb (535.37 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_005.xls">jm0c01468_si_005.xls (184.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_006.csv">jm0c01468_si_006.csv (6.67 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_007.pdf">jm0c01468_si_007.pdf (461.15 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01468&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-4%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01468" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01468" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                14MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"667982186a03d1f3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
